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To understand the entirety of the processes happening during the production of a 
rotavirus-like particle, from the genetics of the viral vector to the infection strategy, 
titer and structure of assembled particles, a bottom-up Systems Biology approach is 
required. 
 
This thesis provides a set of computational models and algorithms which represent 
a step forward to the in silico implementation of the baculovirus/insect cells system. 
Through simulation and numerical optimization codes, novel and improved 
optimization schemes for production of virus particles, viral proteins and/or complex 
protein structures such as virus-like particles can be developed. 
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Foreword 
The present dissertation is the result of four years of research at the Animal 
Cell Technology Unit of the Instituto de Tecnologia Química e Biológica-
Universidade Nova de Lisboa/Instituto de Biologia Experimental e 
Tecnológica, under the supervision of Dr. Rui Oliveira and Prof. Manuel 
Carrondo. 
This thesis intends to provide a set of computational models and 
algorithms, which represent a step forward to the in silico implementation of 
the baculovirus/insect cells system, to assist the design of novel and 
improved optimization schemes for the production of virus particles, viral 
proteins and/or complex protein structures such as virus-like particles. 
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Dissertation Abstract 
Rotavirus-like particles (RLPs), a vaccine candidate against rotavirus 
disease, were produced by infecting Spodoptera frugiperda Sf-9 cells with 
genetically engineered recombinant baculoviruses. RLPs are spherically 
shaped particles composed by three viral proteins (vp) of rotavirus, vp2, 
vp6 and vp7, arranged in a triple layered structure. 
A diversity of protein structures, other than the correctly assembled RLP, 
are observed at the end of a typical production run suggesting that the 
protein assembly process is rather inefficient. Contaminants such as 
trimers of vp6 and vp7, vp6 tube-like structures, single-layered vp2 
particles, double layered particles of vp2 and vp6 or RLPs lacking one or 
more subunits represent almost 88% of the total mass of proteins 
expressed. Thus, optimal control of protein expression concomitant with 
efficient particle assembly are critical factors for economical RLP 
production in the baculovirus/insect cells system. 
In this thesis, experimental activities and mathematical modelling are 
merged together towards the development of an in silico baculovirus/insect 
cells system implementation with the ability to simulate and predict multiple 
protein expression and posterior self assembly into virus-like particles 
(VLPs), using RLPs as model system. 
In Chapter 1, the state of the art on existing mathematical models 
developed for the baculovirus/insect cell system is presented. Brief 
bioengineering notions involved in this expression system, types of 
mathematical models and VLPs are also provided. 
Since the lack of accuracy of baculovirus titers directly affects the 
multiplicity of infection (MOI) and impacts negatively on batch consistency 
and process optimization, a comparative study was performed in Chapter 2 
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to identify the titration methods that better combines accuracy with the 
method’s cost and work intensity. The best compromise was achieved with 
the endpoint dilution, microculture tetrazolium and flow cytometric assays. 
Nonetheless, checking titer’s accuracy against a baculovirus reference 
stock or by titration using two different methods and verification of the 
variability of results is always advisable. Based on these data, it may be 
realistic to expect a MOI variability of around 20%. 
In Chapter 3, the differences between deterministic and stochastic 
infection, and the implications of stochastic baculovirus infection on protein 
expression at high and low MOIs are discussed. The saturation in 
intracellular protein expression occurs due to the existence of a maximum 
translation capacity; hence, there is no advantage in increasing the MOI to 
very high levels as the translation machinery saturates, thus resulting in no 
improvement in protein expression. The total concentration of viral protein 
was shown to be differently affected by the MOI. At MOIs > 10 virus.cell-1, 
no significant improvement in protein concentration was achieved as a 
consequence of protein expression saturation. In addition, since the 
infection at such high MOIs is essentially synchronous and instantaneous, 
the deterministic and stochastic models converged to the same solution. At 
lower MOIs, protein concentration was maximized as result of higher 
infected cell concentration. The outputs of stochastic and deterministic 
model diverged completely since infection is asynchronous and ruled by 
stochasticity. Interestingly, the gene size did not affect the optimal MOI 
ranges for protein expression but impacted negatively on the expression 
levels: the higher the gene size, the lower is the expression of the viral. 
This means that different proteins are expected to have optimal 
productivities around the same MOI obtained for vp2: between 0.01 and 0.1 
virus.cell-1. 
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A thermodynamic equilibrium-based model describing the assembly of 
RLPs was proposed in Chapter 4. The model establishes a relationship 
between particle formation and the Gibbs free energy of protein subunit 
association (ΔG0n) and protein concentration. Model simulations have 
shown that there is a minimum concentration of protein structural subunits 
ensuring a measurable particle formation, i.e. a pseudo-critical 
concentration level. Importantly, this concentration threshold was found to 
be correlated with ΔG0n: as ΔG0n increases, the protein’s pseudo-critical 
concentration also increases. The assembly and disassembly efficiencies 
of RLPs were found to be correlated with Gibbs free energy of vp7 subunit 
association (ΔG0RLP): as ΔG0RLP increases, the assembly increases and the 
disassembly decreases accordingly. Interestingly, this dependency is not 
linear. For Gibbs free energy values below -2 kcal.mol-1, changes in Gibbs 
free energies do no affect significantly the assembly of RLPs. Above this 
threshold, a crisp transition from intact icosahedra to unassembled subunits 
is observed. Noteworthy was the impact of Gibbs free energy on optimal 
initial proteins concentration. For low Gibbs free energies, thermodynamics 
maximizes the formation of intact icosahedra (RLP) whenever proteins are 
provided at the exact RLP stoichiometric ratio. At extremely high Gibbs free 
energies, there is a translocation of the proteins pseudo-critical 
concentrations; so, optimum concentrations were no longer coincident with 
the stoichiometry of the particle. Since host cells can hardly be manipulated 
to operate in such a narrow region of Gibbs free energies and protein 
concentrations, the formation of malformed particles is likely to be 
inevitable in vivo. 
In Chapter 5, a deterministic structured model was developed to 
understand and quantify the effect of different infection strategies on RLP 
production. Two major outcomes of the model were the vDNA replication 
rate, constant at 0.19 ± 0.01 h-1 irrespective of the baculovirus vector 
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(monocistronic or tricistronic), and the apparent higher potential of p10 
promoter for vp7 expression in comparison to the polh promoter. Analysis 
of the time windows for vDNA, mRNA and protein synthesis revealed that 
these intracellular processes are highly correlated and MOI dependent. 
Indeed, higher intracellular vDNA concentrations induce higher mRNA 
transcription levels and, ultimately, higher intracellular protein 
concentrations. In addition, the higher the MOI, the more severe is the 
“metabolic burden” and, consequently, the lower the time window for 
intracellular vDNA, mRNA and protein synthesis. With the use of tricistronic 
baculoviruses (single-infection), the possibility of infected cells not carrying 
all genes required for RLP assembly (genes coding for vp2, vp6 and vp7), 
as it happens with co-infection experiments, was overcome. Therefore, 
protein limitations were remarkably less severe, which, in the end, led to 
the formation of more RLPs when compared to co-infection. 
An in silico analysis of the biological system was performed, namely 
concerning the sensitivity of RLPs and constitutive proteins concentration in 
relation to model parameters (Chapter 6) and to process degrees of 
freedom such as the MOI or ΔG0n (Chapters 3 to 6). Model outputs were 
found to be more sensitive to changes in parameters related with vDNA 
and protein synthesis, such as δ10, kRDNA, S2, mp2 and krib,elong, than to those 
linked to cell growth, infection process, virus budding, re-infection and 
mRNA. 
In Chapter 6, the theoretical effect of MOI and promoter strength on RLP 
production was investigated for single and co-infection strategies using the 
stochastic model developed in Chapter 3. At single-infections, RLP 
production was optimized by manipulating the MOI (lower MOIs) and by 
redesigning baculovirus vectors, in which the promoters controlling viral 
protein expression can be selected according to their strength (lowering the 
strength of the promoter controlling vp7 expression in relation to the other 
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two promoters). For co-infection strategies, high MOIs maximized RLP 
production; the redesign of baculovirus vectors configured a somewhat 
modest improvement potential. Overall, single-infection strategies seem to 
offer significant advantages over co-infection experiments. This is clearly 
evident at low MOIs where the higher cell density achieved at single-
infection led to higher RLP production (30-60 mg.L-1 against the 6-12 mg.L-1 
at co-infection). The assembly efficiencies were also higher: 72% against 
20-40% at co-infection. At high MOIs, the difference in model outputs 
(assembly efficiency and intracellular and total RLP concentration) between 
both strategies was not significant. 
Chapter 7 discusses the implications of the findings presented in the other 
chapters. It summarizes the main achievements of this thesis, identifies the 
main pitfalls of the computational tools developed in previous chapters for 
the optimisation of the baculovirus/insect cell system and outlines potential 
strategies for the production of RLPs in a more efficient way. 
Summarizing, this thesis provides a set of computational models and 
algorithms which represent a step forward to the in silico implementation of 
the baculovirus/insect cells system. Through simulation and numerical 
optimization codes, novel and improved optimization schemes for 
production of virus particles, viral proteins and/or complex protein 
structures such as VLPs can be developed. 
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Resumo da Dissertação 
As partículas semelhantes ao rotavírus (RLPs), vacinas candidatas contra 
a doença do rotavírus, são normalmente produzidas ao infectar células de 
insecto (Spodoptera frugiperda Sf-9) com baculovírus recombinantes 
geneticamente modificados. Estas partículas de formato esférico são 
compostas por três proteínas virais (vp) do rotavírus, nomeadamente vp2, 
vp6 e vp7, dispostas numa estrutura de tripla camada. 
A diversidade de estruturas proteicas observada no final de um ciclo de 
produção de RLPs indica que o processo de montagem é ineficiente. 
Trímeros de vp6 e vp7, estruturas tubulares de vp6, partículas esféricas 
compostas por vp2, partículas esféricas de dupla camada compostas por 
vp2 e vp6 (DLP) ou RLPs que têm uma ou mais subunidades estruturais 
em falta são exemplos de contaminantes do processo, representando 
quase 88% da massa total de proteínas expressas. Como tal, o controlo da 
expressão das proteínas juntamente com a montagem eficiente da 
partícula são factores essenciais para uma produção económica de RLPs 
no sistema de baculovírus/células de insecto. 
Nesta tese, actividades experimentais e modelação matemática são 
combinadas com o objectivo de desenvolver e implementar um sistema de 
baculovírus/células de insecto virtual com a capacidade de simular e 
prever a expressão de múltiplas proteínas e a sua posterior montagem em 
partículas semelhantes a vírus (VLPs), usando as RLP como modelo. 
No Capítulo 1, são apresentados os modelos matemáticos desenvolvidos 
para o sistema de baculovírus/células de insecto. Breves noções sobre as 
questões de bioengenharia deste sistema de expressão, as diferentes 
categorias de modelos matemáticos e os tipos de VLPs existentes são 
igualmente apresentadas. 
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Uma vez que a imprecisão nos títulos dos baculovírus afecta directamente 
a multiplicidade de infecção (MOI – número de vírus por célula) e tem um 
impacto negativo sobre a reprodutibilidade e optimização do processo de 
produção de RLPs, foi realizado um estudo comparativo de modo a 
identificar os métodos de titulação que melhor combinam precisão, custo 
do método e intensidade de trabalho (Capítulo 2). O melhor compromisso 
foi alcançado para os métodos “endpoint dilution”, “microculture 
tetrazolium” e “flow cytometry”. No entanto, é sempre aconselhável verificar 
a precisão do título estimado comparando-o com um “stock” de baculovírus 
de referência ou titulando o “stock” em questão por dois métodos 
diferentes e analisar a variabilidade dos resultados obtidos. Tendo em 
conta os resultados obtidos, é realístico esperar que a MOI tenha uma 
variabilidade a rondar os 20%. 
No Capítulo 3, foram discutidas as diferenças entre a infecção 
determinística e estocástica bem como as implicações da infecção 
estocástica na expressão de uma proteína a MOIs altas e baixas. 
Observou-se uma saturação na expressão de proteína, o que é justificado 
pela existência de uma capacidade máxima de tradução; como tal, não há 
vantagem em aumentar a MOI para valores muito elevados uma vez que a 
maquinaria de tradução satura, não havendo qualquer aumento na 
expressão da proteína. Foi verificado que a concentração total de proteína 
é afectada de diferente forma pela MOI. A MOIs > 10 virus.cell-1, não houve 
aumento significativo na concentração da proteína devido à saturação na 
expressão de proteína. Para além disso, uma vez que a infecção a MOIs 
muito elevadas é essencialmente síncrona e instantânea, o modelo de 
infecção determinístico e estocástico convergiram para a mesma solução. 
Para MOIs mais baixas, a concentração de proteína foi maximizada em 
resultado de uma maior concentração de células infectadas. Os modelos 
de infecção estocástico e determinístico divergiram uma vez que a 
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infecção é assíncrona e regulada pela estocasticidade. Interessantemente, 
o tamanho do gene não afectou o intervalo de MOIs ideal para a expressão 
de proteína, mas teve um impacto negativo sobre os níveis de expressão: 
quanto maior o tamanho do gene, menor é a expressão da proteína. Isto 
significa que é esperado que diferentes proteínas tenham produtividades 
óptimas à volta da mesma MOI que para a vp2: entre 0.01 e 0.1 virus.cell-1. 
No Capítulo 4 foi desenvolvido um modelo matemático que descreve a 
montagem, passo a passo, de uma RLP e que se baseia no equilíbrio 
termodinâmico entre as diferentes estruturas moleculares que constituem a 
RLP. O modelo estabelece uma relação entre a formação de uma partícula 
e a energia livre de Gibbs (ΔG0n) e a concentração de proteína. As 
simulações do modelo mostraram que existe uma concentração mínima de 
subunidades estruturais de proteína que garante uma mensurável 
formação de partículas, isto é, uma concentração pseudo-crítica. Foi 
verificado que esta concentração crítica se encontra correlacionada com 
ΔG0n: um aumento de ΔG0n conduz a um aumento na concentração 
pseudo-crítica de proteína. Foi igualmente observado que a eficiência da 
montagem e desmontagem de uma RLP se encontra correlacionada com a 
energia livre de Gibbs de associação de subunidades de vp7 (ΔG0RLP): à 
medida que aumenta ΔG0RLP, a eficiência da montagem aumenta e a 
eficiência da desmontagem diminui em conformidade. Curiosamente, esta 
dependência não é linear. Para valores de ΔG0n menores que -2 kcal.mol-1, 
variações na energia livre de Gibbs não afectam significativamente a 
eficiência da montagem de RLP. Acima deste limiar, é observada uma 
nítida transição de estruturas icosaédricas intactas (RLP) para 
subunidades estruturais de proteína não associadas. A energia livre de 
Gibbs teve um impacto significativo na concentração inicial óptima de 
proteínas. Para energias livre de Gibbs baixas, a termodinâmica maximiza 
a formação de RLPs sempre que as proteínas sejam fornecidas na relação 
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estequiométrica de RLP exacta. Para energias livre de Gibbs 
extremamente altas, há uma translocação da concentração pseudo-crítica 
de proteínas; deste modo, a concentração ideal já não será coincidente 
com a relação estequiométrica de RLP. Uma vez que a célula hospedeira 
dificilmente pode ser manipulada de modo a operar numa região muito 
restrita de energias livre de Gibbs e de concentrações proteicas, a 
formação de partículas mal-formadas é muito provável que seja inevitável 
in vivo. 
No Capítulo 5, um modelo determinístico/estruturado foi desenvolvido para 
compreender e quantificar o efeito de diferentes estratégias de infecção na 
produção de RLP. Dois resultados importantes foram extraídos do modelo: 
verificou-se que a taxa de replicação de vDNA (0.19 ± 0.01 h-1) é 
independente do vector viral (baculovírus monocistrónico ou tricistrónico) e 
que o promotor p10 apresenta um maior potencial para a expressão de vp7 
do que o promotor polh. Ao analisar os intervalos temporais 
correspondentes à síntese de vDNA, mRNA e proteína constatou-se que 
estes três processos intracelulares estão correlacionados e são 
dependentes da MOI. De facto, concentrações intracelulares elevadas de 
vDNA induzem níveis elevados de mRNA e de proteína. Para além disso, 
quanto maior for a MOI, mais severa é a sobrecarga metabólica e 
consequentemente menor é o intervalo de tempo para a síntese de vDNA, 
mRNA e proteína. A possibilidade de células infectadas não transportarem 
todos os genes necessários para a montagem da RLP (genes que 
codificam para vp2, vp6 e vp7), como acontece na co-infecção, foi 
ultrapassada usando baculovírus tricistrónicos (“single-infection”). Deste 
modo, as concentrações das três proteínas tornaram-se mais adequadas 
para a montagem da RLP, o que, no final, levou à formação de maior 
quantidade de RLP quando comparado com a co-infecção. 
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Foi realizada uma análise ao sistema biológico, nomeadamente sobre a 
sensibilidade da concentração de RLP e proteínas constituintes em relação 
aos parâmetros do modelo (Capítulo 6) e aos graus de liberdade do 
processo tais como a MOI e ΔG0n (Capítulos 3 a 6). Os resultados do 
modelo mostraram-se mais sensíveis a variações nos parâmetros 
relacionados com a síntese de vDNA e de proteína (δ10, kRDNA, S2, mp2 e 
krib,elong) do que aos ligados ao crescimento celular, processo de infecção, 
libertação de novos baculovírus, re-infecção e mRNA. 
No Capítulo 6, os efeitos teóricos da MOI e da força do promotor na 
produção de RLP foram investigados para as estratégias de “single-
infection” e co-infecção usando, para tal, o modelo estocástico 
desenvolvido no Capítulo 3. No caso da estratégia “single-infection”, a 
produção de RLP foi optimizada através da manipulação da MOI (MOIs 
baixas) e do redesenho dos vectores virais, nos quais os promotores que 
controlam a expressão das proteínas virais podem ser seleccionados de 
acordo com a sua força (diminuindo a força do promotor que controla a 
expressão de vp7 em relação aos promotores que regulam a expressão de 
vp2 e vp6). Na estratégia de co-infecção, MOIs elevadas maximizaram a 
produção de RLP; o redesenho dos vectores virais configura-se uma 
alternativa com baixo potencial de melhoramento. Globalmente, a 
estratégia “single-infection” parece oferecer vantagens significativas sobre 
as experiências de co-infecção. Isto é claramente evidente para baixas 
MOIs onde a maior densidade celular alcançada na estratégia “single-
infection” conduziu a uma maior produção de RLP (30-60 mg.L-1 contra os 
6-12 mg.L-1 da co-infecção). As eficiências de montagem de RLPs também 
foram maiores: 72%, contra os 20-40% da co-infecção. Para MOIs 
elevadas, a diferença entre as duas estratégias não é significativa. 
No Capítulo 7 discutem-se as implicações dos resultados apresentados 
nos outros capítulos. Resumem-se os principais objectivos alcançados 
xxiv 
durante a realização desta tese, identificam-se as maiores falhas nas 
ferramentas computacionais desenvolvidas nos capítulos anteriores para a 
optimização do sistema de baculovírus/células de insecto e definem-se 
estratégias que potenciem uma produção de RLP mais eficiente. 
Em resumo, esta tese fornece uma serie de modelos computacionais e 
algoritmos que representam um grande passo na implementação de um 
sistema de baculovírus/células de insecto virtual. Através de simulações e 
códigos de optimização numéricos, novos e melhores esquemas de 
optimização para produção de partículas virais, proteínas virais e/ou 
estruturas proteicas complexas tais como as VLPs podem ser 
desenvolvidas. 
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1. INTRODUCTION 
The baculovirus/insect cell system is a two-stage process where insect 
cells are first grown to a desired cell concentration and then infected by 
genetically engineered baculoviruses for heterologous protein expression. 
This system is considered to be one of the most efficient eukaryotic gene 
expression systems. Over 500 recombinant proteins have been expressed 
to date, from viral, bacterial, fungi, mammalian and plant species, with 
yields ranging between 5 to 70% of the total intracellular protein content [1]; 
the concentrations can reach 500 mg.L-1 [2]. Noteworthy is its capacity to 
express multiple proteins and to form multimeric protein complexes such as 
virus-like particles (VLPs) [3, 4] making this system a basic tool for protein-
protein interaction research and VLP based vaccines development. 
Importantly, most of the proteins expressed in this system can undergo 
post-translational modifications (PTM) similar to the human glycosylation 
pattern [5, 6]. 
Despite its advantages, only two in 151 licensed protein-based 
biopharmaceuticals are produced using the baculovirus/insect cell system 
(Figure 1): the GlaxoSmithKline’s human papillomavirus 16/18 cervical 
cancer vaccine CervarixTM and the recombinant trivalent hemagglutinin 
vaccine against influenza virus, FluBlok®, from Protein Science 
Corporation.  
The baculovirus/insect cell system can be used also for virus production. 
Applications of these viral particles go from high-throughput screening of 
gene functions [7] to drug delivery [8], in vitro assembly studies, design of 
antiviral drugs [9], bio-insecticides [10] or bio-weapons [11]. In material 
science and engineering, they are the building blocks for electronics, 
biosensors and chemistry [12]. Recently, baculoviruses have invited 
renewed interest by virtue of their potential use as a delivery system in 
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gene therapy [13, 14]. Although their replication is limited to arthropods, 
baculoviruses can enter in over 35 mammalian cell lines [15], delivering the 
vDNA into the nucleus. This is possible due to exogenous promoters, such 
as those derived from Rous sarcoma virus or cytomegalovirus.  
 
Figure 1. Number and percentage of proteins approved as biopharmaceuticals 
Evidence points out for promising applications of baculoviruses and protein-
derived complexes to other areas of research in the near future such as 
nanotechnology where they can be used as tools for biomedical science 
[16]. 
1.1. The baculovirus/insect cell system at a glance 
1.1.1. The baculovirus 
Baculoviruses have a dsDNA genome of between 88 and 200 kbp with 90 
to 180 genes [17, 18]. The genome is associated to a 6.5 kDa protein [19] 
and encapsidated into a rod-shaped nucleocapsid formed by a 39 kDa 
protein [20]. The length of the nucleocapsids varies from 200 to 400 nm, 
depending on the genome size, whereas the width ranges between 25 and 
50 nm [21]. These nucleocapsids are packed within a lipoprotein envelope 
to form the virus particle. 
The insertion of a foreign gene occurs normally at the polyhedrin (polh) or 
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p10 gene locus since these are not essential genes for vDNA replication 
and are controlled by very strong promoters. The size of insertions can be 
as large as 100 kb, meaning that not only single but also multiple genes 
can be inserted and expressed simultaneously [22].  
Baculoviruses are stable for 3-4 months when re-suspended in culture 
medium and stored at 4ºC. For long term storage, -80ºC or liquid nitrogen is 
recommended; additives such as glycerol, dimethyl sulfoxide and sucrose 
may avoid loss of infectivity. At -20ºC, viral titers decrease significantly due 
to virus aggregation [23].  
1.1.2. The insect cell 
Typical insect cell cultures do not require CO2 for growth, can resist 
temperature fluctuations between 18 ºC and 35 ºC and osmolarities 
between 300 and  380 mOsm (a significant reduction in protein expression 
is observed if osmolarities then increase by 30mOsm) [24]. The optimum 
pH is around 6.2-6.3; it may reach 5.9 in infected cultures (Table 1). 
Insect cells can be cultivated in static (T-flasks) or in suspension culture 
systems (erlenmeyer, shaker flasks, spinners or bioreactors) to high cell 
densities. They can be cultured indefinitely although for passages beyond 
the 50th, cells began to show morphological changes. Cells are easily 
adapted to suspension cultures, either in media containing serum or in 
serum free media, and are normally stored at -80ºC (working cell bank) or 
in liquid nitrogen (long-term storage). 
Insect cells, infected or not, are sensitive to shear stress generated while 
sparging or by bubble entrainment during agitation [25]. The addition of 
non-ionic copolymers (e.g. pluronic F-68) is essential as they lower the 
culture medium surface tension, impeding the attachment of cells to 
bubbles [26], and interact with the cell membrane, increasing its rigidity and  
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its resistance to hydrodynamic forces.  
The control of the percentage of dissolved O2 (pO2) is essential to avoid 
oxygen limitation or excess, thereby inhibiting the synthesis of proteases or 
oxidative damage to proteins [30]. The specific growth rate of insect cells is 
not significantly affected by pO2 between 5% and 100%; in contrast, protein 
expression is constrained to pO2 values around 25-30% [31]. 
1.1.3. The expression level 
Recombinant protein yields may reach hundreds of milligrams per liter, 
depending on the culture mode (batch, fed-batch, continuous and 
perfusion) and the target protein (glycosylated or not) (Figure 2). These 
high expression levels are explained by the ability of the virus to shut off the 
transcription of early host genes and the consequent allocation of the 
cellular transcriptional and translational apparatus for the expression of the 
heterologous gene(s). 
1.2. Bioengineering issues and caveats 
1.2.1. The promoter 
The combination of promoter’s strength with the correct time for its 
activation is essential to high protein yields [32].Very strong promoters 
commonly overwhelm the processing capacity of the endoplasmic 
reticulum, thus reducing final yields. In addition, with very late promoters, 
the expression of proteins occurs towards the end of the culture when 
proteases negatively impact on correct protein PTM. On the other hand, 
early promoters induce lower protein productivities as in most cases the 
enzymes and transcriptional factors necessary for protein expression are 
not yet active at such early stages.  
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Figure 2. Reported expression levels of some proteins in Sf-9 cells and comparison to other 
expression systems. 
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Although previous reports show that weaker and earlier promoters induce 
correct PTM [65], early promoter-based vectors with productivities similar 
to polh and p10 promoters are difficult to find. 
1.2.2. Baculovirus titration 
To optimize conditions for efficient recombinant protein expression, it is 
important to measure as accurately as possible the titers of baculovirus 
stocks. Traditionally, plaque assays have been used for titer determination. 
Other methods such as endpoint dilution, microculture tetrazolium assay, 
growth cessation and cell size assay, alamarblue assay or electron 
microscopy have been proposed to aid the determination of virus titers. 
However, most of these methods are complicated to handle, time-
consuming and labor intensive [66]. To shorten the titration times, 
techniques based on flow cytometry [67] or real-time polymerase chain 
reaction [68] were developed, showing reliable and comparable results to 
those determined by traditional titration assays. Despite these 
improvements, baculovirus titration remains a challenging task as existing 
methods are unable to differentiate between infectious and non-infectious 
particles, thus rendering difficult the estimation of accurate titers. 
1.2.3. The culture mode 
Proteins can be expressed in batch, fed-batch, continuous or perfusion 
mode. In batch cultures, the control of toxic products formation and 
nutrients consumption is essential to guarantee the normal cellular growth 
and protein expression [69]. To avoid process limitations, selective addition 
of nutrients and/or amino acids may be performed using fed-batch 
strategies [70]. The yields are significantly improved but the scale-up 
becomes expensive since culture medium is inefficiently used. The 
continuous system presents a short throughput time and a small number of 
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production steps. However, continuous reactors operated for long periods 
generate high amounts of defective interfering particles (infectious viruses 
lacking viral genome) [71]; also, the complexity of the bio-product produced 
is generally low. Perfusion mode enhance cellular growth and protein 
expression [72], but require large volumes of media and cell-medium 
separation devices that impact negatively on cellular growth rate, protein 
expression and production cost.  
1.2.4. Key process parameters 
Process parameters such as the multiplicity of infection (MOI - number of 
virus per cell), time of harvest (TOH) and cell concentration at infection 
(CCI) strongly influence protein expression.  
The optimal MOI is dependent on the target product (single or multiple 
protein expression), the production strategy (single- or co-infection) and the 
viral stock. For single protein expression, low MOIs normally induce higher 
volumetric protein productivities than high MOIs as a consequence of 
higher infected cell concentrations [73]. In theory, this difference could be 
balanced with the increase in CCI. However, cell specific productivity 
decreases as CCI increases due to the “cell density effect” [69]. For 
multiple protein expression, the self-assembly of protein complexes is 
highly correlated with the production strategy; thus, several combinations of 
MOI and CCI may maximize product formation. 
Optimal TOH is normally between 72-120 hpi (40 and 70% of cell viability) 
[31]; outside these boundaries, protein degradation is increased and 
downstream processing becomes more difficult as contaminant proteins 
(host and viral) are released to the extracellular medium along with the 
product. 
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1.2.5. The metabolism of insect cells 
The preferred carbon source of insect cells is glucose; once exhausted, cell 
metabolism changes and glutamine becomes an important energy source 
[69]. Amino acids fulfil the nitrogen requirements of insect cells [74, 75]. 
Deprivation of lipids causes cell degeneration and the formation of non-
infectious viruses [76]. Cholesterol is essential for membranes synthesis 
[77]. Vitamins are important for maintenance of insect cells since they act 
as cofactors for key metabolic enzymes [77].  
Accumulation of toxic products is not observed at adequate nutrient and, 
most importantly, oxygen supply [75, 78]. At glucose and glutamine 
limitation levels, accumulation of ammonia is observed, followed by a 
significant reduction in cell growth rate [79]. Lactate is generated under 
oxygen deprivation but does not affect cellular growth until concentrations 
higher than 15 mM; lactate is consumed upon carbohydrates exaustion 
causing the pH to increase towards the end of the culture [80]. 
Nutritional requirements of insect cells upon baculovirus infection have 
been generally considered to remain unchanged; cellular energetics seems 
to be the main limitation to baculovirus and/or protein production [69]. 
1.2.6. Protein quantification methods 
The quantification of protein complexes and constitutive viral proteins is 
traditionally performed by transmission electron microscopy, SDS-PAGE, 
Western blot, ELISA and BCA protein quantification assays [68]. These 
semi-quantitative methods do not differentiate between unassembled and 
assembled proteins; also, they are time-consuming, with low sensitivity and 
require significant amounts of sample. As a consequence, protein yields 
are frequently over or under estimated. Recently developed methods such 
as gel permeation HPLC [63], sodium dodecyl sulfate-capillary gel 
Chapter 1. Introduction 
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electrophoresis [81], MALDI-TOF MS [82] and capillary zone 
electrophoresis [83] may allow a simple, fast and high performance 
quantification of unassembled and assembled proteins in purified and bulk 
samples. 
 
2. VIRUS-LIKE PARTICLES AS VACCINES: THE PROOF OF CONCEPT 
Virus-like particles offer several advantages as antigens and immunogens. 
First, compared to individual proteins or peptides, VLPs present 
conformational epitopes more similar to the native virus; hence, antibody 
reactivity or immune system response is expected to be significantly 
improved. Secondly, because VLPs are non-infectious (they lack the viral 
genome), attenuation or inactivation is not required; this is particularly 
important as epitopes are commonly modified by inactivation treatments 
[84]. Thirdly, using molecular biology methods it is possible to adapt one or 
more antigens to these multimeric protein structures for broader and more 
efficient protection. Finally, VLPs resembling the organizational structure of 
native viruses imply that lower doses of antigen are required to elicit a 
protective response when compared to subunit vaccines. 
The most popular expression system for the production of VLPs is the 
yeast system (Saccharomyces cerevisiae or Pichia pastoris) due to its easy 
protein expression, ability to scale-up and cost of production. However, 
appropriate PTM such as protein glycosylation and correct protein folding, 
protein assembly and codon optimisation may dictate alternative production 
systems. Within those, the baculovirus/insect cell system, mammalian cell 
lines (CHO, BHK-21, Vero E6, HepG2 or HeLa cells) either transiently or 
stably transfected or transduced with viral expression vectors, bacteria (E. 
coli) and various species of plant cells (Solanum tuberosum – potato, 
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Lycopersicon esculentum – tomato, Nicotiana benthamiana – tobacco), 
have been receiving special attention. 
To date, different types of VLPs have been developed for vaccine 
proposes: 1. VLPs of structurally simple viruses; 2. VLPs with lipid 
envelope; 3. VLPs with multiple-protein layers; 4. Chimeric VLPs (Table 2). 
2.1. VLPs of structurally simple viruses 
VLPs of structurally simple viruses are normally composed by one protein. 
One example is the human papillomavirus (HPV)-VLP. Although the native 
virus contains the major and minor capsid proteins of HPV, L1 and L2 
respectively, the HPV-VLP is formed just by the L1 protein organized in 72 
pentameric capsomers. Porcine parvovirus (PPV)-VLP is another example; 
PPV-VLPs are formed by a single protein, VP2, the major structural protein.  
Norwalk virus (Nv)-VLPs expressed in insect cells are used as a source of 
diagnostic antigen to monitor disease outbreaks since the native virus 
production has limited growth in cell culture. Nv-VLPs have shown to be 
effective at stimulating IgG, IgA and humoral responses in mice [85]. 
Preliminary phase I trials in humans have confirmed that they are safe and 
effectively stimulate IgG and IgA responses [86]. 
2.2. VLPs with lipid envelope 
Many pathogenic viruses are surrounded by an envelope consisting of host 
cell membrane lipids and proteins, and viral glycoproteins. These proteins 
are the targets of neutralizing antibodies and essential components of a 
vaccine. Due to the inherent properties of the lipid envelope, assembly of 
enveloped VLPs is technically complex.  
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The first VLP vaccine to be produced consisted of spherical particles with 
diameters between 17 nm and 25 nm formed by the surface antigen of the 
hepatitis B virus (HBsAg) co-assembled with host cellular membranes. 
Following that, other enveloped VLPs have been successfully developed. 
The hepatitis C virus-VLP and VLPs of Ebola and Marburg virus are some 
examples. The first has been tested in mice and baboons and shown to be 
effective at stimulating both cellular and humoral immune responses [98, 
99]. The latter ones have shown to protect small laboratory animals as well 
as non-human primates against lethal challenge by Ebola or Marburg 
viruses [114].  
Simian immunodeficiency virus (SIV)-VLPs, human immunodeficiency virus 
(HIV)-VLPs, Rous sarcoma virus-VLPs, and VLPs for Influenza A H1N1, 
H3N2 and H5N1 viruses are also part of the group of successfully produced 
VLPs with lipid envelope. Although none of the retrovirus derived VLPs 
have gone into clinical trials yet, initial experiments with HIV-VLP [115] and 
SIV-VLP [116] in animal models look promising.  
2.3. VLPs with multiple-protein layers  
VLPs composed by multiple proteins are more challenging to produce than 
those formed by only one protein due to the site of protein expression. 
Proteins encoded by multiple discrete mRNAs tend to be differently 
localized in the cell, which may significantly affect the assembly process. 
Thus, it is essential to guarantee that all proteins are expressed in the 
vicinity of each other and within the same cell.  
These complex VLPs have been efficiently produced for various members 
of the Picornaviridae (poliovirus and enterovirus 71), Birnaviridae 
(infectious bursal disease virus) and Reoviridae families (bluetongue virus 
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and rotavirus); included in this VLP’s category are also the adeno-
associated virus type-2 VLPs. 
Intact and biologically active bluetongue virus (BTV)-VLPs can be produced 
in insect cells by co-infection using two bicistronic baculovirus, one 
encoding VP3 and VP5 and the other encoding VP2 and VP7, or by single-
infection using multicistronic baculoviruses that express simultaneously all 
four structural proteins of the BTV (VP2, VP3, VP5 and VP7). With the use 
of four-gene baculovirus vectors, the possibility of some of the cells not 
being co-infected by the two bicistronic baculovirus is overcome. For this 
reason, single-infection strategies induce the formation of more BTV-VLPs 
than co-infection strategies.  
Biologically functional rotavirus-like particles (RLPs) are normally 
expressed in the baculovirus/ insect cell system using co- or single-
infection strategies. In co-infection, cells are infected with three 
monocistronic baculoviruses, each one coding for vp2, vp6 or vp7. In 
single-infection, cells are infected with tricistronic baculoviruses coding for 
the three viral proteins simultaneously (vp2, vp6 and vp7). Similar to BTV-
VLPs, single-infection strategies appear to be advantageous over co-
infection [68]. In animal models, RLPs have shown to induce a robust 
antibody response and protection when formulated with a potent adjuvant 
and administered intramuscularly [3, 117]. Even intrarectal immunization, 
inducing a local mucosal response, has been reported as sufficient for 
protection from rotavirus infection in animal trials [118]. 
2.4. Chimeric VLPs  
A forthcoming application of VLPs is in the generation of immune 
responses against foreign protein epitopes by fusing or by coupling them to 
VLPs of different origins, resulting in a chimeric VLP. These VLPs are able 
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to carry multiple foreign epitopes [119] and, with the incorporation of tags 
(e.g. polyhistidine), allow easy single-step product recovery [120]. The 
vaccine against HPV infection is an example of a chimeric VLP, in which 
the L2 protein epitopes are inserted into the L1 protein  to confer protection 
against a broader range of HPV types [121]. 
 
3. TYPES OF MATHEMATICAL MODELS 
In biological sciences, mathematical models constitute a compact means of 
describing complex mechanisms and a tool to predict the behavior of a 
system to variations in previously unstudied parameters. Mathematical 
models can be divided in three categories: 1. parametric models, which are 
based on a priori knowledge; 2. non-parametric models, whose structure is 
determined from data; 3. hybrid semi-parametric models, which combine 
parametric and non-parametric components. 
3.1. Parametric models  
A parametric or white-box model is based on First Principles and 
mechanistic knowledge. A functional relationship is derived supported by 
the a priori knowledge relating the different variables. The main bottleneck 
of parametric models is sometimes the low predictive capacity due to the 
over-simplifications of the underlying biological system.  
White-box models can be classified on the basis of their use 
(descriptive/optimization), time dependency (static/dynamic), number of 
time-related data (discrete/continuous), degree of randomness 
(deterministic/stochastic), intracellular processes (structured/non-
structured) and the detail in the description of the cell population 
(segregated/non-segregated). 
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Descriptive models are used to merely assess mathematical relationships; 
an example is the study of the effect of temperature and pH on microbial 
growth [122]. In contrast, optimization models are used to find optimal 
solutions; a successful application is the production optimization of a 
recombinant fusion glycoprotein in Baby Hamster Kidney cells [123]. 
Static models describe the state of the components of a system, not 
accounting for the element of time [124]. In contrast, dynamic models take 
into account the time and are typically represented by ordinary or partial 
differential equations [43, 125]. Within dynamic models, there are discrete 
and continuous models; the difference between both is based on the 
number of time-related data. If the number is finite, the discrete model 
applies quite naturally, no matter whether the data belong to time-points or 
represent changes over time-intervals. Discrete modeling approaches have 
been applied to protein expression dynamics [126], gene regulatory 
networks [127] and epidemiology [128]. For near-infinite data, the 
continuous model fits naturally. 
Deterministic models are those for which the relationships between 
variables are known with certainty [129]; hence, a given set of initial 
conditions will always generate the same output. Models where those 
relationships are not known are said to be stochastic models [73]. A 
stochastic process uses a range of values for variables in the form of 
probability distributions; randomness is present, even when given an 
identical set of initial conditions. 
Unstructured models completely disregard the intracellular state. They only 
consider extracellular state variables; the reaction rates are described 
empirically as functions of extracellular conditions [130]. Structured models 
include details about the intracellular pools, namely concentrations of 
metabolites, enzymes, DNA, mRNA, amongst others [43, 73].  
Production Optimization of Rotavirus-Like Particles: A Systems Biology Approach 
19 
Unsegregated models assume that a culture is composed by a collection of 
cells which have the same characteristics and behave equally [131]. On the 
contrary, segregated models treat each cell as independent, and a 
population as a collection of such distinct cells. Such cell heterogeneity is 
normally modelled using probability functions such as the Poisson or 
Weibull distribution [43, 132]. These models are useful to describe cells at 
different phases of the cell cycle and cellular ageing, different 
morphological types of cells and interactions between different cells. 
3.2. Non-parametric models  
With the advent of high-throughput methods, it became clear that 
mechanistic modelling formalisms were unable to cope with the huge 
amounts of data of large scale molecular networks. Thus, non-parametric 
models were developed and used to analyze such complex networks of 
interactions.  
A non-parametric or black-box model does not use a priori knolwegde 
about the system at hand. It is necessary to estimate not only the values of 
model parameters but also to identify the functional relationships between 
variables and parameters. When a priori information is available, a set of 
functions can be used to reduce the “dimension” of the model. Since that is 
not the case, universal approximation functions with undermined number of 
parameters must be hypothesized in order to cover all the main biological 
mechanisms. This increases the number of empirical parameters and also 
the number of measurements required for their estimation. 
Non-parametric models are able to deal with complex relationships 
between inputs and outputs in systems where little is known about the 
biochemical phenomena occurring within the cell, or to find patterns in data. 
However, this wider applicability has a cost in the robustnesss of the model; 
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in cases where a parametric model is more appropriated, non-parametric 
models have less predictive capacity, i.e. a larger sample size may be 
required to draw conclusions with the same degree of confidence. 
An often used black-box model for bioprocess development is the 
multilayered artificial neural network (ANN) [133]. Basically, it consists of 
an interconnected group of artificial neurons, called nodes, organized into 
different layers and through which correlations between independent and 
dependent variables are established. The input layer receives the 
independent variables of the system while the output layer nodes generate 
the dependent variables. The inner layers are called hidden layers. 
Parameters such as the number of nodes in hidden layers or the number of 
hidden layers determine the structure of the network; this structure may 
vary as result of an adaptation to external or internal information that flows 
through the network during the “model’s learning phase”.  
3.3. Hybrid semi-parametric models 
Hybrid semi-parametric models combine parametric models, based on First 
Principles and mechanistic knowledge, with empirical non-parametric 
models. They can be classified as parallel or serial hybrid structures [134, 
135]. In the former case, the non-parametric model is combined in parallel 
with the full and insufficiently accurate mechanistic model, having access to 
the same input variables and adjusting the mechanistic model outputs. In 
the latter, the non-parametric model collects information from data and 
feeds it into the mechanistic parts of the parametric model that are not 
known, thereby filling the gaps. This approach is particularly appropriate to 
systems where large data sets are available and no direct mechanistic 
interpretation exists.  
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3.4. Outline of modelling approaches in insect cell cultures  
Most of the present models for insect cell culture are parametric/ 
unstructured models, describing only the growth, death and basic metabolic 
features of insect cells; the application of these models in model-based 
process control and process optimisation is therefore limited. To close the 
gap between extra- and intra-cellular compartments, structured models 
have been developed. These models describe the interactions between the 
different cellular pools as well as the extracellular environment using linear, 
algebraic and probability equations, ordinary or partial differential 
equations, traditional Michaelis-Menten equations, amongst many others. 
An illustration of the level of complexity these interaction networks can 
reach is the structured model proposed by Jang and co-workers (2000) 
[136]. In their work, a wide range of energy production and biosynthesis 
pathways were modelled; the concentration of 40 key metabolites in three 
regions (growth medium, cellular cytoplasm and cellular mitochondria) was 
considered. The model includes 1710 differential and algebraic equations 
and 390 model parameters. Due to the model’s complexity and the number 
of parameters, automatic parameters’ estimation was impossible; hence, 
selected heuristical parameters were tuned manually. This illustrates that 
structured models, although attractive due to their wide applicability, suffer 
from the shortcomings of being highly complex, computationally intensive 
and involving a large number of indeterminable parameters.  
Recently, non-parametric and hybrid semi-parametric models have been 
emerging as powerful tools for the mathematical description of complex 
animal cell processes. However, none of these methods have been, to 
date, applied to the baculovirus/insect cell system for process control and 
optimization. 
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4. RLPS PRODUCTION: A SYSTEMS BIOLOGY PERSPECTIVE 
Spurred on by the increase in the “omics” data and the advances in high-
throughput experiments and bioinformatics, Systems Biology has emerged 
as a powerful tool to assist process engineers in accelerating the timeline 
for moving candidate biopharmaceutical products into flexible production 
platforms. In this work, a bottom-up Systems Biology approach was 
adopted for the optimization of RLP production, a vaccine candidate 
against rotavirus disease. 
4.1. The concept of Rotavirus-like particles 
RLPs are multi-protein complexes that mimic the organization and 
conformation of native non-enveloped rotaviruses but lack the viral 
genome. These spherical shaped particles are composed by three viral 
proteins (vp) of rotavirus arranged in a triple layered structure: a core of 60 
dimers of vp2 – 102.7 kDa [137]; a middle shell of 260 trimers of the 
polymorphic protein vp6 – 44.9 kDa [138] and an outer layer of 260 trimers 
of a 37.2 kDa glycoprotein – vp7 [138] (Figure 3).  
 
Figure 3. Illustration of a RLP: molecular weights and sizes of vp2, vp6, vp7, double-layered 
particles of vp2 and vp6 (DLP) and RLP are presented in kDa and nm respectively. 
RLPs are vaccine candidates against rotavirus disease, a disease that, 
according to UNICEF/WHO report of October 2009 focused on diarrheal 
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disease (the second leading killer of children under 5), is responsible for 
more than 600,000 deaths in infants and children worldwide annually 
(source: http://www.unicef.org). 
The main advantage of this vaccine candidate is the absence of viral 
genetic material; adverse effects such as intussusception, has happened in 
1998 with the RotaShield® (Wyeth-Ayerst Laboratories) vaccine, reversion 
to virulence or mutations, are impossible to occur. In addition, it is possible 
to adapt one or more antigens to RLPs for broader and more efficient 
protection against a specific rotavirus serotype [139]. The fact that RLPs’ 
resemble the structure of the native virus means that lower doses of 
antigens are required to elicit a protective response when compared to 
subunit vaccines. For these reasons, RLPs may constitute a viable 
alternative to commercial live attenuated vaccines (RotaTeq®, Merck & Co. 
and Rotarix®, GlaxoSmithKline), which have recently raised efficacy 
concerns in developing countries such as Bangladesh and South Africa 
[140].  
RLPs are normally expressed in the baculovirus/insect cell system either 
using co-infection strategies, where cells are infected with three 
monocistronic baculoviruses enclosing the genes coding for vp2, vp6 or 
vp7, or single-infection strategies, where cells are infected with one 
tricistronic recombinant baculovirus enclosing the genes coding for the 
three viral proteins simultaneously. In single-infection strategies, different 
promoters may induce different expression levels at more convenient times 
for correct particle formation; hence, further optimizations are possible 
through vectors redesign at the promoters’ level. On the other hand, in co-
infection strategies, it is likely that productivities may be highly improved 
through manipulation of key process parameters (MOI, TOI and CCI); this 
poses an optimal control problem requiring an accurate dynamical model of 
the critical events involved in protein expression and RLP assembly. 
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4.2. The fate of an insect cell upon baculovirus infection 
RLP production in the baculovirus/insect cell system involves a number of 
intra- and extra-cellular steps, molecular interactions and genetic regulation 
mechanisms that determine the efficacy of the overall process (Figure 4). 
The process can be divided into the following phases: 
Phase 1. Virus infection and trafficking  
The process begins with the binding of monocistronic or tricistronic 
baculoviruses, enclosing the genes coding for rotavirus vp2, vp6 and vp7, 
to Sf-9 cells membrane, a process mediated by cell surface receptors. 
About 50% of the viruses reach the host cell nucleus; the remaining viruses 
are degraded in lysosomes [141]. 
Once inside the nucleus, viruses and host cell compete for the control of 
the cell’s well-organized and programmed transcriptional machinery, strictly 
regulated for carrying out host processes. To gain control, viruses 
selectively inhibit host cell transcription or eliminate host mRNA. Although 
encoding their own RNA polymerase and transcriptional factors, activators 
and enhancers, baculoviruses require the host RNA polymerase for the 
transcription of early genes, essential for initiation of vDNA replication, and 
expression of anti-apoptotic genes.  
Phase 1 - Stage 1. Early genes (immediate and delayed) 
The expression of early genes occurs immediately upon infection (≤ 2 hpi), 
without requiring de novo synthesis of other virus gene products. The 
immediate early (ie)-1 transcriptional activator starts the transcriptional 
cascade, initiating the replication of baculoviruses. 
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Figure 4. Genetic/molecular regulatory network of RLPs production in the baculovirus/insect 
cell system. The arrows  and  represent transport of material and interaction 
between structures, respectively. In each genetic regulation networks, the line  and the 
arrows  and  indicate an interaction between two genes, the stimulation of one gene 
by a second gene and the stimulation of one gene by itself, respectively. The genes directly 
involved in vDNA replication and transcription are underlined. 
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Other genes involved in this process are the ie-0, ie-2, p143, 39K, anti-
apoptotic p35 genes, viral DNA polymerase (dnapol) and pe-38 (Table 3). 
Phase 1 - Stage 2. Anti-apoptotic genes 
It is upon the expression of ie-1 that increased programmed cell death 
(apoptosis) is observed. Two explanations are possible: 1. apoptosis is 
triggered after vDNA replication due to the expression of ie-1 and also late 
genes; 2. vDNA replication triggers apoptosis by damaging the host cell 
DNA or by disturbing the insect cell cycle. Apoptosis can be delayed by the 
expression of anti-apoptotic genes such as the p35 and the inhibitor 
apoptosis genes.  
Phase 2. vDNA replication  
Replication of vDNA starts in the late phase (~ 6 hpi) after the expression of 
essential genes in the early phase; it relies on six viral genes: ie-1, p143, 
late expression factor (lef)-1, lef-2, lef-3 and dnapol. The dnapol is the 
enzyme involved in initiating vDNA replication; in its absence no vDNA 
replication is observed. The DNA binding proteins, lef-11, ME53, lef-7 and 
pcna, although not essential, are also involved in the process of vDNA 
replication.  
Phase 3. Late gene expression 
The transcription of vDNA into mRNA and the expression of late genes 
occurs in this phase, concurrently with the onset of vDNA replication. There 
are 19 genes implicated or affecting late gene transcription [142]: four 
genes are components of the viral-encoded late RNA polymerase complex 
(lef-4, lef-8, lef-9 and p47); six genes are involved in vDNA replication (ie-1, 
lef-3, p143, lef-1, lef-2 and dnapol) and nine genes indirectly stimulate late 
transcription (p35, ie-2, 39K, lef-5, lef-6, lef-7, lef-10, lef-11 and lef-12). 
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A percentage of the replicated vDNA is encapsidated in this phase, 
resulting in new virions, which then bud from the host cell. Progeny virus 
budding is known to begin around 16 hpi and endures for almost 36 h [43]; 
the newly budded viruses are able to start a second round of infection. The 
packaging of vDNA and the assembly of nucleocapsids is controlled by the 
very late factor (vlf)-1; its absence induces the formation of aberrant tube-
like capsids. The way the virus senses that a genome sequence is 
complete and terminates the encapsidation process remains to be 
determined.  
Phase 4. Very late gene expression (protein biosynthesis) 
The transcription of the so-called “hyperexpressed” genes, such as those 
under the control of the polh or p10 promoters, begins at the very late 
phase of the infection cycle, around 15 hpi (see genetic regulation at the 
polh node in Figure 4). Although regulated and stimulated by the same 
transcriptional factor (vlf-1), gene expression under the control of p10 
promoter is lower and occurs earlier than the polh. This difference may be 
related with the positive effect of the FP25 protein on the transcription rate 
of the polh promoter but not on the p10 promoter. 
Phase 5. Transcription shut-down 
The shut-off of transcription may be related with the 38K gene which 
encodes a protein much similar to a set of enzymes related with the 
regulation of RNA polymerase. 
Phase 6. The assembly process of RLPs 
Newly synthesized proteins are degraded in lysosomes or enter the 
secretion pathway. Once the post-translational modifications are 
completed, the correctly folded proteins are released to the extracellular 
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matrix or assembled into RLPs. Details of the mechanisms involved in 
RLPs assembly are poorly understood; hardly any experimental information 
exists describing the assembly pathway, intra and inter-protein binding 
energies, rates and orders for assembly reactions, dissociation and 
association rates, and formation of stable structural subunits. 
4.3. Comparison of selected models 
Numerous comprehensive mathematical models have been developed for 
the baculovirus/insect cell system. A detailed description of how the most 
relevant variables of the system are addressed is presented below. 
4.3.1. Non-infected cell growth 
The kinetics of uninfected cell population, nu, is normally described using 
simple exponential growth models [43, 59, 125, 130, 132, 172-175]: 
( ) infu d udn k n vdt μ= − −       Eq. 1.1
 
where μ is the cell specific growth rate and kd the intrinsic cell death rate; 
vinf represents the decrease in uninfected cell population due to viral 
infection (see section 4.3.3 for details). 
Most correlations for the specific growth and death rate stem from a 
Monod-type equation with either the substrate [43, 107, 132, 175] 
max= +s
S
K S
μ μ
      Eq. 1.2
 
or the free surface area available for growth and the DO concentration 
( ) ( ) ( )( )max 2
,
, ,
,
L
O L
C z t
z t A z t
K C z t
μ μ
 
=   +      Eq. 1.3
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as limiting factors [125, 173]. The maximum specific growth rate is μmax, z 
the vessel section (z=1 for static operation mode), A(z,t) the dimensionless 
free area, which is dependent on the number of virus per cell, CL the 
dissolved O2 concentration and KO2 the half saturation constant. 
4.3.2. Binding and infection 
The first mathematical models describing baculovirus infection were 
published by Licari and Bailey, Power and De Gooijer in 1992 (Table 4). 
These authors observed that the number of virus infecting an individual cell 
could be described by a Poisson distribution with the mean λ = χ.MOI: 
( )
( )
( )
( )
( )exp
,
!
   
−      
=
nv
u u
v t v t
n t n t
P t nv
nv
χ χ
    Eq.1.4
 
where P(t,nv) is the probability of nv virus infecting a cell at time t, χ is a 
factor describing the effectiveness of infection (virus binding to the cell 
receptors and entry by endocytosis) and v is the virus concentration. 
An important aspect in these models is the definition of the time for the 
onset of virus synthesis, τv, which was considered to be a function of the 
number of viruses infecting a given cell population: 
( ) ( ),max ,min,max
max
1
1
− 
= − − 
− 
v v
v vnv nvnv
τ τ
τ τ     Eq. 1.5
 
where τv,min and τv,max are the mathematical lower and upper bounds for the 
initiation of virus synthesis. Moreover, the virus synthesis was assumed to 
endure for Δτv hours at a constant rate, kv.  
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Table 4. Mathematical models describing the baculovirus infection process. 
References  Virus attachment Virus synthesis Additional terms  
Licari and Bailey (1992) 
and 
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dv
dt inf
− ×nv v
 ( ) ( )
( )
( )
ττ
ττ
τ
dnvtvktA
vv
v
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Power et al. (1992) =
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dt
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Maranga et al. (2003) =
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A – A(1,t)=0 in De Gooijer et al. (1992); B – virus decomposition term; C – physical term of the system; D – Re-infection term; dv/dt – 
extracellular concentration of baculoviruses per unit of time; αb and βb - fitted parameters; nb - number of uninfected cells plus cells 
infected for less than 15-20 h; φ - proportion of successful collisions between virus particles and cells; R - host cell radius; k - Boltzmann’s 
constant; T – temperature; η - viscosity of the medium; r - virus particle radius; kr – infection rate constant; Kv –saturation-like parameter; a 
– surface area for growth per unit reactor volume; ka – experimental measured attachment rate constant; ϕ - efficiency factor (reflect the 
dependency of the binding rate upon the medium matrix composition); B – is a slope constant, C – is the time at which 50% of the 
response is reached; D – is the maximum bound virus; kads - virus depletion rate due to infection; kprod – virus budding rate; ξ - the 
dependency of extracellular virus on the physical system; θ - time windows for re-infection; S - rate-limiting substrate; Ks –Monod constant. 
In 1994, Power and co-workers included in their model the concept of virus 
decomposition constant, kdv; virus attachment was also modified, being 
described by an empirical function dependent on virus concentration. In 
1996, they used the Valentine and Allison model [176] to estimate the 
attachment of viruses to insect cells. Although neglecting the dependency 
between virus adsorption rate and virus concentration, results were 
consistent with the ones published previously.  
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Kumar and Schuler (1995) described virus formation using a Michaelis-
Menten equation: at low virus concentration, virus synthesis follows a first-
order kinetics as observed in static cultures [34] whereas at high 
concentration, a zero-order kinetics best describes the synthesis of new 
virions in suspension cultures [172]. In Petricevich et al. (2001), virus 
synthesis was modelled using the derivative of a sigmoidal curve [177]. 
The Dee and Schuler trafficking model is the most complete mathematical 
description of the baculovirus infection process [130, 178]. It includes 
receptor trafficking, binding, internalization, endosomal fusion and transport 
to nucleus. Virus production was not addressed in these studies.  
In Jang et al. 2000 [136], an extra parameter ξ is used to account for the 
dependency of virus production on the physical system (culture volume, 
medium flux…). In batch cultures, this parameter is tuned to zero; in fed-
batch cultures, ξ is a function of input and output fluxes.  
None of the aforementioned deterministic models considered re-infection 
as a critical factor for progeny virus synthesis. Re-infection was only 
considered in Hu and Bentley’s models [43, 107]. The re-infection rate was 
assumed to decrease linearly with time, consistent with experimental 
observations [178], and the probability of an infected cell being re-infected 
was described by a Poisson distribution function: 
( )
( )
( )
( )
( )inf infinf inf
inf
exp
,
!
− −
−
   
−      
=
nv
re re
re
v t v t
n t n t
P t nv
nv
χ χ
   Eq. 1.6
 
where χre-inf is a factor describing the effectiveness of re-infection. The 
effect of infected cell’s metabolic state, amount of internalized virus and 
nutrient’s concentration on progeny virus synthesis was also incorporated 
in the model (Table 4). 
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In Gotoh et al. (2004), progeny virus synthesis is described by the Weibull 
distribution function instead of the traditional Poisson distribution: 
( ) ( ) 









−
−
=
i
ii
i
etP
i
i
ii
ρ
σ
τ
ρ
ρ τσ
ρ
σρ 1,,       Eq. 1.7
 
where ρi and σi are calculation parameters. To account for the cell density 
effect on virus synthesis rate, a dimensionless factor was also included: 
lowhigh
ICDhigh
act XX
XX
f
−
−
=         Eq. 1.8
 
where XICD is the cell concentration at the t=0, and Xlow and Xhigh are the 
lower and upper bound of uninfected cell concentration, respectively.  
4.3.3. Infected cell population 
The equation describing the infected cell density, ninf, consists of two terms: 
one for the increase in infected cells concentration due to binding of 
baculoviruses to uninfected cells and a second to represent the cell death. 
The increase in infected cells due to infection is generally described by: 
=
inf
a u
dn
k n v
dt      
  Eq. 1.9
 
where ka is the attachment constant of virus to uninfected cells [174]. In 
Maranga et al. (2003), an extra parameter was added (ϕ) to cope with the 
dependency of the binding rate upon the medium matrix composition. On 
the other hand, Kumar and Schuler (1995) considered that the infection 
rate was saturable in virus concentration: 
( ) ( ) ( )( )
, ,
,
,
=
+
inf
r u
v
dn z t MOI z t
k n z t
dt K a MOI z t
 
 
  Eq. 1.10
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In Licari and Bailey (1992), Hu and Bentley (2000, 2001) and Gotoh et al. 
(2004), the infected cell population was described using a frequency 
function:  
( ),=inf udn P t nv ndt    
   Eq. 1.11
 
where P(t,nv) is given by the Poisson or the Weibull distribution function.  
The loss of infected cells due to infection can be represented by:  
= −
inf
d inf
dn
k n
dt      
  Eq. 1.12
 
where kd is the death rate of an infected cell. The kd was assumed constant 
throughout the infection process in Gotoh et al. (2004). In contrast, Power 
et al. (1992) and Hu and Bentley (2000, 2001) described kd as a function of 
the time a cell has been infected. This implies that kd is constant at kd1 from 
time of infection until the time when rapid death of the population has been 
observed experimentally (td); upon this threshold, the rate increases 
significantly (kd2). The td has been described as a constant [174] or as 
dependent on the MOI [43, 107]. 
4.3.4. vDNA and mRNA 
The intracellular dynamics of vDNA was defined by Jang et al. (2000) as:  
, ,= + − − ×dna inf dna rep bud
ddna r r r dna
dt
ξ     Eq. 1.13 
where rdna,inf represents the rate of infection (i.e. number of viruses 
penetrating uninfected and infected cells within a specific time interval), 
rdna,rep the vDNA replication rate, rbud the virus budding rate and ξ a 
parameter accounting for the loss of vDNA templates due to the physical 
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system. Remaining models describing the replication of vDNA neglect the 
influence of virus budding on the levels of intracellular vDNA [68, 179]. 
The dynamics of vDNA transcription into mRNA was defined as:  
,= − ×rna s
drna r rna
dt
ξ
      Eq. 1.14
 
where rrna,s is the formation rate of mRNA [136]. In both kinetics, vDNA 
replication and transcription, Jang and co-workers assumed that all the 
rates were constant throughout the process. 
4.3.5. Protein synthesis 
The net synthesis of heterologous protein can be defined by:  
, , ,= − − − ×prot s prot d prot sec
dprot r r r prot
dt
ξ    Eq. 1.15 
where rprot,s is the protein synthesis rate, rprot,d the protein degradation rate 
and rprot,sec the protein secretion rate. 
Most models describe the protein synthesis rate as a constant [42, 136, 
173-175, 177, 180-182]; others explicitly describe it as a function of 
process-related parameters: 
( ) ( ), (1, )= −prot s L pr A tnv nv
ζ
τ τ
 
Ref.: [125] Eq. 1.16
 
, , ( )
Δ + −
=
Δ +
p p
prot s prot s
p s
Sr k f nv
K S
τ τ τ
τ
Ref.: [43, 107] Eq. 1.17
 
( ), , ,=prot s prot s ur k P t nv n  Ref.: [132] Eq. 1.18 
where ζ is the maximum quantity of foreign protein produced per cell, τL 
and τp the times post-infection for the onset of cell lysis and protein 
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synthesis, respectively (which are a function of the number of viruses 
infecting a given cell population – similar to τv - Eq. 1.6), kprot,s the protein 
synthesis constant and Δτp the time-window over which recombinant 
protein is produced. 
The protein degradation rate is written as rprot,d = kprot,d × prot, where kprot,d 
is the degradation constant [132]. The quantity of protein secreted to the 
extracellular medium is proportional to the concentration of intracellular 
protein and constrained in time [τLK,τL] (τLK is the time post-infection at 
which leakage begins); hence, rprot,sec = rprot,sec × prot, where kprot,sec is the 
protein secretion constant [125]. 
4.3.6. The assembly of VLPs 
The assembly of complex protein structures composed by several protein 
subunits is poorly understood. Little experimental information exists 
describing intra and inter-subunit binding energies, rates and orders for 
assembly reactions, and formation of nucleating structures.  
So far, there are two models dealing with VLP formation in the baculovirus/ 
insect cell system [43, 59, 107]. In Maranga et al. (2003), a mathematical 
model was developed to account for the effects of virus multiplicity, cell 
concentration and nutrient limitations on VLP productivity; no detailed 
description of the assembly process is formulated. The Hu and Bentley 
model is the only one that tries to describe the assembly of VLPs; it uses a 
thermodynamic equilibrium based approach where the Gibbs free energy of 
subunit association and concentration of viral protein subunits are key 
factors for the efficiency of the overall process.  
Nevertheless, the mathematical modelling of VLP formation in the 
baculovirus/insect cell system is not a closed chapter, especially in what 
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concerns post-infection intracellular dynamics. Probably due to the lack of 
knowledge and experimental evidence on viral genes expression 
regulation, there are no stuructured dynamic models in the literature that 
describe early, late and very late gene expression cascade upon infection. 
Moreover, VLP formation is ruled by thermodynamic and kinetic factors. 
While a few studies addressed the assembly of simple structures, the 
complexity of multi-layered particles has never been attempted before. 
 
5. SCOPE OF THE THESIS 
The secret to overcoming the bioengineering challenges imposed by the 
production of RLPs in the baculovirus/insect cell system is to define 
properly the main steps involved in the overall process, identify the main 
factors affecting each individual step and delineate optimization schemes 
capable of maximizing the objective function – RLP production (Figure 5). 
The diversity of protein structures observed at the end of RLP production 
runs indicates that the assembly process is highly inefficient (Figure 6). 
Contaminants such as trimers of vp6 and vp7, vp6 tube-like structures, 
single-layered vp2 particles, double layered particles of vp2 and vp6 (DLPs) 
or RLPs lacking one or more subunits represent almost 88% of the total 
mass of proteins expressed. 
To understand the entirety of the processes happening during the 
production of a RLP, from the genetics of the viral vector to the infection 
strategy, titer and structure of assembled particles, a bottom-up Systems 
Biology approach was pursued. 
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Figure 6. Electron micrograph of negatively stained RLPs (A), DLPs (B), single-layered vp2 
particles (C) and vp6 tube-like structures (D) [81]. Scale bars correspond to 100 nm. 
A basic requirement for data generation, modelling and optimisation of the 
baculovirus/insect cell system is measuring and controlling the MOI, which 
is the most important manipulated variable in this process. Unfortunately, 
measuring baculovirus titers is costly and inaccurate while the ability to 
control MOI to sufficient accuracy is still debatable. As such, this Thesis 
starts (Chapter 2) with a comparative study of titration methods in what 
concerns accuracy, cost and work intensity. The most critical issues of 
each method were identified and suggestions of improvements were 
presented. 
Mathematical models for in silico baculovirus/insect cell simulation and 
prediction of protein synthesis and self assembly of polyhedral protein 
complexes were developed. The present thesis integrates a complex 
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network of mathematical/statistical model formulations (stochasticity, 
segregation, molecular scale, kinetics and thermodynamics), with 
experimental intra- and extra-cellular data (vDNA replication, very late 
transcription, protein synthesis and RLP formation). It adresses the most 
relevant mechanisms of the baculovirus/insect cell system for recombinant 
protein production and self assembly of proteins, namely: 
• Stochastic vs deterministic infection: the attachment of baculoviruses 
to insect cell’s membrane was described as a stochastic process. This 
allowed studying the differences between deterministic and stochastic 
infection and the implications of stochastic infection on protein 
expression at high and low MOIs (Chapter 3); 
• Segregated infected cells: due to random baculovirus entry into insect 
cells, each infected cell undergoes distintictive infection dynamics with 
impact on viral proteins expression and RLP syntehisis. To take this 
effect into account, population models were developed (Chapter 3); 
• Thermodynamic RLP assembly: a thermodynamic equilibrium-based 
model describing the assembly process of RLPs. A detailed in silico 
analysis of the biophysical mechanisms involved in the assembly 
process and their controllability is presented (Chapter 4); 
• Infection strategy: a deterministic structured model was developed to 
analyze the relevant intracellular events (baculovirus trafficking, vDNA 
replication, mRNA synthesis, protein expression and RLP assembly) 
and their variability with the MOI at different infection strategies (single- 
and co-infection) (Chapter 5); 
In silico analysis of the baculovirus/insect cell system was performed in 
what concerns the sensitivity of RLPs and constitutive proteins 
concentration in relation to model parameters (Chapters 6) and to process 
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degrees of freedom such as the MOI or the Gibbs free energy of protein 
subunit association (Chapters 3 to 6). It should be noted that the latter 
parameter can be considered as an indirect process degree of freedom as 
it can be manipulated to some extent by designing the environment for 
protein assembly. 
The theoretical effect of MOI and promoter strength on RLP production, at 
single- and co-infection strategies, was explored using the in silico 
stochastic model developed in Chapter 3. Optimal culture conditions for 
RLP production were determined and potentially better infection strategies, 
capable of increasing RLP yields, were proposed (Chapters 6). 
Summarizing, this thesis provides a set of computational models of the 
baculovirus/insect cell system to assist the development of novel and 
improved optimization schemes for production of virus particles, viral 
proteins and/or complex protein structures such as virus-like particles. 
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Summary  
The success of baculovirus/insect cells system in heterologous protein 
expression depends on the robustness and efficiency of the production 
workflow. It is essential that process parameters are controlled and include 
as little variability as possible. The multiplicity of infection (MOI) is the most 
critical factor since irreproducible MOIs caused by inaccurate estimation of 
viral titers hinder batch consistency and process optimization. This lack of 
accuracy is related to intrinsic characteristics of the method such as the 
inability to distinguish between infectious and non-infectious baculovirus. In 
this study, several methods for baculovirus titration were compared. The 
most critical issues identified were the incubation time and cell 
concentration at the time of infection. These variables influence strongly the 
accuracy of titers and must be defined for optimal performance of the 
titration method. Although the standard errors of the methods varied 
significantly (7% to 36%), titers were within the same order of magnitude; 
thus, viral titers can be considered independent of the method of titration. A 
cost analysis of the baculovirus titration methods used in this study showed 
that the alamarblue, real time Q-PCR and plaque assays were the most 
expensive techniques. The remaining methods cost on average 75% less 
than the former methods. Based on the cost, time and error analysis 
undertaken in this study, the end-point dilution assay, microculture 
tetrazolium assay and flow cytometric assay were found to be the 
techniques that combine better all these three main factors. Nevertheless, it 
is always recommended to confirm the accuracy of the titration either by 
comparison with a well characterized baculovirus reference stock or by 
titration using two different methods and verification of the variability of 
results. 
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1. INTRODUCTION 
Heterologous protein expression implies the introduction of a recombinant 
gene into an expression host cellular system using appropriate vector 
systems allowing the maintenance and the expression of the gene of 
interest in the host cell. Within the different systems available today, the 
baculovirus/insect cells system has gained interest due to its high 
expression capacity and easy culture conditions. Nonetheless, its success 
depends on the robustness and efficiency of the production workflow. For 
this purpose, the critical process parameters must be controlled. The 
multiplicity of infection (MOI) is the most critical factor since irreproducible 
MOIs caused by inaccurate estimation of viral titers have a profound impact 
on the process performance and batch consistency. Indeed, under-
estimated titers result in higher MOIs than expected, thus leading to a 
severe metabolic burden effect which causes low protein productivity. 
Similarly, overestimated titers result in low production levels due to non-
synchronous infection [1]. Thus, the selection of a titration method capable 
of distinguishing between infectious and non-infectious virus is essential to 
reduce errors of titers and MOI variability. 
Traditional baculovirus titration methods are based on cell viability [2-4], 
plaque infectivity [5-7] and antibody-based assays [8; 9]. Within cell based 
methods, end-point dilution (TCID50), microculture tetrazolium (MTT), cell 
size and growth cessation assays are used most commonly. All these 
methods rely on cellular morphological changes caused by infection such 
as the decrease of cell viability and the increase of cell size. The extent of 
those phenomena is dependent on the virus dose and thus can be 
correlated with viral titers. The main advantage of plaque infectivity assay 
over cell based methods is the production of countable events, namely 
plaque forming units (pfu) per ml, which is the appropriate form to represent 
viral titers. However, the specificities of this method make difficult the 
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assessment of accurate viral titers. Antibody-based methods present even 
greater challenges since in many cases immunoreagents and antibodies 
against baculoviral proteins are not available commercially or are very 
expensive. All these methods, directly or indirectly, rely on host and cell-
specific infectivity, yielding significant errors due to their semi-quantitative 
nature.  
In an effort to increase accuracy, cell viability techniques using reporter 
proteins [10] and colorimetric indicators [11] have been developed. The 
use of fluorescent proteins such as the green fluorescent protein (GFP), 
which expression results from viral infection, improves the detection of 
infected cells (green fluorescence foci) and reduces both the viral titer 
variability and the titration time. Likewise, the use of dyes, such as the 
alamarBlue®, allows more rapid estimation of titers than standard cell 
viability assays since the correlation between cytopathic effect caused by 
infection and titer is assessed easily. Nonetheless, neither the presence of 
reporter proteins is always desirable nor the use of expensive dyes is 
always feasible. In addition, these techniques are labour intensive. Thus, 
novel baculovirus titration methods using real time Q-PCR [12-14] and flow 
cytometry [15-17] were developed recently. Real time Q-PCR assay is 
based on the intensity of a fluorescent signal generated during PCR 
amplification. By comparing the signal intensity obtained for standards of 
known viral concentrations with the signal intensity of the viral stock 
sample, viral titers are estimated. However, this requires the design of 
primers targeting a specific strand of nucleic acids corresponding to the 
protein of interest and the respective standards, which can be very 
complex. In addition, artefacts such as primer-dimers and defective 
interfering particles (non-infectious particles) decrease the accuracy of the 
titers measured. Flow cytometric assays involve the staining of viral 
genome or coat proteins of baculovirus with highly fluorescent specific 
dyes. The fluorescence intensity of stained virus stocks when compared 
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with the fluorescence intensity of calibration standards allows the 
estimation of viral titers. However, the lack of sensitivity, instability and 
insolubility in aqueous media of many dyes compromise the accuracy of 
titers. Some dyes are also difficult to synthesize and expensive. Recently, 
Kärkkäinen et al. (2009) developed a titration method able to correlate the 
percentage of cells expressing GFP to the baculovirus titers calculated by 
TCID50. The disadvantage of this technique is the fact that it involves the 
expression of a reporter protein which is not desirable for protein production 
processes designed for human use. 
In summary, some titration methods show great potential to reduce the 
variability of viral titers but do not decrease the labour and titration times 
significantly. On the other hand, other methods reduce labour and titration 
time, but do not improve the accuracy of the method of titration. These 
inconsistencies stress that no method is ideal per se and the diversity of 
methods is still large. Indeed, depending on the virus/system specificities 
and available financial/technical resources, the proper titration method to 
use may differ. It is important that the selected method estimates viral titers 
with sufficient accuracy to control better the MOI. A comparative study to 
evaluate the accuracy of titers and cost/time-effectiveness would be 
valuable considering the enormous diversity of existing titration techniques. 
In this study, recombinant Autographa californica multiple nucleopoly-
hedrovirus (AcMNPV) were amplified by infecting Spodoptera frugiperda 
Sf-9 cells at an MOI of 0.01 pfu/cell and titrated using different methods 
(Figure 7). Mathematical formulations and statistical tools were used to 
determine and compare the titers obtained by each method. Specificities 
and inter-relationships between various methods were studied to determine 
the method presenting the best association between time, cost and 
accuracy. 
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Figure 7. Overview of recombinant baculovirus titration methods and time required to 
perform each method.  
 
2. MATERIALS AND METHODS 
2.1. Cell culture and baculovirus amplification 
Sf-9 and Sf-21 cell lines were obtained from American type culture 
collection (ATCC, Washington D.C., USA) and were cultivated in serum 
free media SF900II (Gibco, Glasgow, UK) at 27 ºC in 500 ml erlenmeyers 
(50 ml working volume) (Duran, Mainz, Germany) stirred at 90 rpm and 
diluted routinely every four days using an inoculum of 0.3×106 cell/ml. 
Recombinant AcMNPV coding for the main rotavirus proteins, vp2 (102.7 
kDa [18]) fused to GFP, vp6 (44.9 kDa [19]) and vp7 (37.2 kDa [19]), were 
amplified by infecting Sf-9 cells at a cell concentration of 1×106 cell/ml and 
MOI of 0.1 pfu/cell in 250 ml working volume spinner flasks (Wheaton 
Science, New Jersey, USA) stirred at 150 rpm and at 27 ºC. Baculoviruses 
were harvested at 60-70% of cell viability, approximately 96-120 hours 
post- infection (hpi), by centrifugation at 200 × g for 15 min at 4 ºC and viral 
stocks were prepared. Stock A and B correspond to baculovirus coding for 
vp2-GFP, stock C for vp6 and stock D for vp7. The baculovirus were kindly 
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provided by Dr. Jean Cohen (Centre National pour la Recherche 
Scientifique-Institut National Recherche Agronomique, Gif-sur-Yvette, 
France). All genes were under the control of the polyhedrin promoter.  
2.2. Baculovirus titration methods 
2.2.1. TCID50 for baculovirus with and without GFP 
Different end-point dilutions were used. Stocks of baculovirus coding for 
rotavirus proteins fused to GFP (Stock A and B) were titrated according to 
Cha et al. (1997) whereas those without GFP (Stocks C and D) were 
titrated based on standard protocols [7; 20; 21]. 
In the TCID50 method for baculovirus with GFP, the detection of infection is 
easier and more rapid than in standard methods since green fluorescence 
foci are indicative of infection. Briefly, 10 μl of viral stocks diluted 10-2 to 10-8 
times were added to 100 μl of 1×105 cell/ml Sf-9 cells seeded previously 
onto a 96-well tissue culture plate (Sarstedt, Newton, USA). Plates were 
incubated at 27 ºC for four to five days and checked for infection using a 
Leica DM IRB inverted microscope (470/480nm wavelength) (Leica 
Microsystems, Wetzlar, Germany).  
TCID50 for baculovirus without GFP was based on standard methods. 
Briefly, 100 μl of 2×105 cell/ml Sf-9 cells were seeded onto a 96-well tissue 
culture plate (Sarstedt, Newton, USA) and allowed to settle for 1 h at 27 ºC. 
In each well, 10 μl of viral stocks diluted 10-2 to 10-8 times were added. 
Plates were incubated at 27 ºC for seven days and cell morphology was 
observed using a Leica DM IRB inverted microscope (Leica Microsystems, 
Wetzlar, Germany). Positive/negative wells were determined based on the 
increase of the diameter of the cell and on inhibition of cell growth. 
However, since these morphological changes are difficult to observe by an 
“untrained eye”, a second round of infection was necessary. Therefore, 20 
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μl of each viral suspension was added to 80 μl of Sf-9 cells (2.5×105 cell/ml) 
seeded previously onto a 96-well tissue culture plate (Sarstedt, Newton, 
USA). Plates were incubated at 27 ºC for four additional days and 
visualized using a Leica DM IRB inverted microscope (Leica Microsystems, 
Wetzlar, Germany) for detection of foci of infection.  
Virus titers were calculated using the mathematical equations described by 
Reed and Muench (1938), Possee and King (1992) and Darling et al. 
(1998) (see Table 5). 
2.2.2. MTT assay 
The cell viability assay was performed as described by Mena et al. (2003). 
Briefly, 100 μl of 5×105 cell/ml of Sf-21 cells were seeded onto a 96-well 
tissue culture plate (Sarstedt, Newton, USA) and were allowed to settle for 
1 h at 27 ºC. Supernatant was removed and 100 μl of viral stocks diluted 
10-1 to 10-10 times was added per well and plates incubated six days at 27 
ºC. Thiazolyl blue tetrazolium bromide (Sigma-Aldrich, St. Louis, USA) was 
added (10% (v/v) of total volume per well at 5 mg/ml) and plates incubated 
at 27 ºC for 4 h. The supernatant was removed and formazan crystals 
solubilised by adding 150 μl/well of dimethyl sulfoxide (Sigma-Aldrich, St. 
Louis, USA). Plates were agitated for 10-20 min in a wellmix shaker WM-
506 (Denley, Needham, USA) and absorbance (570/690nm wavelength) 
measured using a SPECTRAmaxTM microplate reader (Molecular Devices 
Corporation, Sunnyvale, USA).  
Collected data was analyzed using Prism 4 for Windows (GraphPad 
Software Inc., La Jolla, USA) to determine the tissue culture lethal dose 50 
(TCLD50) (see Table 5). The conversion of TCLD50 to viral titers (pfu/ml) 
was carried out using the mathematical regressions reported in this study 
(see section 2.2.1) and in Mena et al. (2003). 
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2.2.3. Alamarblue assay  
In this study, an experimental design similar to that described by Pouliquen 
et al. (2006) was adopted. Briefly, 100 μl of 3×104 cell/ml Sf-21 cells seeded 
previously onto a 96-well tissue culture plate (Sarstedt, Newton, USA) were 
infected with 100 μl of serial dilutions (1/2 to 1/1458 times) of virus stock. 
AlamarBlue® (Sigma-Aldrich, St. Louis, USA) was added to plates (10% 
(v/v)) and plates were incubated at 27 ºC. The percentage of alamarBlue® 
reduction at 0 and 24 hpi was determined by measuring the fluorescence 
intensity and absorbance with an FL500 microplate fluorescence reader 
(530excitation/590emissionnm wavelength) (Bio-Tek Instruments, Winooski, USA) 
and a SPECTRAmaxTM microplate reader (570/690nm wavelength) 
(Molecular Devices Corporation, Sunnyvale, USA), respectively, for t0 and 
t24 values assessment.  
Data was analyzed by Prism 4 for Windows (GraphPad Software Inc., La 
Jolla, USA) and titers calculated using the mathematical equations 
described by Pouliquen et al. (2006) (see Table 5). 
2.2.4. Cell size assay 
Viral titers can be estimated based on the increase of the diameter of cell 
caused by infection as described by Janakiraman et al. (2006). Briefly, 10 
ml of Sf-9 cells at 1×106 cell/ml cultured in 125 ml erlenmeyers (20ml 
working volume) (Duran, Mainz, Germany) at 27 ºC were infected with 10 
ml of viral serial dilutions ranging from 10-1 to 10-4 times. Samples at time 0 
and 24 hpi were collected and the viable cell diameter and the 
concentration were measured using a Casy®1 Cell counter plus Analyzer 
System Model TTC (Innovatis AG, Reutlingen, Germany).  
Viral titers were determined using the solver function in Microsoft excel 
(Microsoft®, Redmond, USA) by applying different methods for parameter 
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estimation: method of moments, maximum likelihood estimates and the 
logistic function (see Table 5).  
2.2.5. Growth cessation assay 
Cells normally stop growing immediately after infection at MOIs higher than 
5 [22; 23]. Viral titers can be determined using this property since the 
inhibition of cell growth is dependent on the virus dose and thus related to 
the amount of virus infecting a given cell population. Briefly, 10 ml of Sf-9 
cells at 1×106 cell/ml cultured in a set of 125 ml erlenmeyers (20ml working 
volume) (Duran, Mainz, Germany) were infected with 10 ml of virus serial 
dilutions ranging from 10-1 to 10-4 times. Positive and negative controls 
corresponding to cells infected with undiluted virus stock and to uninfected 
cells, respectively, were also performed. Erlenmeyers were incubated for 
20-24 h at 27 ºC and cell concentration determined by counting cells on a 
fuchs-rosenthal haemocytometer (Brandt, Wertheim/Main, Germany) using 
the trypan blue exclusion dye (Merck, Darmstadt, Germany) method or by 
Casy®1 Cell counter plus Analyzer System Model TTC (Innovatis AG, 
Reutlingen, Germany).  
Raw data was analyzed using the 4-parameter method, which assumes a 
sigmoidal inhibition curve with lower and upper asymptote and an 
estimated TCID50, implemented in microsoft excel (Microsoft®, Redmond, 
USA) and solved using the solver function. Viral titers were estimated by 
multiplying the ratio seeding density/TCID50 by the conversion factor 0.69 
[7] (see Table 5). 
2.2.6. Real time Q-PCR 
Titers can be estimated within a couple of hours (2 to 3 h) using real time 
Q-PCR as described by Vieira et al. (2005). Briefly, viral DNA extraction of 
samples from stocks A to D was performed using the high pure viral nucleic 
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acid kit (Roche Diagnostics, Mannheim, Germany). Purified baculovirus 
DNA were analyzed by real-time quantitative PCR in LightCycler®1.5 
instrument (Roche Applied Science, Indianapolis, USA) using Fast start 
DNA master SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) 
and sequence-specific primers for the genes coding for the viral proteins 
vp2, vp6 and vp7 [13]. For each recombinant baculovirus stock, viral titers 
were estimated in pfu/ml using the standard calibration curve of cross 
points vs log concentrations of the purified DNA standard with known 
concentration (pfu/ml). 
2.2.7. Plaque assay 
The plaque assay technique was carried out as described by Possee and 
King (1992). Briefly, 2 ml of Sf-21 cells at a concentration of 1×106 cell/ml 
were seeded onto a NunclonTM Surface 6-well plate (Nunc®, Langenselbold, 
Germany) and allowed to attach for 1 h. Meanwhile, serial viral dilutions 
were prepared (10-5 to 10-8 times) in serum free media SF900II (Gibco, 
Glasgow, UK) supplemented with 10% of fetal calf serum (Gibco, Glasgow, 
UK). The supernatant was removed and 500 μl of virus dilutions were 
added to the plates. Plates were incubated at 27 ºC for 1-4 h, the time 
period needed for virus adsorption and internalization [24] before removal 
of the supernatant. Two millilitres of an agarose overlay (1 part 3% (w/v) 
SeaPlaque® low gelling temperature agarose (Cambrex Bio Science 
Rockland, Inc., Rockland, USA) plus 2 parts serum free media SF900II 
(Gibco, Glasgow, UK) supplemented with 10% of fetal calf serum (Gibco, 
Glasgow, UK)) were added to each well. Plates were incubated for 3 to 4 
days at 27 ºC, before staining with 500 μl of Neutral Red (Sigma-Aldrich, 
St. Louis, USA). Any excess of Neutral Red was removed 24 h later and 
plates were further incubated at room temperature for plaque visualization. 
Titers were estimated according to the method described by Possee and 
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King (1992) (see Table 5).  
2.2.8. Flow cytometry assay 
In this study, viral titers of stocks A and B were estimated by flow cytometry 
using a mathematical equation that correlates the percentage of cells 
expressing GFP with the concentration of baculovirus at infection [15]. 
Baculovirus stocks C and D do not express any reporter protein and were 
not considered for titration by flow cytometry. Briefly, 500 μl of Sf-9 cells at 
1.5×106 cell/ml seeded onto 2.2 ml storage plates (ABgene Limited, Epsom, 
UK) were infected with 500 μl of serial virus dilutions. It is important to 
stress that virus dilutions must be carefully selected since only those which 
induce a percentage of cells expressing GFP bellow 10% are considered 
for titer calculation. Thus, for titers estimated to be around 108 pfu/ml, 
dilutions from 1/300 to 1/9600 times are preferable while for those around 
107 pfu/ml, the ideal dilutions are 1/150 to 1/4800 times. After incubation of 
plates at 27 ºC for 18 h in an IKA KS 260 orbital shaker at 370 rpm (Sigma-
Aldrich, St. Louis, USA), cell suspensions were transferred to 3.5 ml tubes 
(Sarstedt, Newton, USA) and the percentage of cells expressing GFP 
determined using a CyFlow® space flow cytometer (Partec, Görlitz, 
Germany).  
Titers were estimated according to the method described by Kärkkäinen et 
al. (2009) (see Table 5).  
2.3. Statistical analysis 
For each viral stock (A-D) and titration method used in this study, replicates 
were performed, varying from a minimum of n = 3 to a maximum of n = 11. 
All titers were expressed as the mean ± standard deviation (SD). A 
statistical hypothesis test was used to evaluate if the titers estimated by 
each method were equal or not: H0 (Null hypothesis): titerMethod1 = titerMethod2 
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= … = titerMethod9 versus H1 (alternative hypothesis): not all titers were equal. 
The correct statistical test to use considering the number of methods 
involved was the one-way ANOVA. This analysis was based on the 
assumption that errors were independently, identically, and normally 
distributed. We could confirm this by performing two tests: 1) the Shapiro-
Wilk test to confirm that the distribution of values in each method followed a 
normal distribution – the normality is verified for p-value (p) > a = 0.05; 2) 
the Levene’s test to verify that the variance of data in each method was the 
same – variances are considered equal for p > a = 0.05. After verified this 
assumption, one-way ANOVA was performed in SPSS 13.0 for Windows 
(SPSS Inc., Chicago, USA) for a level of confidence of 95% (a = 0.05). 
According to the resulting p-value, the null hypothesis was rejected (p < a = 
0.05) or not (p > a = 0.05); the higher the p-value the more evidence we 
had that titers were not statistically different. In case of rejection of H0, the 
method estimating titers statistically different from the mean was identified 
by performing a multiple comparison test – Sheffé test. This test consisted 
in comparing the titer obtained by a certain method with the remaining 
ones; for example, the titer of method 1 (M1) with M2, M1 with M3, M1 with 
M4 and thereafter. For each set of comparisons, the correspondent p-
values specified if the null hypothesis was to be rejected or not (H0: titerM1 =  
titerM2 versus H1: the two titers were not equal). The null hypothesis was 
rejected for p < a = 0.05. The method presenting p-values < a = 0.05 in all 
comparisons was that estimating titers statistically different from the mean.  
 
3. RESULTS 
3.1. TCID50 for baculovirus with and without GFP 
Based on the literature, there are two major variables that have to be 
considered when using TCID50 method [10]: cell concentration at the time 
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of infection (CCI) and virus-cell incubation time. In order to determine the 
effect of CCI on estimated titers, cells at a seeding density between 3×104 
and 4×106 cell/ml were infected with recombinant baculovirus of stocks A 
and B and titers determined as described in section 2.2.1. Our results 
showed that for CCIs between 1×105 and 1×106 cell/ml there was no 
significant difference in titers obtained for both stocks (Figure 8). To test the 
effect of the incubation time on estimated titers, independent studies were 
performed for baculovirus with and without GFP since the two titration 
protocols are based on different assumptions for identification of 
positive/negative wells. 
 
Figure 8. TCID50 method for baculovirus with GFP: effect of cell concentration at the time of 
infection (CCI) and incubation time on viral titers of stock A (A) and stock B (B). Caption 
denotes the incubation time, error bars denote standard errors and the lines represent curve 
fittings. 
In the first study for baculovirus with GFP, different incubation times were 
tested (2-8 days) using two strategies: 1. performing the infection without 
removing the supernatant of the seeded cells; 2. discarding the supernatant 
before virus addition. In strategy 1, titers varied around 18% while in 
strategy 2 titers variability reached 68%. For the incubation time, the titers 
variability of stocks A and B was on average 17% and 4%, respectively, for 
4, 5 and 6 days of incubation; for the remaining times tested, the variability 
of stocks A and B titers increased to 57% and 39% respectively (data not 
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shown). Thus, the effect of incubation time on the accuracy of titers can be 
considered negligible for the time-frame of 4 to 6 days of incubation. Based 
on these results, further experiments using the recombinant baculovirus 
with GFP (Stock A and B) were performed at a CCI of 1×105 cell/ml, using 
strategy 1 and 4 to 5 days of incubation.  
In the second study for baculovirus without GFP, four incubation times were 
tested (4, 5, 6 and 7 days). Results indicate that the detection of 
positive/negative wells was only possible from day seven as the inhibition 
of cell growth and the increase of cell size became visible when compared 
to uninfected cells used as negative control (Figure 9A vs 9B). 
Nevertheless, this screening was difficult and highly susceptible to errors 
since the cell morphological changes were not markedly perceptible even 
for a “trained eye”. Thus, the infection of a second 96-well plate with the 
virus solution from the plate one was required to increase the accuracy of 
titers. Consequently, it was necessary to evaluate the effect of different 
incubation times (4, 5, 6 and 7 days) on final titers in this second infection 
procedure. The results indicated that four days of incubation was sufficient 
to identify clearly infection foci. Indeed, we observed a more pronounced 
inhibition of cell growth and a notorious increase of cell size combined to 
the loss of the characteristic round cellular shape in cells infected for 7+4 
days compared to both uninfected and seven days infected cells (Figures 
9A-C). These findings were confirmed using a baculovirus with GFP as 
indicated in figures 9D and 9E. Therefore, further experiments using the 
recombinant baculovirus without GFP were performed at a CCI of 2×105 
cell/ml using method 1 and incubation time of 7+4 days. 
The mathematical equations available in literature for viral titer estimation 
(see Table 5) were compared. Results showed that the variability in titer 
yields was on average 9-17%, demonstrating that any of the mathematical 
equations could be used without compromising final titer estimations.  
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Figure 9. Assessment of positive/negative wells using the TCID50 method: screening of 
uninfected (A) and infected cells with recombinant baculovirus from stock A (B to G). Figures 
B and C show infection foci identification based on the inhibition of cell growth and changes 
of shape and size of infected vs uninfected cells, for days 7 and 7+4 respectively. The 
presence of green fluorescence due to GFP allows an easier identification of the infected 
cells (Figures D and E). Figures F and G are the respective overlapping of Figures B with D 
and C with E. IC, infected cells; UC, uninfected cells. Scale bar 50 μm. 
Data collected from a run of experiments were analysed and viral stock 
titers assessed (Table 6). Titer yields were within the same log, 107 pfu/ml, 
and standard errors between 18 and 35%.  
3.2. MTT assay 
Two major points were evaluated in this method: the effect of CCI on 
TCLD50 values and the correlation between TCLD50 and pfu/ml.  
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Table 6. Comparison of different methods for baculovirus titration. 
 Baculovirus stock titers (pfu.ml-1) × 107 
 Stock A Stock B Stock C Stock D 
Method 
standard error 
(average) 
TCID50 for baculovirus w/o GFP - - 2.2 ± 0.8 3.5 ± 0.7 27% 
TCID50 for baculovirus w/GFP 1.7 ± 0.3 1.1 ± 0.3 - - 22% 
MTT assay 1.5 ± 0.3 2.5 ± 0.8 1.2 ± 0.1 0.9 ± 0.2 20% 
Alamarblue assay 0.9 ± 0.3 1.1 ± 0.3 5 ± 1 1.4 ± 0.4 28% 
Cell size assay 2.3 ± 0.4 1.0 ± 0.1 6.2 ± 0.5 14 ± 3 13% 
Growth cessation assay 1.4 ± 0.5 50 ± 18 4.4 ± 1.6 2.4 ± 0.9 36% 
Real time Q-PCR 741 ± 134 279 ± 6 55 ± 7 451 ± 34 10% 
Plaque assay 1.63 ± 0.06 0.54 ± 0.05 0.30 ± 0.02 0.57 ± 0.06 7% 
Flow cytometry assay 2.7 ± 0.3 1.6 ± 0.2 - - 13% 
Stock standard error 
(average) 20% 28% 27% 29%  
To define the CCI range within which no significant differences in TCLD50 
values were observed, Sf-21 cells seeded at densities ranging from 2×104 
to 4×106 cell/ml were infected with recombinant baculovirus of stock A. 
Results showed two completely different patterns: a linear relationship 
between TCLD50 and CCI at low cell concentration (104 to 105 cell/ml) and 
an apparent TCLD50 plateau at CCIs higher than 105 cell/ml (Figure 10). 
Thus, further experiments were performed at a CCI of 5×105 cell/ml. 
To allow direct comparison with other methods, it was necessary to 
correlate the TCLD50 values obtained by MTT assay with pfu/ml. Therefore, 
parallel MTT and TCID50 assays were performed at CCIs from 2×104 to 
4×106 cell/ml. By representing log (pfu/ml) vs log (TCLD50/ml), we 
determined a linear regression with a slope of 0.8 ± 0.2 and a y-intercept of 
3 ± 1 (r2 = 0.85) that allowed the estimation of viral stock titers (Table 6). 
The titers obtained were within the same log, 107 pfu/ml, and methods intra-
variability between 12 and 30% which is in agreement with literature [4; 
25]. Interestingly, an average difference of 27% was observed between 
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these titers and those calculated using the equation proposed by Mena et 
al. (2003). This emphasises the need to assess the correlation between 
TCLD50 and pfu/ml for accurate titer estimation. 
 
Figure 10. Microculture tetrazolium (MTT) assay for baculovirus from stock A: effect of cell 
concentration at the time of infection (CCI) on TCLD50/ml values. Error bars denote 
standard errors and the lines represent curve fitting. 
3.3. Alamarblue assay 
In this technique, three major variables affected strongly viral titer 
estimation: cell concentration at the time of infection, cell line and 
incubation time. 
An initial screening to assess the seeding densities inducing a linear 
alamarBlue® reduction response, indicative of optimal conditions, was 
performed. For this purpose, different concentrations ranging from 1×103 to 
5×105 cell/ml were tested. The results showed an optimal linear relation for 
cell concentrations between 1.5×104 cell/ml and 3×104 cell/ml. To evaluate 
the precision of estimated titers at these two concentrations, Sf-9 and Sf-21 
cells were infected with recombinant baculovirus from stock C and titers 
determined according to Pouliquen et al. (2006). Two incubation times, 24 
and 34 h, were also tested. Results showed that titers obtained at 1.5×104 
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cell/ml were on average 40% higher than those at 3×104 cell/ml; however, 
their variability was much higher (45% vs 20%). Assays performed with Sf-
9 cells were incoherent and the titers impossible to calculate, whereas the 
titers obtained using Sf-21 cells were consistent and presented significant 
precision. The reason underneath this discrepancy of results is not 
understood. For incubation times, titers obtained at 34 hpi were on average 
65% lower than those at 24 hpi. 
Based on these results, recombinant baculovirus of stocks A to D were 
titrated using Sf-21 cells at a CCI of 3×104 cell/ml and incubation time of 24 
h (Table 6). Titers were within the 107 pfu/ml yield and method variability 
between 26-32% which was in close agreement with the results obtained 
for other methods. 
3.4. Cell size assay  
The definition of optimal incubation time was critical for this technique. 
Thus, Sf-9 cells infected with recombinant baculovirus from stocks A to D at 
a CCI of 1×106 cell/ml with virus serial dilutions ranging from 10-1 to 10-4 
times were incubated during different times (18-72 h) and titers were 
calculated as described in section 2.2.4. Results showed 2-log difference 
between titers obtained for incubation times around 18-24 h and higher 
than 24 h (see stocks A and B in Figure 11). These differences were 
related to the extent of the cell swelling phenomenon after infection caused 
by the different amount of virus existing at each incubation time tested. For 
incubation times higher than 24 h, virus underwent at least two replication 
cycles resulting in a higher amount of virus than the initial viral amounts. 
Consequently, the increase of cell size was more pronounced than 
expected leading to an overestimation of viral titers. On the other hand, for 
incubation times lower than 24 h, since virus were only able to complete 
one replication cycle, the cell swelling effect was mainly due to initial virus 
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dosage ensuring that the estimated titers reflect the real population of virus 
used for the infection. Based on these results, further experiments were 
performed with incubation times around 20-24 h.  
The mathematical equations available in literature to determine the 
parameter EPIC,n and consequently the titer of baculovirus stocks (see 
Table 5) were compared; an average variability around 16% was 
calculated. Overall, estimated titers were within 107 to 108 pfu/ml with 
standard errors below 17% (Table 6). 
 
Figure 11. Cell size assay for baculovirus from stock A to D: effect of incubation time on 
recombinant baculovirus titers. Caption denotes the viral stock and error bars methods 
variability. 
3.5. Growth cessation assay 
Similarly to cell size assay, the most critical issue in this technique was the 
incubation time. Thus, to evaluate the effect of this variable on final titers, 
Sf-9 cells infected with recombinant baculovirus from stocks A to D at a CCI 
of 1×106 cell/ml with virus serial dilutions ranging from 10-1 to 10-4 times 
were incubated during different times (24, 36, 48, 72 and 105 h) and titers 
determined as described in section 2.2.5. Results showed that titer yields 
varied significantly for the incubation times of 24 h and higher than 24 h (1 
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to 1.5-log difference). This observation was explained by the different 
extent of the cell growth inhibition phenomenon after infection caused by 
the different amounts of virus existing at each incubation time tested. 
Taking into account that baculovirus replication times range from 16 to 18 
h, for incubation times lower than 24 h, virus were only able to complete 
one replication cycle. In these conditions, the inhibition of cell growth 
observed was attributed to the amount of virus initially used for the infection 
and thus directly correlated with the viral titer. Conversely, for incubation 
times higher than 24 h, the cell growth inhibition effect was more 
pronounced than expected since it was a consequence of the viral amounts 
used for the infection combined with the amount of newly replicated virus; 
consequently, in these conditions, the viral titers were overestimated. 
Based on these results, further experiments were performed using 
incubation times of 20 to 24 h.  
Viral titers of all four recombinant baculovirus stocks were within the same 
order of magnitude, 107 pfu/ml with the exception of stock B (Table 6). The 
standard errors for this method were significant, with an average of 36%. 
3.6. Real time Q-PCR 
Based on the method described in section 2.2.6, viral titers of baculovirus 
stocks A to D were determined (Table 6). Estimated titers were within 108-
109 pfu/ml and method standard errors between 2-18%. Interestingly, the 
titers obtained by real time Q-PCR were 1 to 2-log higher than those 
determined by the other techniques.   
3.7. Plaque assay 
In this method, there were three major variables that influenced strongly 
titer estimation: incubation time, medium to use in the agarose overlay and 
cell concentration at the time of infection (CCI).  
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In order to define optimal conditions, several experiments were set up. 
Results showed that 3 to 4 days of incubation induced plaque formation 
with a reasonable size and the number of plaques being between 10 and 
150 as recommended in Possee and King (1992). In addition, the use of 
serum free medium (SF900II) improved the quality and the definition of the 
plaques compared to the tissue culture medium (TC100). In terms of CCI, 
concentrations below 106 cell/ml yielded only few or no plaques (confluence 
was not achieved and cell detachment was visible). On the other hand, too 
high cell concentrations hindered plaque visualization because the cells 
reached confluence too soon and superposition between plaques and cells 
became too pronounced. Based on these results, further experiments were 
performed with a CCI of 106 cell/ml using serum free medium (SF900II) in 
the agarose overlay for 3 to 4 days of incubation. 
Baculovirus stock titers determined by this method were lower than the 
titers determined by other techniques with the exception of the baculovirus 
stock A whose titer was within the same order of magnitude, 107 pfu/ml 
(Table 6). These lower titers may be related to non efficient virus/cell 
contacts or agarose overlay temperature, factors that affect strongly the 
amount of countable plaque forming units.  
    3.8. Flow cytometry assay 
This technique allowed titer estimation within one working day, similar to 
the growth cessation and cell size assays. However, titer precision was 
higher. Indeed, the error associated to flow cytometry assay, around 13%, 
was lower than the other two techniques, in the order of 17 to 35% (Table 
6). In terms of stock titers, they were within the same order of magnitude, 
107 pfu/ml. The ratio between infectious particles obtained by flow 
cytometry and TCID50 was calculated to be 1.5, which is in agreement with 
what is reported in Shen et al. (2002). 
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3.9. Statistical analysis 
In the case of stock A, both normality and variance equality were verified 
(0.05 < p < 0.69). However, the one-way ANOVA results suggested that 
viral titers were statistically different (p = 2.77×10-15 < a = 0.05), thus it was 
necessary to perform the Sheffé test to identify possible outliers. This 
multiple comparison test identified real time Q-PCR as the technique 
presenting significant differences in viral titers (p < 0.05 for all multiple 
comparisons). A new statistical test performed excluding this technique 
suggested that there was no statistical difference between titers (p = 0.082 
> a = 0.05). This means that viral titers determined by real time Q-PCR 
were statistically different from the average.  
For stock B, one-way ANOVA was performed after verified the normality of 
data and the variance equality (0.14 < p < 0.48). The resulting p-value, 
2.04×10-43, was lower than a = 0.05 meaning that viral titers were 
statistically different. The Sheffé test indicated real time Q-PCR technique 
as the method contributing most for such differences (p < 0.05 for all 
multiple comparisons). Excluding this technique from further statistical 
analysis, the one-way ANOVA presented a p-value (p = 1.1×10-21) above 
0.05 suggesting that, apart from real time Q-PCR, another method was 
responsible for such significant variability. By performing a new Sheffé test, 
growth cessation assay was detected as that reporting viral titers 
significantly different from the rest (p < 0.05 for all multiple comparisons) 
and consequently excluded from further statistical analysis. The new one-
way ANOVA was performed and results indicated that there was sufficient 
evidence (p = 0.158 > a = 0.05) suggesting that there was no statistical 
difference between titers. This means that viral titers determined by real 
time Q-PCR and growth cessation assay were statistically different from the 
average. 
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Similarly, in stock C, two Sheffé tests were necessary for identification of 
outliers, namely real time Q-PCR and plaque assay. Excluding these two 
techniques from further statistical analysis, one-way ANOVA performed 
after verification of data normality and variance equality (0.06 < p < 0.66) 
indicated that there was sufficient evidence (p = 0.065 > a = 0.05) to 
suggest that viral titers were statistically not significantly different. This 
means that viral titers determined by real time Q-PCR and plaque assay 
were statistically different from the average. 
For stock D, two methods were excluded from further statistical analysis 
since both yielded p-values lower than 0.05 in the Sheffé test, namely the 
real time Q-PCR and the cell size assay. Multiple comparisons of the 
remaining techniques were assessed using the Sheffé test and all p-values 
were higher than 0.05 with the exception of the relation between TCID50 
and plaque assay, were p = 0.02 < a = 0.05. Since this difference in viral 
titers was statistically significant, plaque assay method was not considered 
in further tests. The final one-way ANOVA test indicated that there was 
sufficient evidence (p = 0.055 > a = 0.05) to suggest that viral titers were 
not significantly different. This means that viral titers determined by real 
time Q-PCR, cell size assay and plaque assay were statistically different 
from the average. 
In summary, this analysis indicates that the real time Q-PCR and the 
plaque assay were the techniques estimating viral titers statistically 
different from the average. The remaining techniques estimated similar 
titers for all baculovirus stocks tested. Therefore, the probability of 
estimating a viral titer statistically different from the real one using one of 
these two methods is significantly higher than with any other method tested 
in this study. 
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4. DISCUSSION 
4.1. Critical issues in baculovirus titration 
Baculovirus titration is a very complex task since results are highly 
dependent on the method used for titration. Often, the same viral stock 
titrated in different laboratories lead to different results; this lack of 
harmonization originates difficulties in the interpretation and comparison of 
results. Our aim was to identify the critical parameters affecting virus titer 
estimation for different analytical methods and procedures commonly used 
in laboratories worldwide.  
4.1.1. Effect of cell origin  
The best cell line to use for baculovirus titration has to be capable of 
estimating viral titers with significant accuracy. Sf-21 and Sf-9 cells are 
usually used for titration but a clear utilization of one or the other cell line is 
not obvious since both cell lines are optimal for some titration methods and 
sub-optimal for others. Indeed, our results showed that some methods 
estimated titers with higher accuracy using Sf-9 cell line and other methods 
using Sf-21 (see Table 7). The reasons for these differences are not fully 
understood but cell size (Sf-21 cells have a wider size distribution than Sf-
9) (O'Reilly et al. 1994), resistance to shear stress (Sf-9 cells are slightly 
less fragile than Sf-21), ability to form regular monolayers (Sf-21 cells form 
more irregular monolayers than Sf-9) [26] and different susceptibility to 
infection by baculovirus [27] might be factors responsible for these 
discrepant behaviours.  
4.1.2. Effect of CCI and baculovirus inoculation procedure 
Optimal CCIs were dependent on the method of titration (see Table 7). This 
fact can be explained by the different detection methods used for 
identification of infection, either based on the expression of a foreign  
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protein (TCID50 w/GFP and flow cytometry assays), or cell viability (MTT 
and alamarblue assays), or cytopathic effects caused by infection (TCID50 
w/o GFP, cell size and growth cessation assays), or even plaque formation 
(plaque assay). The type of culture system is another possible explanation. 
Since some methods use static cultures whereas others require cells in 
suspension, the cell concentrations to be used for each method are 
completely different.  
In relation to the inoculation procedure, results for TCID50 demonstrated 
that the removal of the supernatant prior to the addition of viral serial 
dilutions had a negative impact on virus titers. Dehydration of attached 
cells, insufficient incubation times, plate type, medium exchange and cell 
concentration are possible reasons for this negative effect. 
The volume of cell and baculovirus inoculum was different for the methods 
tested. Higher volumes for assays using suspension cultures (flow 
cytometry, cell size and growth cessation assays) and lower ones for static 
cultures (MTT, TCID50, plaque assay and alamarblue assays).  
4.1.3. Effect of incubation time 
Optimal incubation times varied from hours to days (Table 7). These 
differences are associated with the method used for the detection of the 
infection. The methods based on the expression of GFP (TCID50 assay), 
the cleavage of thiazolyl blue tetrazolium bromide by a mitochondrial 
enzyme in viable cells (MTT assay) or the formation of plaque forming units 
(plaque assay) require high incubation times for identification of infection. 
Other techniques, based on cytopathic effects resulting from infection of 
cells by baculovirus (cell size and growth cessation assays) require lower 
incubation times. It is important to underline that, in these later cases, the 
incubation time is dependent on the replication cycle time of the virus. 
Incubation times higher than virus replication time lead to an overestimation 
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of viral titers since the inhibition of cell growth and the increase of cell size 
is the result of both initial and newly replicated virus. On the other hand, 
incubation times lower than the virus replication time restrains the 
estimation of viral titers since the viruses are unable to affect efficiently the 
cell growth or the increase of cell diameter.  
4.1.4. Effect of defective interfering particles 
Defecting interfering particles (DIPs), although lacking envelope or capsid 
proteins responsible for virus infectivity, contain genetic material. 
Techniques quantifying viral particles by detection of the viral DNA are 
unable to discriminate between infectious particles and DIPs and 
consequently will overestimate the viral titer. This was the case for the real 
time Q-PCR method presented here, that yielded titers that were 
significantly higher than the titers estimated by the other assays. 
The propagation of baculovirus from a reference stock containing DIPs 
and/or accumulation of DIPs derived from incorrect propagation process 
increases exponentially the risk of generating a viral stock with significant 
percentage of these particles. Strategies can be implemented to avoid the 
accumulation of DIPs such as the addition of a purification step prior to viral 
titration. An alternative is to propagate the virus and quantify newly 
synthesized genomes, as described by [28]. Nonetheless, these strategies 
may impact negatively on final titers due to baculovirus aggregation 
associated with the purification step [29] or insufficient incubation time for 
the formation of progeny virus.  
4.1.5. Mathematical analysis 
Most of the methods presented in this study relied on specific mathematical 
correlations for the estimation of viral titers (indirect methods). The 
exceptions were the plaque assay and the real time Q-PCR which 
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quantified directly viral particles (direct methods) (see Table 7). To allow 
direct comparison between methods, it was necessary to standardize titers 
to pfu/ml. Therefore, correlations between viral genomes/ml and pfu/ml, in 
direct methods, and between TCLD50, TCID50, % of cells expressing GFP 
and EPIC,n values and pfu/ml, in indirect methods, were used.    
4.2. Error assessment in baculovirus titration methods 
Based on the statistical analysis performed in section 3.9, the standard 
error for each stock was calculated. The results showed average standard 
errors between 20 to 29% which was acceptable considering how different 
the methods are. The standard error for each method was also estimated. 
Plaque assay and real time Q-PCR presented the lowest average standard 
errors (7% and 10% respectively) while alamarblue and growth cessation 
assays presented the highest ones (28% and 36% respectively). These 
results are in agreement with literature values and within acceptable viral 
titer variations defined by regulatory agencies (± 0.5 log10) [4; 25; 30].    
Despite the variability in the standard errors of the methods, viral titers were 
within the same order of magnitude, 107 pfu/ml. The exception was real 
time Q-PCR by the reasons mentioned in section 4.1.4. Thus, viral titers 
can be considered independent of the method of titration.  
4.3. Estimated accuracy of titers 
In order to verify the accuracy of estimated titers, two different runs of 
experiments (I and II) were performed. In each one, the infection kinetics of 
Sf-9 cells, at a cell concentration around 106 cell/ml, with stock A 
baculovirus at MOIs of 0.1, 0.3, 1 and 3 were followed. Collected samples 
were analysed by flow cytometry for assessment of percentage of cells 
expressing GFP.  
Considering the error associated to process parameters CCI and MOI, both 
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profiles in experiments I and II can be considered identical (Figure 12). This 
means that the confidence interval, [-SD+titer, titer+SD], for the stock A 
baculovirus is narrow, otherwise infection kinetics profiles would vary 
significantly. In addition, results prove that viral stock titers were estimated 
accurately.  
 
Figure 12. Estimated accuracy of titers: infection kinetics of Sf-9 cells, at a cell 
concentration of approximately 106 cell/ml, with stock A baculovirus at MOIs of 0.1, 0.3, 1 
and 3. Caption denotes the MOI used and lines curve fittings. Symbols represent 
experimental data: experiment I (dark diamonds) and experiment II (grey squares). 
4.4. Methods cost, time and error analysis 
A cost analysis of the baculovirus titration methods used in this study was 
performed (Figure 13). This analysis was based on the cost of 
consumables such as reagents, plastic ware, medium and other material 
necessary for the assays. The costs associated with equipment and human 
resources were not considered since these differ from lab to lab. The 
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alamarblue assay was the most expensive technique and TCID50 method 
for baculovirus with GFP the least expensive one. The real time Q-PCR 
and plaque assay presented costs which were almost half of that of 
alamarblue assay. The costs associated with the remaining techniques 
were on average 75% lower than that of alamarblue assay. 
 
Figure 13. Cost analysis of baculovirus titration methods. Titration costs were normalized for 
easier comparison. TCID50 (GFP) and TCID50 represent the end-point dilution method for 
baculovirus with and without GFP respectively.  
Based on the cost, time and error analysis here performed, the techniques 
that combine better all these three main variables are the TCID50, MTT and 
the flow cytometric assays. Nevertheless, it is always recommended to 
confirm the accuracy of the titration either by comparing it with a well 
characterized baculovirus reference stock or by titration using two different 
methods and verification of the variability of results. Since standards stocks 
are not always easy to obtain, especially when dealing with a significant 
number of different baculovirus, the second alternative would allow for a 
better knowledge on the accuracy of estimated titers. 
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Summary 
In this paper, a stochastic dynamical model for heterologous protein 
expression in the baculovirus/insect cell system is presented. The model 
describes foreign protein expression under the control of the polyhedrin 
promoter, which is the most commonly used promoter in this system. The 
present study explores the hypothesis of gene size being the main factor 
affecting the rate of protein expression in the host cell. The infection 
process, prior to protein expression, is of stochastic nature. Thus, the 
combination of infection and intracellular dynamics results in a complex 
stochastic/structured dynamical model which is very challenging in a 
systems engineering perspective. Due to the randomness of virus binding 
to the host cells, the intracellular dynamics of individual cells show unique 
patterns, potentially leading to a very large scale stochastic problem. The 
size of the problem was reduced by considering a finite number of 
subpopulations of “equal” cells. A discrete time formulation was adopted for 
realization of the stochastic infection and numerical integration. The method 
is illustrated by the application to the production of rotavirus protein vp2 in 
suspended cultures of Spodoptera frugiperda Sf-9 cells infected with 
recombinant Autographa californica multiple nucleopolyhedrovirus 
enclosing the gene coding for vp2. 
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1. INTRODUCTION 
The Baculoviridae are a family of occluded DNA viruses, which are 
pathogenic to some arthropods, namely to insects of the order 
Lepidopteran, and totally safe to humans. These viruses have a large, 
double-stranded, circular DNA genome of 88-200 kbp [1]. The use of 
baculovirus remotes to the early 1950s, when they were used as natural 
control agents of insect pest populations. At present, genetically 
engineered recombinant baculovirus are seen as powerful vectors for 
expressing heterologous proteins in insect cells, both in vivo and in vitro. 
In heterologous protein production, one of the most used processes 
consists on the infection of Sf-9 cells with Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV) [2-8]. This system offers some 
advantages over prokaryotic and other eukaryotic systems such as: 1. the 
very strong polyhedrin (polh) promoter with protein expression levels up to 
500 mg.L-1 [9]; 2. ability to express large proteins (> 50 kDa); 3. similar 
efficacy in protein folding and posttranslational modifications to mammalian 
cells; 4. low cost and 5. ability to express large cDNA inserts as well as 
multiple genes. 
The main steps involved in the production of foreign proteins using the 
AcMNPV/Sf-9 system are depicted in Figure 14. Firstly, recombinant 
baculoviruses (rBac) containing the gene(s) of interest k, vk, bind to the 
host cell membrane mediated by cell surface receptors. About 1/2 of the 
viruses reach the host cell nucleus, with the remaining viruses being 
degraded in lysosomes. Details of AcMNPV trafficking in insect cells can be 
found elsewhere [10-13]. Once inside the host cell nucleus, viral genes are 
expressed in a well orchestrated cascade that is normally divided in three 
stages: early, late and very late gene expression [14]. Viral DNA (vDNA) 
replication starts in the late phase, around 6 hours post-infection (hpi), after 
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essential genes for vDNA replication are expressed in the early phase (1-6 
hpi). The expression of foreign genes under the control of the polh 
promoter starts in the very late phase around 24 hpi. Also in the very late 
phase, some of the replicated vDNA, dnak, is encapsidated resulting in new 
virions, which then bud from the host cell. Virus budding is known to occur 
around 16 hpi and endures for almost 36 hours (h) [10; 15; 16]; the newly 
budded virus are able to start a second round of infection. The free vDNA is 
routed to the transcription pathway. The foreign genes are then transcribed 
into the corresponding mRNAs, rnak (step 2). In step 3, mRNA is translated 
into the corresponding polypeptide chains in the ribosomes, vpk. These 
newly synthesized proteins can be degraded or enter the secretion pathway 
(step 4). Once completed the post-translational modifications, the correctly 
folded proteins are released to the extracellular matrix or remain 
intracellularly. 
 
Figure 14. Network of heterologous protein production in AcMNPV/Sf-9 system. Step 1: 
extracellular baculovirus, vk, enter the cell by adsorptive endocytosis. As the pH inside 
endosome drops, viruses’ nucleocapsids containing the viral DNA are released to cytoplasm 
and migrate to cell nucleus. Once inside the nucleus, viral DNA replication is initiated, dnak. 
Step 2: viral DNA is routed to the transcription pathway where foreign genes are transcribed 
into the corresponding mRNAs, rnak. Step 3: mRNA leaves the nucleus to ribosomes for 
protein synthesis, vpk. Step 4: the secretory pathway delivers these newly synthesized 
proteins to the extracellular matrix. 
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The multiplicity of infection (MOI – number of virus per cell) and time of 
infection (TOI) are key parameters for AcMNPV/Sf-9 system optimisation. It 
has been shown for several proteins that the maximum productivity is 
obtained at relatively low MOIs, within the range of 0.01 to 0.1 virus.cell-1 
[15-18]. At such MOIs, the statistics of infection becomes an important 
factor for process modelling. Licari and Bailey (1992) proposed an implicit 
stochastic model for monolayer Sf-9 cultures where the probability of 
infection was calculated by the Poisson distribution. Protein expression was 
defined empirically with zero order kinetics with the time window for protein 
expression dependent on the number of virions infecting the host cell. Their 
model confirmed that protein productivity has a maximum at low MOIs. A 
similar approach was followed by Hu and Bentley (2000, 2001) for 
suspended Sf-9 cultures. Protein expression was considered to follow zero 
order kinetics and the kinetic constant was defined as a function of the 
number of virions infecting the host cell. Roldão et al. (2006, 2007) 
proposed a structured model describing the intracellular dynamics of vDNA, 
mRNA and foreign protein expression. The model assumed a deterministic 
infection, which is acceptable for synchronous infection at high MOIs.  
The main objective of the present work is to bind intracellular dynamics 
based on traditional mass-action kinetics with the stochastic infection 
process into a stochastic dynamical model valid for both low and high 
MOIs. 
 
2. PROPOSED OPTIMISATION METHOD  
In this section, a method is presented for the optimisation of the MOI in the 
AcMNPV/Sf-9 system. The method is confined to the expression of foreign 
proteins under the control of the polh promoter. When dealing with the 
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synthesis of large and complex particles, biological details become vital for 
process optimisation. Therefore, the more complex scenario of stochastic 
structured modelling was adopted. The main guidelines for this optimisation 
model are the following: 
• Stochastic infection. Low MOIs are important for process optimisation; 
thus, the stochastic nature of the infection process is considered in this 
method; 
• Structured protein expression. The intracellular dynamics of vDNA, 
mRNA and viral protein are considered; 
• Gene size. The main distinguishing factor in the intrinsic protein 
expression kinetics of different proteins is the size of the underlying 
gene; 
• Maximum translation capacity. This hypothesis states that there is a 
maximum translation capacity of mRNA blocks coming from the 
polyhedrin promoter. 
2.1. Stochastic infection model 
Due to the high computation power requirements, the Sf-9 cell population, 
with an initial cell density n(0) (cell.ml-1), is partitioned in npop 
subpopulations with a cell count of ni = n(0) / npop (cell.ml-1) each. Then, 
the dynamics of cell density in subpopulation i is given by the equation: 
iidii
i nkn
dt
dn
,−= μ        Eq. 3.1 
with μi (h-1) the specific growth rate of subpopulation i defined as:  


=
ectedinf ion 'i' isif populat,
 healthyion 'i' isif populat,μμ maxi 0     Eq. 3.2 
and kd,i (h-1) the cell death rate of subpopulation i defined as: 
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
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=
otherwise,k
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k
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*
iinf,dint,d
i,d
δ     Eq. 3.3 
In equation 3.3, kd,int (h-1) is the intrinsic cell death rate of Sf-9 cells, kd,inf 
(h–1) represents the increase in cell death rate due to infection, TOIi (h) is 
the time of infection of subpopulation i and δ* (hpi) is the time required for 
the infection to accelerate host cell death. The increase in cell death rate 
due to infection is correlated with the intracellular viral load [19]:  



= 
k
kdinf,d dnaLOGkk 10Δ      Eq. 3.4 
with Δkd (h-1) the increase in cell death rate due to infection correspondent 
to 10 intracellular vDNA copies and dnak (dna.cell-1) the intracellular vDNA 
concentration delivered by virus k (k denotes the foreign gene in the virus). 
The rate of virus k entry into subpopulation i, rinf,k,i (dna.cell-1h-1) is defined 
as: 


+>
+≤
=
infrei
infreii,k
i,kinf, TOIt,
TOIt,X
dtr δ
δ
0
     Eq. 3.5 
with Xk,i a random variable denoting the number of viruses k per unit cell 
(dna.cell-1) which penetrate the cells of subpopulation i in the time interval 
[t, t+dt] and δreinf (hpi) the time period over which cells continue to be re-
infected. It is here assumed that the random variable Xk,i follows the 
Poisson probabilistic model: 
( )
!nk
)t()t(expP
nk
nkX i,k
λλ−
=
=
     Eq. 3.6 
In Licari and Bailey (1992), the shape parameter λ(t) of the Poisson 
distribution was defined as the “dynamic” MOI (the ratio of extracellular 
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virus to host cells at time t) multiplied by an infection efficiency parameter 
(α). Here we follow a different approach. The kinetics of virus entry into Sf-9 
cells can be described accurately by a first order adsorption equation [11; 
20]. The stochastic infection characterized by equations 3.5 and 3.6 must 
be in accordance with this observation, confirmed experimentally by many 
authors. We assume that the first order attachment rate defines the 
average behaviour for the stochastic process. Thus the shape parameter is 
defined here as follows:  
dttvkt ka )()( =λ        Eq. 3.7 
with ka (ml.cell-1.h-1) the first order attachment constant and vk (dna.ml-1) the 
concentration of extracellular virus k. Equation 3.7 can be interpreted as 
the average number of virus binding to a single cell in the time interval [t, 
t+dt]. The dynamics of extracellular virus vk is then given by: 
 n)rr(
dt
dv npop
i
ii,k,budi,kinf,
k 
=
+−=
1
     Eq. 3.8 
Extracellular virus concentration has two contributions: the depletion of 
virus due to infection and also virus budding, which are the newly 
synthesized virus in the host cells secreted to the extracellular medium. 
This latter term is discussed in the next section. 
It should be noted that equations 3.1 to 3.8 take into account the 
phenomena of re-infection in a very straightforward way. In the work of Hu 
and Bentley (2000, 2001), the probability of re-infection is also calculated 
and used to correct the depletion of extracellular virus. But, because no 
explicit stochastic formulation was adopted, viruses coming from re-
infection were assumed to be degraded in lysosomes. With the method 
adopted here, viruses arriving to the host cell nucleus through infection or 
re-infection are treated in the same way. 
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2.2. A structured model for intracellular protein expression 
The equations presented in the lines below refer to a given subpopulation i. 
To simplify the notation, the index i is omitted hereon. The intracellular 
dynamics of vDNA delivered by virus k, dnak (dna.cell-1), is defined by: 
00 =−+= )(dna      ,rrr
dt
dna d
kk,budk,dnarepkinf,t
k η    Eq. 3.9 
The first term in the right-hand side is the rate of infection (see equation 
3.5) multiplied by the trafficking efficiency, ηt. According to Dee et al. 
(1997a), half of the internalized virus are degraded in lysosomes, thus ηt = 
0.5. The second term is the vDNA replication rate, rdnarep,k (dna.cell-1.h-1), in 
the host cell nucleus, here defined as: 



≤≤



−
−−
−
=
otherwise,
t,)TOIt(dnakr
*
low,DNA
low,DNA
*
*
kRDNA
k,dnarep
0
1 δδδδ
δ
  Eq. 3.10 
Three main features of vDNA replication process can be outlined: 1. vDNA 
replication follows first order kinetics, i.e., template limited replication where 
kRDNA (h-1) represents the first-order vDNA replication constant; 2. there is a 
well defined time window (t-TOI) ∈ [δDNA,low, δ*] for vDNA replication, where 
δDNA,low (hpi) represents the time for its beginning and 3. the rate of vDNA 
replication decreases linearly in time. This linear decrease is attributed to 
the metabolic burden caused by the synthesis of virus related molecules 
[15; 16; 18; 19]; vDNA replication stops at the critical time instant δ* when 
host cell activities are permanently shutdown due to the infection. This 
critical time was shown to decrease with increasing MOIs [15; 16; 18] or 
equivalently with increasing intracellular viral load [19]: 


= 
k
k
*
dnaLOG
δδ
10
10
      Eq. 3.11 
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with δ10 (hpi) the critical time instant correspondent to 10 intracellular vDNA 
copies. The third term in equation 3.9 is the virus budding rate, rbud,k 
(dna.cell-1.h-1): 

 ≤−≤
=
otherwise,
TOIt,dnak
r high,budlow,budkbudk,bud 0
δδ     Eq. 3.12 
with δbud,low (hpi) and δbud,high (hpi) the time of onset and halt of virus 
budding, respectively, and kbud (h-1) the first-order virus budding constant. 
The transcription of foreign gene k into the corresponding mRNA under the 
control of polh promoter is defined by equation 3.13: 
00 =−= )(rna    ,rnakr
dt
rna d
kkk,DRNAk,transc
k     Eq. 3.13 
with rnak the intracellular concentration of mRNA coding for protein k 
(rna.cell-1), rtransc,k (rna.cell-1.h-1) the transcription rate of gene k and kDRNA,k 
(h-1) the first order degradation rate. The transcription rate is as follows: 



≤−≤



−
−−
−
=
otherwise,
TOIt,)TOIt(
S
dnakr
*
low,polh
low,polh
*
*
k
k
elong,rna
k,transc
0
1 δδδδ
δ   Eq. 3.14 
with krna,elong (bp.h-1) the RNA polymerase elongation rate, Sk (bp) the size 
of gene k and δpolh,low (hpi) the characteristic time post infection for the 
onset of polh promoter transcription. Also a linear decay in vDNA 
transcription is considered due to the metabolic burden effect. The 
translation of mRNA into viral proteins is defined by equation 3.15: 
0)0(     ,, == kktransl
k vpr
dt
dvp      Eq. 3.15 
with vpk (μg.cell-1) the concentration of intracellular viral protein k and the 
rtransl,k (μg.cell-1.h-1) the corresponding synthesis rate:  
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


≤−≤



−
−−
−
=
otherwise,
TOIt,i)TOIt(mp
S
rnakr
*
low,polhtransl
low,polh
*
*
k
k
k
elong,rib
k,transl
0
1 δδδδ
δ  Eq. 3.16 
with krib,elong (bp.rna-1.h-1) the ribosomal elongation rate, mpk (μg) the 
molecular weight of vpk and itransl an adimensional parameter to account for 
the hypothesis of a maximum translation capacity. The term itransl is defined 
here as:  



>
≤
=
max,transltransl
transl
max,transl
max,transltransl
transl LL,
L
L
LL,
i
1
     Eq. 3.17 
where Ltransl,max (rna.bp.cell-1) is the maximum translation capacity and 
Ltransl (rna.bp.cell-1) the translation machinery utilization in case of all mRNA 
molecules being translated at the same time, defined by: 
=
k
kktransl rnaSL       Eq. 3.18 
 
3. CASE STUDY: PRODUCTION OF VP2 
3.1. Model calibration 
The expression of vp2 by infecting Sf-9 suspended cultures with 
monocistronic recombinant baculoviruses is addressed in this study. Intra 
and extracellular data of vDNA, mRNA and viral protein, collected over time 
in experiments with MOI of 5 virus.cell-1 and a starting cell density n(0) = 
106 cell.ml-1, was used to calibrate the model parameters. Nonlinear fitting 
by the Levenberg-Marquardt method was adopted using MATLABs’ 
functions lsqnonlin and nlpaci. The latter was used for the determination of 
parameters’ 95% confidence limits. Table 8 compiles the calibrated 
parameters along with the parameters taken from the literature. 
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Table 8. Mathematical model parameters 
Parameter Value Reference 
μmax 0.03 h-1 [21] 
kd,int 0.0008 h-1 [16; 19; 22] 
Δkd 0.0017 ± 0.0003 h-1 [19] 
δreinf  10 hpi [16] 
ka 7.8×10-8 ml.cell-1.h-1 [20] 
ηt 0.5 [11] 
kRDNA 0.49 ± 0.03 h-1 [23] 
δDNA,low 6 hpi [10; 24; 25] 
δ10   233 ± 7 hpi [19] 
δbud,low 16 hpi [15; 16] 
δbud,high 52 hpi [15; 16] 
kbud 0.07 ± 0.02 h-1 [23] 
kDRNA,2   0.019 ± 0.004 h-1 [19] 
krna,elong 325 ± 69 bp.h-1 [23] 
S2 2690 bp [19] 
δpolh,low   15 hpi [14; 19] 
krib,elong   5.5 ± 0.6 ×106 bp.rna-1.h-1 [23] 
mp2 1.69 ×10-13 μg [26] 
Ltransl,max  1.1 ± 0.3 ×107 rna.bp.cell-1 [23] 
Figure 15A compares model and experimental data of intracellular dna2, 
rna2 and of total (intracellular plus extracellular) vp2. This data shows an 
initial “lag” phase corresponding to early-gene expression. Although 
baculoviruses encode their own RNA polymerase and transcriptional 
factors, activators and enhancers, it is during this phase that they require 
the host RNA polymerase for the transcription of early genes essential for 
initiation of viral DNA replication such as the DNA polymerase and the anti-
apoptotic p35 gene, amongst others. 
This phase is followed by an exponential dna2 increase with a characteristic 
vDNA replication rate of 0.49 h-1. Budding of replicated viruses is known to 
commence around 16 hpi and enduring for almost 36 h. Virus budding is 
the direct cause of the decrease in intracellular dna2 shown in figure 15A. 
The dna2 continues to replicate until a characteristic time instant, around 48 
hpi, after which the host cell machinery is no longer capable to express viral 
proteins - the metabolic burden effect. 
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Figure 15. Process kinetics of vDNA replication, mRNA synthesis and viral protein 
production for the genes coding for vp2 (A) and vp6 (B). The lines indicate model 
simulations: the full line (⎯) and dashed line (– – –) represents intracellular dnak (dna.cell-1) 
and rnak (rna.cell-1) respectively, whereas the dotted line (⋅⋅⋅⋅) indicates total vpk 
concentration (mg.L-1). Experimental data is denoted by closed triangles () and diamonds 
() in the cases of intracellular dnak and rnak respectively, and open squares () for total 
vpk concentration. 
Figure 15B shows model simulations for a viral protein with a different gene 
size, rotavirus vp6. The production of rotavirus protein vp6 is achieved by 
infecting Sf-9 cells with monocistronic recombinant baculovirus a MOI of 5 
virus.cell-1 and a starting cell density n(0) = 106 cell.ml-1. The gene coding 
for this protein has S6 = 1356 bp. All model parameters were kept in this 
simulation except for the new value of the gene size and the mRNA 
degradation rate [19; 27]. It can be seen that viral protein prediction is 
within the range of the measurements, given the high error associated with 
some of the techniques used. Also, the vDNA and mRNA simulations are in 
agreement with the experimental data. 
3.2. Stochastic simulation 
The model equations 3.1 to 3.18 is a large stochastic ordinary dynamical 
system. With a population number npop = 1000 (the number adopted in all 
calculations in this study), 5000 nonlinear ordinary differential equations 
(ODE) must be solved over a time window of 0-100 h. Several simulation 
trials should also be repeated in order to extract the average behaviour of 
BA 
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the system. To solve this large system at bearable computation time, an 
explicit discrete time formulation was adopted. The value of Xk in equation 
3.5 was obtained by a random number generator according to the Poisson 
distribution equations 3.6 and 3.7 (MATLABs’ poissrnd function) over a 
fixed time step, T(h), whereas the dynamics over this time step were 
computed either by the direct Euler method or by a 4th/5th order Runge-
Kutta solver (MATLABs’ ode45 function). Table 9 shows the computation 
time along with the final prediction of vp2 and infected cell concentrations 
for different time steps. For time steps between 0.25 h and 0.01 h, the Euler 
method produces fairly constant results. The increase of the population 
number from 100 to 10000 does not improve significantly the accuracy. The 
ode45 solver results in a much higher computation times. The ode45 
results converge with those of the Euler method as the time step is 
decreased. From the analysis above, the Euler method with T = 0.1 h and 
npop = 1000 was taken as a reasonable compromise between accuracy 
and computation time. These settings were adopted in all calculations 
presented in Table 9. 
Table 9. Computation time and accuracy. 
Method dt (h) npop vp2 (mg.L-1) ni (cell.ml-1) Cpu (s) 
2 100 52.4 2997285 2 
1 100 68.3 2945690 3.75 
0.5 100 74.7 2865203 7.4 
0.25 100 80.5 2880747 14.3 
0.1 100 82.1 2845599 35.4 
0.01 100 80.7 2800949 372.2 
0.1 1000 79.9 2772313 286.5 
Euler 
0.1 10000 79.0 2741385 2808.8 
2 100 78.9 2568988 51.9 
1 100 79.4 2609264 98.9 
0.5 100 80.2 2678395 191.4 
0.25 100 78.6 2674363 374.5 
0.1 100 79.9 2735712 930.2 
ode45 
0.05 100 84.1 2847619 1837.6 
To illustrate the effect of the stochastic infection process equations 3.5 to 
3.7, the statistics of final vp2 productions for 100 trials and a MOI = 0.1 
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virus.cell-1 are presented in the histogram of Figure 16. 
 
Figure 16. vp2 distribution in the stochastic infection process. Frequency histogram of total 
vp2 concentration (mg.L-1) for Ntrials = 100 and MOI = 0.1 virus.cell-1. 
3.3. Population dynamics 
The dynamics of healthy, nu (cell.ml-1), and infected, ni (cell.ml-1), cells for 
MOI = 0.01, 0.1, 1, 10 and 40 virus.cell-1 are shown in Figures 17A and 17B 
respectively. For high MOIs, 100% infection occurs within the first 3 hours. 
The total cell density practically does not increase above the initial cell 
density. On the other extreme, for MOIs in the range 0.1-0.01 virus.cell-1 a 
high percentage of cells remain healthy and growing in the first 36 h. It is 
with virus budding at 16-36 hpi, starting the second round of infection, that 
a major increase of the infected cell population occurs (see the case of MOI 
= 0.1 virus.cell-1). In the second round of infection, all healthy cells are 
finally infected at MOI = 0.1 virus.cell-1. In the case of MOI = 0.01 virus.cell-1 
a residual percentage of healthy cells remains at end of the run. 
Figure 17C compares model simulations with experimental data of Hu and 
Bentley (2001) for MOIs of 0.1, 1 and 10 virus.cell-1. It can be observed an 
excellent agreement between model simulations and experimental 
percentage of infected population. This data is consistent with a saturation 
of the budding rate to 1.5 dnak.cell-1.h-1.  
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Figure 17. Kinetic profile of uninfected nu (cell.ml-1) (A) and infected ni (cell.ml-1) (B) cells 
population. Process simulations where performed using the stochastic infection model for 
MOI = 0.01, 0.1, 1, 10 and 40 virus.cell-1, and Ntrials = 30. Infection efficiency vs time, 
comparison of model predictions with Hu and Bentley (2000) data (C). Model predictions are 
indicated by lines, the numbers next to the lines indicate the MOI used. Experimental data is 
denoted by symbols: MOI = 0.1 (), MOI = 1 () and MOI = 10 virus.cell-1 (). 
3.4. Intracellular dynamics 
Figure 18 shows the dynamics of intracellular dna2, rna2 and vp2 in the 
host Sf-9 cells after infection for different MOIs. The lines represent the 
average values over all infected populations.  
By increasing the MOI, the maximum vDNA contents is reached sooner but 
it does not necessarily translates into higher intracellular vDNA contents. 
The maximum intracellular vDNA content is a trade-off between two 
different factors: high MOI represents more ‘seeds’ for vDNA replication but 
reduces the time window for vDNA replication. The other important factor is 
BA 
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that for low MOIs virus budding is extended over a long period of time, 
which will continuously infect and re-infect the existing host cells. For MOI = 
10 and 40 virus.cell-1, only the first round of infection occurs while for MOI = 
1, 0.1 and 0.01 virus.cell-1 the second round of infection is also active. For 
low MOIs, it is only after the second round of infection that the increase in 
intracellular vDNA becomes visible. 
 
 
Figure 18. Intracellular dna2 (dna.cell-1) (A), rna2 (rna.cell-1) (B) and vp2 (mg.cell-1) (C) profile 
for MOI = 0.01, 0.1, 1, 10 and 40 virus.cell-1. Process simulations where performed using the 
stochastic infection model for Ntrials = 30. 
As expected, the intracellular rna2 follows closely the vDNA patterns since 
a direct first order transcription law was applied. The rna2 is produced in the 
very late phase and, as a rule, it can be stated that high dna2 loads result in 
high rna2 levels. The rna2 and dna2 synthesis halts at approximately the 
same time. The decay observed in rna2 is due to degradation. Finally, the 
intracellular vp2 dynamics follows closely the dna2 and rna2 dynamics. 
BA 
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Saturation is however observed for high MOIs. This means that it does not 
bring any advantage to increase the MOI to very high levels as the 
translation machinery saturates, thus resulting in no improvement in protein 
expression. 
3.5. Productivity assessment 
The final process productivity is a compromise between high intracellular 
vp2, obtained at high MOIs, and high infected cell density, obtained at low 
MOIs. An optimal midterm MOI exists that maximises process 
productivities. Figure 19 plots the final vp2 production (mg.L-1) for MOIs 
within the range of 10-4 to 102 virus.cell-1 in the case of the stochastic 
infection model whereas in the deterministic one the MOI varies from 10-0.3 
to 102 virus.cell-1. 
 
Figure 19. Effect of MOI on vp2 production levels. Simulations of total vp2 concentration 
(mg.L-1) using the stochastic and the deterministic model are represented by closed () and 
open diamonds () respectively. The MOI interval tested for the stochastic case ranges 
from 10-4 to 102 virus.cell-1 whereas in the deterministic one the MOI varies from 10-0.3 to 102 
virus.cell-1. Ntrials = 30. 
This curve shows a maximum productivity at MOI around 10-2 virus.cell-1 
and a local minimum at MOI = 10 virus.cell-1. The local minimum at MOI = 
10 virus.cell-1 can be attributed to the following two peculiar factors: the 
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MOI is sufficiently high for 100% infection in the first infection cycle but 
insufficient for the saturation of the translation machinery. By the time that 
virus budding commences, re-infection is no longer possible, thus the 
intracellular protein expression remains below the saturation level. For 
higher MOIs than 10 virus.cell-1, no significant improvement in vp2 
production is observed due to the protein expression saturation. Moreover, 
the infection at such high MOIs becomes essentially synchronous and 
instantaneous, thus both deterministic and stochastic models are expected 
to converge to the same solution. 
These results are in agreement with the data of Hu and Bentley (2000) who 
showed that vp2 production increases as the MOI decreases from 10 to 0.1 
virus.cell-1. The vp2 production at MOI = 10 virus.cell-1 was measured to be 
slightly higher than the productivity at MOI = 1 virus.cell-1 suggesting that 
the local minimum is somewhere between 1 and 10 virus.cell-1 but probably 
close to 10 virus.cell-1. The dynamic patterns and characteristic time 
windows are remarkably similar in both studies. The final vp2 values are 
however not comparable due to different cell growth conditions. Also Power 
et al. (1994) [28] determined experimentally that the production of β-
galactosidase in the AcMNPV/Sf-9 system decreases with increasing MOI 
from 0.01 to 10 virus.cell-1. Between MOI of 10 and 100 virus.cell-1 no 
significant increase in the productivity was observed supporting the 
possibility of a local minimum around MOI of 10 virus.cell-1. 
Figure 20 evaluates the effect of the gene size and MOI on the final protein 
production. This simulation shows that the increase in gene size results in 
the decrease of the protein productivity as showed elsewhere [6]. 
Interestingly, the optimal MOI seems to be independent of the gene size. 
This result is rational because the recombinant gene size does not affect 
either the infection kinetics or the vDNA replication rate or the budding of 
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progeny virus. It only affects the transcription and translation mechanisms, 
meaning that it only impacts on the intracellular accumulation of protein. 
 
Figure 20. Gene size and MOI effect on final recombinant protein production. Surface plot 
of viral protein production (mg.L-1) for a MOI range between 10-4 to 102 virus.cell-1 and gene 
sizes varying within 102 to 103.5 bp, and Ntrials = 30. 
 
4. CONCLUSIONS AND FUTURE PERSPECTIVES 
In this paper, a stochastic simulation model of the baculovirus/insect cells 
system is proposed. The model combines an explicit stochastic infection 
process with mass action kinetics describing the dynamics of intracellular 
vDNA, mRNA and foreign protein. By combining these two factors, the 
proposed model represents an advance over previous modelling studies for 
the baculovirus/insect cells system. The model was show to describe the 
typical behaviour of experimental data. The study clearly shows that a 
stochastic modelling framework is essential for the optimisation of protein 
expression in this system. The results confirm that the optimal MOI is 
typically low, in agreement with many experimental observations and other 
modelling studies [16]. This model could be particularly useful in designing 
co-infection experiments for the production of virus-like particles (VLPs) 
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since the statistics of infection becomes a crucial factor as one must 
guarantee that the infected cells carry all genes required for VLP assembly. 
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Summary 
In this study, a thermodynamic equilibrium-based model describes for the 
first time the in vitro assembly of rotavirus-like particles. Assembly and 
disassembly data collected at different in vitro physicochemical conditions 
is analyzed at the aid of this model. Equilibrium calculations show that 
under favourable conditions particles distribution are dominated by 
structural subunits and completely built icosahedra, while other 
intermediates are present only at residual concentrations. There is a 
minimum concentration of structural subunits that ensures measurable 
particle formation, i.e. the pseudo-critical concentration level. This threshold 
concentration value is shown to be coupled to the Gibbs free energy of 
subunit association. For low Gibbs free energies, thermodynamics 
maximizes the formation of intact icosahedra whenever proteins are 
provided at the exact stoichiometric ratio. At high Gibbs free energies, there 
is a translocation of proteins pseudo-critical concentrations; so, optimum 
concentrations are no longer coincident to the particle stoichiometric 
composition. The dependency between assembly efficiency and Gibbs free 
energy of subunit association is not linear. For values of Gibbs free energy 
of subunit association below -2 kcal.mol-1, changes in Gibbs free energy 
have no significant effect on the assembly efficiency. Above this threshold, 
a crisp transition from intact icosahedra to unassembled subunits is 
observed. In the end, this work provides a computational framework for the 
analysis of multilayered particles assembly and clearly demonstrates that 
particle formation can be controlled through the oriented manipulation of 
the Gibbs free energy of subunit association. 
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1. INTRODUCTION 
In vivo assembly of virus-like particles (VLP) results many times in 
predominantly malformed structures because the host biology does not 
provide the adequate thermodynamic environment for the correct assembly 
of such particles. A well known example is the prophylactic human 
papillomavirus (HPV)-VLP vaccine developed by Merck & Co., Inc. 
(GardasilTM) where in vitro disassembly and reassembly steps are essential 
to maximise the production of the correctly assembled VLP from the L1 
proteins of HPV types 6, 11, 16 and 18. 
The in vivo assembly of complex multilayered particles, as the rotavirus-like 
particles (RLP) model studied here, is even more challenging. RLP are 
spherical shaped particles composed by three viral proteins (vp) of 
rotavirus arranged in a triple layered structure: vp2 - 102.7 kDa (innermost 
layer) [1]; vp6 - 44.9 kDa (middle shell) [2]; vp7 - 37.2 kDa (outer layer) [2]. 
In vivo assembly efficiency data shows that contaminants such as trimers 
of vp6 and vp7, vp6 tube-like structures, single-layered vp2 particles, 
double layered particles of vp2 and vp6 (DLP) or RLP lacking one or more 
subunits represent almost 88% of the total mass of proteins expressed [3]. 
Unfortunately, few experimentally supported information exists of intra and 
inter-protein binding energies, rates and orders for assembly reactions that 
could enlighten the causes of particle malformation. A recent study of in 
vitro assembly/disassembly of RLPs explored how physicochemical 
parameters affect the formation and stability of RLPs [4]. This study 
showed that protein macrostructures are highly dependent on the pH, ionic 
strength and temperature. However, designing the ideal physicochemical 
environment for VLP assembly is nontrivial as the assembly pathway is 
complex involving many intermediate species. Mathematical models built 
on stability principles of protein macrostructures and respective assembly 
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pathways may be of great value to better understand and design in vitro 
VLP assembly experiments. 
During the last decade, many mathematical models have described viral 
capsid assembly based on molecular dynamics [5], thermodynamics as 
self-organization of discs on a sphere [6], combinatorial optimization 
studies [7], “local rules” approach [8], stochastic icosahedral capsid growth 
[9] and protein aggregation by nucleated polymerization [10]. Others have 
used the viral tilling theory (VTT) to describe the assembly of structural 
subunits formed from pentamers that differ by the structure of the inter-
subunit bonds that surround them, by combining the information on local 
environments around pentamers with the thermodynamic-equilibrium model 
of Zlotnick [11]. The major drawback in VTT is that distinct configurations 
may be energetically preferred when attaching a further building block; this 
gives rise to a tree of assembly pathways rather than a single assembly 
pathway as in Zlotnick’s model, significantly complicating the assembly 
process. The simplest way to describe the self-assembly of virus capsids is 
using Zlotnick’s thermodynamic-equilibrium formalism where the 
concentration of structural subunits and the Gibbs free energy of subunit 
association (ΔG0n) are the key variables that control particle assembly [12-
16]. 
In this study, the self-assembly of RLP was modelled using Zlotnick’s 
thermodynamic-equilibrium method. A hierarchical macroassembly model 
is postulated assuming that the anchorage of outer layer proteins is only 
possible upon the complete formation of the inner layers. The effect of the 
initial concentrations of protein structural subunits and ΔG0n on SLP 
assembly efficiency was analysed. The distribution dynamics of RLP 
intermediate structures with ΔG0n was also investigated; scenarios of 
protein limitation and excess are explored. The dependency of particle 
Chapter 4. Thermodynamic-equilibrium based RLP assembly 
116 
formation and stability with the Gibbs free energy of vp7 subunit association 
was explored by comparing in silico model simulations with in vitro 
assembly and disassembly experiments. Thermodynamic- and 
stoichiometric-based assembly efficiencies were estimated at different 
protein concentrations and Gibbs free energy of subunit association to 
assess the controllability for RLPs assembly. 
 
2. MATERIALS AND METHODS 
2.1. RLPs production, purification and analysis 
The production of RLPs, DLPs and vp7 have been described in detail 
elsewhere [17, 18]. Briefly, for RLP production, Spodoptera frugiperda Sf-9 
cells were infected at a cell concentration of 3×106 cell.ml-1 with three 
monocistronic recombinant baculoviruses enclosing the genes coding for 
vp2 fused to GFP (BacRF2A-GFP) [1], vp6 (BacVP6C) [19] and vp7 
(BacRF7), all of bovine rotavirus strain RF. The multiplicity of infection 
(MOI), i.e., number of virus per cell used was 3 (vp2) + 3 (vp6) + 3 (vp7). 
For DLP production, Sf-9 cells were infected at a cell concentration of 
3×106 cell.ml-1 with two monocistronic recombinant baculoviruses coding for 
vp2 fused to GFP (BacRF2A-GFP) and vp6 (BacVP6C); the MOI used was 
3 (vp2) + 3 (vp6). For vp7 production, Sf-9 cells were infected at a cell 
concentration of 1×106 cell.ml-1 with monocistronic recombinant 
baculoviruses coding for vp7 (BacRF7); the MOI used was 5 virus.cell-1. All 
productions were performed in a 2 L stirred tank bioreactor (Sartorius-
Stedim Biotech GmbH, Melsungen, Germany). The glass bioreactor was 
equipped with two Rushton turbines (standard geometry), a water 
recirculation jacket to control the temperature and a sparger for gas supply; 
culture temperature and gas flow were kept constant at 27 ºC and 0.01 vvm 
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(gas volume per culture volume per minute), respectively. The percentage 
of dissolved oxygen in the culture was controlled at 30 % with the agitation 
rate (70 to 250 rpm) and the concentration of oxygen in the gas mixture (0 
to 100%) (control cascade). The pH was monitored but not controlled since 
it did not vary significantly throughout the culture time. The 
abovementioned conditions were previously optimized [20]. 
The purification of RLPs, DLPs and vp7 was performed using in-house 
developed methods consisting in depth filtration, ultrafiltration, affinity-, size 
exclusion- and anion exchange-chromatography as stepwise unit 
operations [18, 21]. The total protein content in purified RLPs, DLPs and 
vp7 was determined using the BCA protein quantification assay kit (96-well 
plate protocol) (Pierce, Rockford, US) [17, 18]. 
The analysis of intact RLPs and DLPs in in vitro assembly and disassembly 
experiments was performed by capillary zone electrophoresis [4]. 
2.2. In vitro assembly and disassembly assays 
As described in [4], in vitro RLPs assembly experiments using purified DLP 
and vp7 were carried out in TNC buffer at pH 5.5, 25 ºC, NaCl 0.1 M and 
Ca2+ 1 mM. The initial concentrations of DLP and vp7 were 10 pM and 7.8 
nM, respectively. The rational for this choice is providing DLPs and vp7 at 
concentrations that obey to the RLP stoichiometric composition 
(vp2:vp6:vp7 - 120:780:780 molecules). The effect of physicochemical 
parameters on the Gibbs free energy of vp7 subunit association and 
assembly efficiency was investigated. Higher pH (8), temperature (35 ºC), 
concentration of NaCl (0.5 M) or Ca2+ (5 mM) were tested (see Table 13). 
Once solution reaches equilibrium, assembly efficiency was calculated as: 
e
eff
0
[DLP]Ass =1-  
[DLP]
      Eq. 4.1 
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with [DLP]0 the initial concentration of DLP and [DLP]e the concentration of 
DLP at equilibrium. 
In vitro RLP disassembly experiments were performed with chelating 
agents (EDTA or EGTA at 1 mM and 2 mM in D-PBS and TNC) at 35 ºC. 
The composition of D-PBS and TNC buffers was as follows: D-PBS (137 
mM NaCl, pH 7.4, 0.9 mM CaCl2 and 0.493 mM MgCl2); TNC (20 mM Tris-
HCl, 100 mM NaCl, pH 7.3 and 0.9 mM CaCl2). The initial concentration of 
RLP was 7 nM. In addition, in vitro RLP spontaneous disassembly, at 4 ºC, 
was followed for different storage times (4, 12 and 15 months). 
The disassembly efficiency was calculated as follows: 
e
eff
0
[RLP]Dis =1-  
[RLP]
      Eq. 4.2 
with [RLP]0 the initial concentration of RLP and [RLP]e the concentration of 
RLP at equilibrium.  
The reassembly of the particles previously disassembled with EDTA or 
EGTA 2 mM was studied using dialysis; the conditions used for the 
reassembly were 5 mM of Ca2+ and 25 ºC. 
These data allowed estimating the Gibbs free energies of vp7 subunit 
association to DLP by fitting the model described next. 
 
3. A MODEL FOR ROTAVIRUS-LIKE PARTICLE ASSEMBLY 
The self-assembly of many spherical viruses provide excellent models to 
study the assembly of RLPs. Bacteriophage P22 and PRD1, cowpea 
chlorotic mottle virus, turnip crinkle virus, southern bean mosaic virus or 
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polyomavirus are some examples [22-29]. These viruses possess the 
same icosahedral geometry as RLPs, being composed by 20 structural 
subunits (icosahedron faces), each an equilateral triangle with a specific T-
number of identical proteins per asymmetric unit (Figure 21). More 
importantly, the build-up of these viruses’ capsids is well known. These 
mechanisms can be extended to the stepwise assembly of multilayered 
particles using the Zlotnick’s equilibrium method as described below. 
 
Figure 21. The quasi-equivalence theory of icosahedral virus assembly. An icosahedron has 
20 faces (structural subunits), each an equilateral triangle with three asymmetric units (AU). 
The quasi-equivalence theory of Caspar and Klug explains how a structural subunit 
assembles from an integral number (T) of smaller triangles in viruses with more than 60 AU. 
The T-number is the number of identical proteins within each AU and is defined by 
T=h2+hk+hk2 where h and k are pairs of integers. The AUs are equivalent whereas the T 
proteins comprising the AU are not. Structures with T=1, T=3, T=4, T=7, T=13 and T=25 
icosahedral symmetry are shown for bacteriophage P22 and PRD1, cowpea chlorotic mottle 
virus (CCMV), turnip crinkle virus (TCV), southern bean mosaic virus (SBMV), polyomavirus 
and rotavirus. 
 
Chapter 4. Thermodynamic-equilibrium based RLP assembly 
120 
3.1. Zlotnick’s equilibrium framework 
The self-assembly of a generic polyhedral virus can be described 
mathematically using the equilibrium theory proposed by Zlotnick in 1994. 
This modelling approach is based on the following principles: 
• Structural subunits are very stable protein aggregates forming the 
building blocks in the assembly process; 
• Structural subunits are sequentially added to the most stable 
intermediate until a complete layer is formed (see Table 10, 11B 
and 12); 
• Only the most stable conformation, i.e. the arrangement with the 
greatest number of inter-subunit contacts, is considered; 
• Assembly reactions are rapid, reaching equilibrium in milliseconds; 
• Only ideal icosahedral geometry is allowed for each intermediate; 
• Nucleation and cooperativity are neglected; 
• The contact between adjacent subunits results in a characteristic 
Gibbs free energy variation, ΔG0n; 
• All interactions between identical subunits have the same 
characteristic ΔG0n, irrespective of the particle size. 
The assembly of structural subunits into a complete layer involves a series 
of equilibrium reactions, statistical components and thermodynamic factors. 
The association constant, Kn, of a species n, a specific arrangement of m 
structural subunits, can be uncoupled into statistical components S1,n  and 
S2,n, and a non-statistical association constant K’n : 
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[ ]
[ ][ ]
'
n 1,n 2,n n
n
K =S S K =
n 1 1−
     Eq.4.3 
The structural subunit m = n = 1 is defined as the stable building block and 
n-1 is defined as the intermediate composed of m-1 subunits. S1,n  is 
defined as the ratio between two factors: the number of ways of forming a 
species n (from the preceding most stable intermediate, n-1, and free 
subunit n = 1 – build-up) and the number of ways of dissociating the 
intermediate species n into the respective reactants, n-1 (build-down). S2,n 
describes the degeneracy of the incoming subunit in species n; this 
statistical factor depends on the number of equivalent orientations that 
each incoming icosahedral asymmetric unit, called oligomer (cluster of 
proteins – the fundamental of the assembly reaction), adopts in a structural 
subunit m. The non-statistical association constant K’n is a function of the 
number of contacts between subunits for each newly formed species n, 
Nc,n, and ΔG0n , and does not include the degeneracy of the interaction: 
0
c,n n'
n
N G
K =exp
RT
 Δ
−   
      Eq.4.4 
with R=1.987 cal.mol-1K-1 the ideal gas constant and T the temperature (K). 
The concentration of each intermediate species n can be estimated by 
rearranging equations 4.3 and 4.4, so that: 
[ ] [ ][ ] [ ]
0 0nc,n n c,
1,n 2,n 1, 2,
2
N G N G
n = n 1 1 S S exp S S exp 1
RT RT
ΨΨ Ψ
Ψ Ψ
Ψ=
   Δ Δ
− − = −         
∏
 Eq.4.5 
The concentration of each species is a function of the stable building block, 
species 1, and ΔG0n. The total protein in solution at time t, Prot (t), can be 
calculated from the species concentration 1 to n: 
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( ) [ ]n 2,n
1
Pr ot t m S zΨ
Ψ=
= Ψ      Eq.4.6 
where mΨ represents the number of structural subunits in species ψ = n 
and z the number of proteins in each oligomer.  
3.2. Application to the self-assembly of RLP  
The modelling method proposed above is directly applicable to the 
equilibrium of n stable structural subunits forming icosahedra. Here we 
extend this method to the formation of the three RLP icosahedral layers. 
The formation of RLPs is hypothesized to be a sequence of 3 main steps: 
1st step – assembly of SLPs; 2nd step – assembly of DLPs by attachment of 
vp6 to SLPs; 3rd step – RLPs assembly by vp7 attachment to DLPs. This 
sequence of steps is supported by experimental evidence that the three 
viral proteins are synthesized in different ribosomes: vp2 and vp7 are 
synthesized on free ribosomes while vp7 is synthesized on ER-associated 
ribosomes [30, 31]. This suggests that DLPs may assemble in the 
cytoplasm, bud into the endoplasmic reticulum and then acquire the outer 
vp7 layer [32]. The common feature to all phases is the pathway by which 
the end product is generated (Table 10, 11b and 12). The distinguishing 
factor is the attachment of the first vp6 and vp7 subunits to SLPs and 
DLPs, respectively.  
Such an assembly model implies that particles composed by vp6 and vp7 
or by vp2 and vp7 are never formed. Indeed, experiments showed that 
particles can assemble in vivo or in vitro without vp2, although their 
amounts are negligible. The same applies for most structures of vp6 or vp7, 
namely trimer aggregates in the form of tubules or sheets [33]. In addition, 
these unusual complexes are rather heterogeneous and have extremely 
low stability. Finally, we also assume that the assembly of viral proteins into 
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oligomers (dimmers, trimers or pentamers) and from these into stable 
subunits is not affected by the presence of the reporter protein GFP. 
3.2.1. Formation of the vp2 layer 
In the absence of any other protein, recombinant vp2 form SLPs with 
diameters of about 45 nm and hexagonal outlines; no monomeric structures 
are observed [1, 34, 35]. This suggests that inner RLP layer and native 
rotavirus vp2 share the same unusual T=1 icosahedral geometry. The 
assembly of such structure consists in the aggregation of vp2 molecules 
into dimers, subsequent formation of a stable structural subunit from 3 
dimers and vp2 layer construction by the sequential addition of structural 
subunits to the most stable assembly intermediates. The formation of 
structural subunits is assumed to be an equilibrium process yet favoring the 
assembled subunits. The interaction between the three dimers in a subunit 
occurs at the 3-fold axes whereas the contact between consecutive 
subunits occurs at the 5-fold axes. 
Table 10 lists the assembly intermediates and factors describing the 
assembly of SLPs. The Gibbs free energy of vp2 subunit association is 
defined by ΔG0SLP. The subunits of SLPs are linked by strong hydrophobic 
interactions; thus, ΔG0SLP << 0 kcal.mol-1.  
Modeling parameters for this layer are: n=20 - vp2 layer has icosahedral 
geometry with 20 structural subunits; S2,n=3 - each structural subunit 
consists of 3 icosahedral asymmetric units, z=2 - each asymmetric unit is 
formed by 2 proteins; ΔG0SLP = -4.08 kcal.mol-1 [36, 37]. 
The effect of calcium concentration, pH and temperature on the Gibbs free 
energy of vp2 association was not considered in the model and is open for 
future studies. 
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3.2.2. Formation of the vp6 layer 
Recombinant vp6 rapidly forms oligomers in vivo, mostly as trimeric 
structures. The dimeric form of the protein stabilized by disulfide bonds may 
exist but represent either a step in the formation of trimers or an abnormal 
oligomerization; monomers of vp6 are rare [35]. Upon treatment of DLPs 
with 1.5 M of CaCl2, the outer layer is removed but trimers do not 
disaggregate. These experimental evidences support the idea of vp6 
trimers being the building blocks of a RLP vp6 layer with T=13 quasi-
equivalent icosahedral geometry similar to the native rotavirus vp6. In such 
an icosahedral lattice, there are five quasi-equivalent trimers: P, Q, R, S, 
and T [38, 39]; the precise juxtaposition of these trimers varies slightly in 
accordance with the requirements of quasi-equivalence (Figure 22).  
 
Figure 22. Diagram of the juxtaposition of vp6 trimers in relation to vp2 dimers. The precise 
juxtaposition of vp6 trimers varies slightly in accordance with the requirements of quasi-
equivalence for the completion of a T=13 lattice with 260 vp6 trimers. There are five quasi-
equivalent trimers, P, Q, R, S, and T, with T trimer providing the center of the cluster located 
at the 3-fold axes. 
The vp6 layer is formed by 20 structural subunits, each one consisting of 13 
vp6 trimers. The assembly of one subunit involves the initial contact of vp6 
trimer T with the vp2 layer at its icosahedral 3-fold axes and subsequent 
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interactions between trimer T and trimers Q, R, S and P (Table 11a and 
Figure 22). The assembly of vp6 layer results from the addition of structural 
subunits to the most stable assembly intermediates (Table 11b). 
The contact that aligns the vp6 trimer T with the icosahedral vp2 layer is the 
strongest (ΔG0vp6,T) whereas vp6 trimer-trimer interactions within each 
subunit (ΔG0vp6,PQRS) and vp6 subunit-subunit interactions (ΔG0DLP) are 
weaker [40]. The contact between vp6 trimers P of adjacent subunits is 
ensured by strong lateral non-equivalent interactions and occurs across the 
quasi 2-fold axes but closer to the 3-fold axes and at the icosahedral 5-fold 
axes. The X-ray structure of rotavirus vp6 shows that trimer interface at the 
base contains mostly hydrophilic/negatively charged residues [40]. Since 
these residues participate in inter-layer vp2-vp6 interactions and 
solubilisation of vp6 layer is only accomplished using chaotropic agents, it 
is possible to assume for recombinant DLPs that 
ΔG0DLP, ΔG0vp6,T and ΔG0vp6,PQRS << 0 kcal.mol-1 
In virtue of model simplification and computation time, the assembly of vp6 
structural subunits was lumped; hence, the Gibbs free energy of vp6 
subunit association can be defined as 
ΔG0DLP = ΔG0vp6,T + 24 × ΔG0vp6,PQRS 
and [free vp6] = [vp6trimers]13, where [free vp6] is the concentration of 
unassociated vp6 subunits at equilibrium (M) and [vp6trimers] the 
concentration of vp6 trimers, the building blocks of a vp6 structural 
subunits. 
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Table 11a. The assembly of the first vp6 structural subunit on top of the RLP vp2 layer. 
Build n Model 
up down 
S1,n Nc,n [n] 
20.1  20 1 20/1 1 [ ] [ ]
01 Gvp6,T
RT
trimers20 20 e vp6
 ×Δ 
−   × ×  
20.2  3 1 3/1 2 [ ] [ ]
0 01 G 2 Gvp6,T vp6,PQRS
RT
2
trimers20 60 e vp6
 ×Δ + ×Δ 
−   × ×  
20.3 
 
2 2 2/2 2 
[ ] [ ]
0 01 G 4 Gvp6,T vp6,PQRS
RT
3
trimers20 60 e vp6
 ×Δ + ×Δ 
−   × ×  
20.4 
 
1 3 1/3 2 
[ ] [ ]
0 01 G 6 Gvp6,T vp6,PQRS
RT
4
trimers20 20 e vp6
 ×Δ + ×Δ 
−   × ×  
20.5 
 
6 1 6/1 2 
[ ] [ ]
0 01 G 8 Gvp6,T vp6,PQRS
RT
5
trimers20 120 e vp6
 ×Δ + ×Δ 
−   × ×  
20.6 
 
5 2 5/2 2 
[ ] [ ]
0 01 G 10 Gvp6,T vp6,PQRS
RT
6
trimers20 300 e vp6
 ×Δ + ×Δ 
−   × ×  
20.7 
 
4 3 4/3 2 
[ ] [ ]
0 01 G 12 Gvp6,T vp6,PQRS
RT
7
trimers20 400 e vp6
 ×Δ + ×Δ 
−   × ×  
20.8 
 
3 4 3/4 2 
[ ] [ ]
0 01 G 14 Gvp6,T vp6,PQRS
RT
8
trimers20 300 e vp6
 ×Δ + ×Δ 
−   × ×  
20.9 
 
2 5 2/5 2 
[ ] [ ]
0 01 G 16 Gvp6,T vp6,PQRS
RT
9
trimers20 120 e vp6
 ×Δ + ×Δ 
−   × ×  
20.10 
 
1 6 1/6 2 
[ ] [ ]
0 01 G 18 Gvp6,T vp6,PQRS
RT
10
trimers20 20 e vp6
 ×Δ + ×Δ 
−   × ×  
20.11 
 
3 1 3/1 2 
[ ] [ ]
0 01 G 20 Gvp6,T vp6,PQRS
RT
11
trimers20 60 e vp6
 ×Δ + ×Δ 
−   × ×  
20.12 
 
2 2 2/2 2 
[ ] [ ]
0 01 G 22 Gvp6,T vp6,PQRS
RT
12
trimers20 60 e vp6
 ×Δ + ×Δ 
−   × ×  
20.13 
 
1 3 1/3 2 
[ ] [ ]
0 01 G 24 Gvp6,T vp6,PQRS
RT
13
trimers20 20 e vp6
 ×Δ + ×Δ 
−   × ×  
n – represents the species involved in the assembly of a vp6 structural subunit; Build-up – number of ways of forming a species n from 
the preceding stable intermediate, n-1, and free subunit n=1; Build-down – number of ways of dissociating the intermediate species n into 
equivalent reactants, n-1; S1,n – ratio Build-up/Build-down; S2,n = 1 – degeneracy of the incoming subunit (each subunit consists of 1 
icosahedral asymmetric unit); Nc,n – number of contacts a vp6 trimer does with adjacent trimers and the vp2 layer at the n-th species; 
ΔG0vp6,T – Gibbs free energy associated with the contact between vp6 trimer T and the icosahedral vp2 layer (cal.mol-1); ΔG0vp6,PQRS – 
Gibbs free energy associated with the contact between vp6 trimers (cal.mol-1); R – gas constant (1.987 cal.mol-1K-1); T – temperature (K); 
[n] – concentration of each intermediate species n (M); [vp6trimers] – concentration of vp6 trimers, the building blocks of vp6 structural 
subunit (M). 
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Table 11b lists the assembly intermediates and factors describing the 
assembly of the second RLP layer. Modeling parameters for this layer are: 
n=20 - vp6 layer has icosahedral geometry with 20 structural subunits; 
S2,n=13 - there are 13 equivalent orientations for the each trimer in the 
incoming subunit, z=3 - each asymmetric unit is formed by 3 proteins; 
ΔG0DLP = -4.08 kcal.mol-1 [36, 37]. 
3.2.3. Formation of the vp7 layer 
The structure of the outer RLP layer is similar to the vp6 layer: 780 
molecules of vp7 arranged as 260 trimers in a T=13 quasi-equivalent 
icosahedral geometry. This layer has 20 stable subunits, each one formed 
by 13 vp7 trimers. The assembly of vp7 trimers into a structural subunit and 
this into a complete layer obeys to a specific sequence similar to the 
assembly of the vp6 layer. 
In the native virus, there are solvent channels that go across the rotavirus 
structure, through which mRNA transcripts emerge from the viral particle 
and aqueous material and biochemical substrates are transported into and 
out of the capsid; these channels persist even after the assembly of the 
outer layer. This suggest that vp7 trimers interact in a one-to-one fashion 
with the vp6 trimers in the inner layer by contacting top of one with bottom 
of the other. Here, the same type of interaction was assumed; vp7 trimer T 
contacts the outer DLP layer at the 3-fold axes at vp6 trimer T locus. This 
contact is the strongest (ΔG0vp7,T) whereas the vp7 trimer-trimer interactions 
(ΔG0vp7,PQRS) and the interaction between vp7 trimers P of adjacent subunits 
(ΔG0RLP) are weaker. 
The solubilisation of the outer layer from the RLP is achieved using low 
calcium concentration (~ 1 mM), by the addition of chelating agents such as 
EDTA or EGTA at concentrations around 1-10 mM or by lowering the 
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temperature [4]. No significant effect is observed on SLPs or DLPs. These 
results suggest that 
ΔG0SLP ≅ ΔG0DLP > ΔG0RLP 
Table 12 lists the assembly intermediates and factors describing the 
assembly of vp7 RLP layer. 
In virtue of model simplification and computation time, the assembly of vp7 
structural subunits is lumped; hence, the Gibbs free energy of vp7 subunit 
association can be defined as 
ΔG0RLP = ΔG0vp7,T + 24 × ΔG0vp7,PQRS 
and [free vp7] is the concentration of unassociated vp7 subunits at 
equilibrium (M). 
Modeling parameters for this layer are: n=20 - vp7 layer has icosahedral 
geometry with 20 structural subunits; S2,n=13 - there are 13 equivalent 
orientations for the each trimer in the incoming subunit, z=3 - each 
asymmetric unit is formed by 3 proteins; ΔG0RLP = -4.08 kcal.mol-1 [36, 37]. 
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4. RESULTS AND DISCUSSION 
4.1. Pseudo-critical protein concentration 
Model simulations show that initial concentrations of protein structural 
subunits play a critical role on particle assembly. A small change in their 
concentrations has a profound effect on assembly efficiency. Likewise, a 
small change in ΔG0n may result in a significant degradation or 
improvement in particle assembly. Such variations can be illustrated by 
analysing the simplest case of SLP formation. Figure 23 shows the SLP 
assembly efficiency as function of the initial vp2 concentration, [vp2]0, for 
different values of Gibbs free energy of vp2 subunit association (ΔG0SLP). 
The assembly efficiency curves follow a sigmoidal shape with respect to 
[vp2]0. Independently of ΔG0SLP, few particles are formed at very low 
[vp2]0; above a given critical [vp2]0 value, most subunits assemble into 
macrostructures. This threshold represents the minimum initial 
concentration of vp2 needed to ensure a measurable SLP formation, i.e., a 
pseudo-critical concentration, Kd,app, that satisfies the constraint [1] = [20] = 
Kd,app at equilibrium for a specific ΔG0SLP; Kd,app can be derived from Table 
10: 
( )0 19SLP
d,app
30 G RTln 3 20
K =exp
19RT
 Δ −   
    Eq. 4.7 
It is clear that Kd,app increases with the increase in ΔG0SLP; Kd,app = 3.6 μM 
for ΔG0SLP = -4.38 kcal.mol-1 whereas at a higher ΔG0SLP, -3.78 kcal.mol-1, it 
increases almost 4-fold to 17.5 μM. These results confirm that there is a 
crisp transition between unassembled structural subunits and intact 
icosahedra. 
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Figure 2 3. SLP assembly efficiency as function of the initial vp2 concentration, [vp2]0, for 
different Gibbs free energy values, ΔG0SLP. The full line represents ΔG0SLP = -4.08 kcal.mol-1 
as estimated by Zlotnick 1994, the dash lines represent ΔG0SLP > -4.08 kcal.mol-1 and the dot 
lines represent ΔG0SLP < -4.08 kcal.mol-1. Kd,app represents the pseudo-critical concentration 
that satisfies the constraint [1] (concentration of unassociated vp2 subunits at equilibrium - 
[1] = [svp2]e) = [20] (complete SLP) = Kd,app at equilibrium for a specific ΔG0SLP. 
4.2. The effect of the number of association contacts 
The aforementioned pseudo-critical concentration Kd,app can be also 
interpreted as the dissociation constant for a single contact in the final 
structure when the concentration of species 1 and 20 coincide [37]. As 
shown in Figure 23, decreasing ΔG0SLP also decreases the Kd,app, 
suggesting that the reaction SLP  20 × vp2 is not favoured. In other 
words, the more negative is ΔG0SLP the higher is the association constant 
for a subunit-subunit interaction, Kcontact [41]: 
( )0SLP contactG =-RT ln KΔ ×      Eq. 4.8 
Since the overall SLP assembly constant, Klayer, is proportional to Kcontact 
[41]:  
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20 Nc,nn 1
layer contactK K

=
≈       Eq.4.9 
an increase in Kcontact favours the reaction 20 × vp2  SLP, increasing 
species 20 formation and consequently the assembly efficiency. In the end, 
equations 4.8 and 4.9 clearly demonstrate that as more contacts are 
established per subunit, the lower is Kd,app i.e., more stable is the particle 
formed. 
4.3. Simulation of RLP assembly 
The concentration of species 1 to 60 at equilibrium can be calculated as 
functions of initial protein concentrations in solution before equilibrium. For 
given initial protein concentrations [vp2]0, [vp6]0 and [vp7]0, the 
concentrations of intermediate species needs to be calculated iteratively to 
ensure that protein material balances are obeyed, i.e. the initial amount of 
vp2, vp6 and vp7 must be equal to the sum of the amounts of proteins 
incorporated in all intermediate species. This translates into the following 
balance equations: 
[ ] [ ] [ ] [ ]20 602 2 2,n n 2,n 2,n0 e
n 2 n 21
vp svp S z n m S z n 20S z
= =
= + +   Eq. 4.10 
[ ] [ ] [ ]( ) [ ]40 606 6 2,n n 2,n 2,n0 e
n 21 n 41
vp svp S z n m 20 S z n 20S z
= =
= + − +   Eq. 4.11 
[ ] [ ] [ ]( )607 7 2,n n 2,n0 e
n 41
vp svp S z n m 40 S z
=
= + −  Eq. 4.12 
where [svp2]e, [svp6]e and [svp7]e are the concentrations of unassociated 
vp2, vp6 and vp7 subunits at equilibrium, respectively, [n] the concentration 
of species n, mn the number of structural subunits in species n, S2,n the 
degeneracy of the incoming subunit in species n and z the number of 
proteins in each oligomer. Parameters S2,n and z are specific for each layer: 
S2,n = 3 and z = 2 (vp2 layer); S2,n = 13 and z = 3 (vp6 and vp7 layers) (see 
Section 3 for details). This system can be solved easily by manipulating 
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iteratively the free amounts of vp2, vp6 and vp7 until the balance equations 
4.10 to 4.12 are obeyed to a given tolerance. 
RLP assembly simulations were performed for three initial protein 
concentration scenarios: 1) [vp2]0 = 1.2 M, [vp6]0 = 7.8 M and [vp7]0 = 7.8 
M; 2) [vp2]0 = 1.2 M, [vp6]0 = 7.8 M and [vp7]0 = 0.78 M; 3) [vp2]0 = 12 M, 
[vp6]0 = 7.8 M and [vp7]0 = 7.8 M. The rational for this choice of 
concentrations is testing either protein limitation or excess in relation to the 
RLP stoichiometric composition (vp2:vp6:vp7 - 120:780:780 molecules). In 
this way, vp6 is provided at the exact stoichiometric ratio while scenarios of 
vp7 limitation and excess of vp2 are also explored. The Gibbs free energy 
of subunit association was assumed to be equal for all layers (ΔG0SLP = 
ΔG0DLP = ΔG0RLP = -4.08 kcal.mol-1). Figure 24 shows the particles 
distribution at equilibrium for the three initial protein concentration scenarios 
allowing to make the following observations: 
• When initial protein concentrations (vp2, vp6 and vp7) obey the RLP 
stoichiometric ratio, the distribution of particles at equilibrium is dominated 
by a very small number of more stable structures, namely subunit 1 (i.e. [1] 
= [svp2]e) and structure 60 (complete RLP). The remaining intermediates 
are present but at residual concentrations. This shows that, for low Gibbs 
free energies, thermodynamics favours the formation of intact icosahedra 
whenever the respective proteins are not limiting. 
• When vp7 is limiting, and according to Le Chatelier's principle, it 
should be expected that the equilibrium composition of the lumped reaction 
DLP + 20 × vp7  RLP shifts to the left with more DLP and less RLP 
formed. Indeed, when comparing the concentration of structure 40 (DLP) in 
this case with the one where proteins are provided at the exact 
stoichiometric ratios, a significant increase is observed; the opposite occurs 
to the concentration of structure 60.  
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Concomitantly, moderate sized structures such as species 39, 41 or 42 
start to appear at significant concentrations. This demonstrates that protein 
limitation negatively impacts particle assembly even beyond the 
stoichiometric rational, since intermediate structures accumulate which 
represent unnecessary waste of proteins. 
• An excess of vp2 concentration shifts the equilibrium of the lumped 
reaction 20 × vp2  SLP towards the generation of more SLP (Le 
Chatelier's principle). For this reason, the concentration of structure 20 
(SLP) is higher than the one obtained when proteins are provided at the 
exact stoichiometric ratios. This equilibrium shift has also a profound impact 
on moderate sized structures such as species 17 to 23 or 39 to 41; their 
concentrations increase significantly. The high concentrations observed for 
intermediate structures 20, 17-23 and 39-41 indicate that the reaction 20 × 
vp2  SLP + 20 × vp6  DLP + 20 × vp7  RLP is not product-favoured. 
This demonstrates that proteins in excess impact negatively on final RLP 
yields while reducing the assembly efficiency due to the accumulation of 
unassembled proteins. 
4.4. In vitro RLPs assembly experiments 
The in vitro assembly of RLPs can be described by the lumped reaction  
ass
dis
k
DLP 20 vp7 RLP
k
+ × ↔
 
where kass and kdis are the reaction rate constants of RLP assembly and 
disassembly, respectively. The ratio of the reaction rate constants is known 
as the equilibrium constant, Keq: 
[ ]
[ ] [ ]
ass
eq 20
dis
RLPkK
k DLP vp7
= =
×
     Eq. 4.13 
Based on equation 4.9, the equilibrium constant Keq is related with the 
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Gibbs free energy of vp7 subunit association, ΔG0RLP, by: 
( ) 600RLP eq c,n
n 40
G RT ln K 1 N
=
 Δ = − × ×   
    Eq. 4.14 
The Gibbs free energy of vp7 subunit association for the in vitro RLPs 
assembly experiments was calculated using the formula (see Table 12): 
[ ] [ ]
[ ]
2020
0
RLP
40 13 2 free vp7 RTG ln
60 50
 × × × Δ = ×  
   Eq. 4.15 
where [40] is the concentration of DLP at equilibrium, [DLP]e, [free vp7] is 
the concentration of unassociated vp7 subunits at equilibrium, [svp7]e and 
[60] is the concentration of RLP at equilibrium, [RLP]e. The obtained results 
are summarized in Table 13.  
Results show that the increase in pH, [NaCl] or [Ca2+] had a negative 
impact on the Gibbs free energy of vp7 subunit association; the ΔG0RLP 
values are higher than the one estimated for the standard condition of 
assembly (pH 5.5, 25 ºC, 0.1 M of NaCl and 1 mM of Ca2+). This indicates 
that the equilibrium constants for the assembly reactions at pH 8, [NaCl] = 
0.5 M or [Ca2+] = 5 mM decreased and, if Keq decreased, product formation 
became less favoured; hence, the assembly efficiencies are lower. The 
effect of temperature variation on Gibbs free energy of vp7 subunit 
association and assembly efficiency is discussed below. 
4.5. Temperature dependency 
The dependency between temperature T and the equilibrium constant Keq 
is described by the van't Hoff equation: 
( )
( )
0eqln K H
1/ T R
∂ Δ
= −
∂
      Eq. 4.16 
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Table 13. In vitro assembly and disassembly of RLPs. 
Assembly condition Asseff 
Temperature 
(K) 
ΔG0RLP 
(cal.mol-1) 
ΔG0layer,vp7 
(kcal.mol-1) 
pH 5.5 / [NaCl]=0.1 M / [Ca2+]=1 mM 0.48 298.15 -4830 -242 
pH 8.0 / [NaCl]=0.1 M / [Ca2+]=1 mM 
pH 5.5 / [NaCl]=0.5 M / [Ca2+]=1 mM 
pH 5.5 / [NaCl]=0.1 M / [Ca2+]=5 mM 
< 0.10 298.15 > -4675 > -234 
Assembly 
pH 5.5 / [NaCl]=0.1 M / [Ca2+]=1 mM < 0.10 308.15 > -4832 > -242 
       
Disassembly condition Diseff 
Temperature  
(K) 
ΔG0RLP 
(cal.mol-1) 
ΔG0layer,vp7 
(kcal.mol-1) 
EGTA 1 mM 0.72 -3298 -165 
EDTA 1 mM 0.72 -3297 -165 
EGTA 2 mM 0.22 -3609 -180 
TNC buffer 
EDTA 2 mM 0.19 
308.15 
-3655 -183 
EGTA 1 mM 0.66 -3320 -166 
EDTA 1 mM 0.46 -3420 -171 
EGTA 2 mM 0.33 -3507 -175 
D-PBS buffer 
EDTA 2 mM 0.99 
308.15 
-3175 -159 
4 months 0.75 -2947 -147 
12 months 0.81 -2928 -146 
Disassembly 
Storage time 
15 months 0.85 
277.15 
-2915 -146 
       
Disassembly 
condition 
Reassembly 
condition Asseff 
Temperature 
(K) 
ΔG0RLP 
(cal.mol-1) 
ΔG0layer,vp7 
(kcal.mol-1) 
EGTA 2 mM (TNC) 0.47 -3626 -181 
EDTA 2 mM (TNC) 0.28 -3586 -179 
EGTA 2 mM (D-PBS) 0.54 -3570 -179 
Reassembly 
EDTA 2 mM (D-PBS) 
[Ca2+]=5 mM  
and  
T=25 ºC 
0.80 
298.15 
-3524 -176 
Asseff - assembly efficiency; [DLP]0 - initial concentration of DLP (M); [DLP]e - concentration of DLP at equilibrium (M); Diseff - 
disassembly efficiency; [RLP]0 - initial concentration of RLP (M); [RLP]e - concentration of RLP at equilibrium (M); ΔG0RLP - Gibbs free 
energy of vp7 subunit association (cal.mol-1); ΔG0layer,vp7 - Gibbs free energy of vp7 layer assembly on top of DLPs; [NaCl] - sodium 
chloride concentration (M); [Ca2+] - calcium concentration (M); T – temperature (K) 
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where ΔH0 is the standard enthalpy of reaction (cal.mol-1). The ΔH0 and the 
standard entropy of reaction, ΔS0 (cal.mol-1.K-1), can be calculated by 
plotting the natural logarithm of the equilibrium constant versus the 
reciprocal temperature as follows: 
0 0 0G H T SΔ = Δ − Δ       Eq. 4.17 
( )0 eqG RT ln KΔ = − ×       Eq. 4.18 
( ) 0 0eq H 1 Sln K R T R
 Δ Δ
= − × +   
     Eq. 4.19 
where the slope is equal to minus the standard enthalpy change divided by 
the gas constant and the intercept is equal to the standard entropy change 
divided by the gas constant. 
Based on equation 19 and the in vitro assembly experiments carried out at 
25 ºC and 35 ºC (Table 13), the standard entropy and enthalpy of vp7 layer 
assembly on top of DLPs, ΔS0layer,vp7 and ΔH0layer,vp7 respectively, were 
calculated. The ΔS0layer,vp7 and ΔH0layer,vp7 of the reaction DLP + 20 × vp7  
RLP are positive (~100 cal.mol-1.K-1) and negative (~ -240 kcal.mol-1) 
respectively, meaning that the reaction is spontaneous and exothermic, and 
consistent with ΔG0RLP ~ -5 kcal.mol-1. The entropy contribution to the Gibbs 
free energy of vp7 layer assembly on top of DLPs, ΔG0layer,vp7, is smaller 
than that of enthalpy, which is reflected in the fact that while the association 
changes significantly with the temperature, ΔG0layer,vp7 does not, i.e., the 
association is enthalpy driven. When ΔH0 < 0, then Keq decreases with 
increasing temperature, in accordance with Le Chatelier's principle. If Keq 
decreases, RLP formation is less favoured and, consequently, the 
assembly efficiency decreases. For this reason, the increase in 
temperature reduced significantly the efficiency of RLP assembly (Table 
13). 
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4.6. Interpretation of in vitro disassembly data 
In vitro disassembly experiments were performed at different 
concentrations of EGTA and EDTA (see Table 13). For each experiment, 
the Gibbs free energy of vp7 subunit association was calculated based on 
equation 4.15; the obtained results are summarized in Table 13. 
It is clear from equations 4.13 and 4.14 that the equilibrium constant Keq is 
inversely proportional to the Gibbs free energy of vp7 subunit association 
and to the disassembly efficiency; the lower the Keq, the higher is the 
ΔG0RLP and the disassembly efficiency. Therefore, the optimal condition to 
disassemble RLP is to use EDTA 2 mM in D-PBS as it presents the highest 
ΔG0RLP (Table 13). Interestingly, the concentration of chelating agent 
appears to be correlated with the ΔG0RLP; higher concentrations induce 
lower ΔG0RLP. The exception is the case of EDTA 2 mM in D-PBS where 
ΔG0RLP is higher than the one achieved at EDTA 1 mM.  
Upon the disassembly of RLPs with EDTA and EGTA 2 mM, reassembly 
was performed with dialysis against buffer with calcium 5 mM and 
decreasing the temperature to 25 ºC (Table 13). As a rule, the ΔG0RLP 
values for the reassembly experiments are lower than the ones obtained for 
the disassembly. This happens because lowering the temperature in an 
exothermic reaction enhances product formation by shifting the equilibrium 
to the right (DLP + 20 × vp7  RLP). Moreover, by increasing the 
concentration of calcium, the vp7 attachment to DLP is increased. 
However, very high concentrations of calcium (5 mM; see Table 13) seem 
to have a deleterious effect on the association. Summing up, the combined 
effect of optimal calcium concentration and temperature resulted in the 
increase in Keq and the subsequent decrease in ΔG0RLP.  
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The effect of storage time on ΔG0RLP was also evaluated; results are 
summarized in Table 13. The ΔG0RLP increases with storage time, indicating 
that the transition from RLP to DLP is favoured as time progresses (Keq 
decreases). The highest disassembly efficiency is achieved at a storage 
time of 15 months which corresponds to the highest ΔG0RLP. 
4.7. Design of optimal thermodynamic conditions for global RLP 
assembly  
The assembly of protein complexes such as RLP can be optimized through 
the manipulation of viral protein concentrations and solution properties with 
impact on Gibbs free energy of subunit association (such as temperature, 
pH, ionic strength and particular ions concentration, namely Ca2+). In order 
to find the theoretical optimal conditions for RLP assembly, model 
simulations were performed for different values of Gibbs free energy of 
subunit association and vp6 and vp7 initial protein concentrations, [vp6]0 
and [vp7]0, respectively. The concentration of vp2, [vp2]0, was kept 
constant at 1 M and the Gibbs free energies of vp2, vp6 and vp7 subunit 
association were considered equal (ΔG0SLP = ΔG0DLP = ΔG0RLP). 
The RLP assembly efficiency is defined as the ratio between the mass of 
intact RLP and the mass of initial proteins. To assess the implications of 
equilibrium, the assembly efficiency predicted by the thermodynamic model 
was compared to that of an irreversible assembly reaction based on the 
mass composition of RLP: 1 × vp2 + 2.84 × vp6 + 2.35 × vp7  6.19 × RLP. 
In the irreversible assembly model, the efficiency of assembly will be 
controlled by the limiting protein.  
Figure 25A shows the RLP assembly efficiency for the irreversible model 
while Figures 25B to 25F show the assembly efficiency of the 
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thermodynamic model for ΔG0RLP values of -4.08, -2.58, -1.5, -0.75 and -
0.408 kcal.mol-1, respectively.  
As expected, the irreversible model predicts higher efficiencies than the 
equilibrium model; as the ΔG0RLP decreases, the equilibrium model 
converges to the irreversible model.  
The maximum RLP efficiency is obtained for initial proteins concentrations 
coincident to the particle stoichiometric ratio (vp2:vp6:vp7 - 120:780:780 
molecules). This optimum is observed for the irreversible model and also 
for the equilibrium model with low ΔG0RLP, namely ΔG0RLP = -4.08, -2.58 and 
-1.5 kcal.mol-1. Significant deviations are only obtained for high ΔG0RLP such 
as -0.75 and -0.408 kcal.mol-1, where the optimal point becomes [vp6]0/ 
[vp2]0=6.5 + [vp7]0/[vp2]0=10.1 and [vp6]0/[vp2]0=4.7 + [vp7]0/ 
[vp2]0=10.1, respectively.  
This shows that, for low Gibbs free energies, thermodynamics maximizes 
the formation of intact icosahedra whenever vp2, vp6 and vp7 are provided 
at the exact RLP stoichiometric ratio. At high Gibbs free energies, there is a 
translocation of proteins pseudo-critical concentrations; so, optimum 
concentrations are no longer coincident to the stoichiometric ratio of RLPs. 
A noteworthy result is that the dependency between assembly efficiency 
and Gibbs free energy of subunit association is not linear. For values of 
Gibbs free energy of subunit association below -2 kcal.mol-1, changes in 
Gibbs free energy have no significant effect on the assembly efficiency 
since the initial concentrations of proteins are above a pseudo-critical 
value, which guarantees that particle formation is maximized. Above this 
threshold, the limiting factor becomes the Gibbs free energy of subunit 
association; hence, as Gibbs free energy increases, a crisp transition from 
intact icosahedra to unassembled subunits is observed. 
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Figure 25. The effect of initial protein concentrations and Gibbs free energy of subunit 
association on RLP assembly. The initial concentration of vp2 was kept constant at 1 M 
while the initial concentrations of vp6 and vp7 varied from 0.1 M to 1000 M. The Gibbs free 
energies of vp2, vp6 and vp7 association were considered equal. Graph A shows the RLP 
assembly efficiency for the irreversible model while graphs B to F show the assembly 
efficiency of the thermodynamic model for ΔG0RLP values of -4.08, -2.58, -1.5, -0.75 and -
0.408 kcal.mol-1, respectively. The RLP assembly efficiency is defined as the ratio between 
the mass of intact RLP and the mass of initial proteins. 
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5. CONCLUSION 
In this study, a thermodynamic equilibrium-based model describes for the 
first time the assembly of a protein complex with three different layers. 
Simulations showed that whenever proteins are provided at the VLP 
stoichiometric composition, particles distribution is dominated by structural 
subunits and completely formed icosahedra; remaining intermediates are 
present but at residual concentrations. If such stoichiometric ratio is not 
obeyed, several other intermediates are formed. Variations in the Gibbs 
free energy of subunit association impact on optimal initial proteins 
concentration and on assembly efficiency. For low Gibbs free energies, 
thermodynamics maximizes the formation of intact icosahedra whenever 
proteins are provided at the exact stoichiometric ratio. At high Gibbs free 
energies, there is a translocation of proteins pseudo-critical concentrations; 
so, optimum concentrations are no longer coincident to the particle 
stoichiometric composition. The dependency between assembly efficiency 
and Gibbs free energy of subunit association is not linear. For values of 
Gibbs free energy of subunit association below -2 kcal.mol-1, changes in 
Gibbs free energy do no affect significantly the assembly efficiency. Above 
this threshold, a crisp transition from intact icosahedra to unassembled 
subunits is observed. Summarizing, the concentration of correctly formed 
particles is maximized whenever structural proteins are provided at the 
exact stoichiometric ratio and at high initial concentrations. Particle 
malformation increases drastically when such conditions are not met. Host 
cells can hardly be manipulated to operate in such a narrow region, thus 
the formation of malformed particles is likely to be inevitable in vivo. 
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Summary 
Rotavirus disease is the prime cause of severe gastrointestinal illness in 
children, with an incidence estimated at 111 million episodes and a total of 
440.000 deaths per year in children with less than 5 years of age. 
Rotavirus-like particles (RLPs) are excellent vaccine candidates against 
rotavirus infection since they are non-infectious, highly immunogenic, 
amenable to large-scale production and safer to produce than attenuated or 
inactivated vaccines. This work focuses on the analysis and modelling of 
the major events taking place inside Spodoptera frugiperda Sf-9 cells 
infected by recombinant baculovirus that may be critical for the expression 
of rotavirus proteins (vp), vp2, vp6 and vp7. For model calibration and 
validation, several experiments were performed adopting either a co-
infection or a single-infection strategy using monocistronic, bicistronic or 
tricistronic baculovirus vectors. A characteristic viral DNA (vDNA) 
replication rate of 0.19 ± 0.01h-1 was obtained irrespective of the infection 
strategy and the synthesis of progeny virus was found to be negligible in 
comparison to intracellular vDNA concentrations. The timeframe for vDNA, 
mRNA and protein synthesis tends to decrease with increasing multiplicity 
of infection due to the metabolic burden effect. The rate of protein synthesis 
varies due to codon usage and/or size of protein and also the time for 
maturation. The model exhibits acceptable prediction power of the 
dynamics of intracellular vDNA replication, mRNA synthesis and protein 
production for the three proteins involved. This model is intended to be the 
basis for future RLP process optimization and also a means to evaluating 
different baculovirus constructs for RLP production. 
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1. INTRODUCTION 
According to UNICEF/WHO report of October 2009 focused on diarrheal 
disease, the second leading killer of children under 5, rotavirus disease is 
responsible for more than 600,000 deaths in infants and children worldwide 
annually (source: http://www.unicef.org). More than 82% of deaths occur in 
developing countries where medical care centers are scarce and in most 
cases inexistent. In developed countries, the most prominent burden is 
economic (Table 14). 
Table 14. The burden caused by rotavirus disease. 
 Portugal  Europe  USA  
Number of cases  66.565  2.800.042  3.000.000  
Doctor visits  16.641  700.000  400.000  
Hospitalizations  2.080  87.000  100.000  
Cost Hospitalization (millions of euros)  3  125,48  200,4  
Cost Hospitalization / child (euros)  1.442  1.442  2.004  
Total cost (millions of euros)  11,4  476  760  
% of hospitalization due to gastroenteritis  40%  40-50%  40-50%  
Number of deaths  3  231  20-100  
Sources: Sociedade Portuguesa Pediatria, US Centers for Disease Control and Prevention, US National Institute of Allergy and Infectious 
Diseases 
Rotavirus disease is caused by rotavirus, a non-enveloped double-stranded 
RNA virus with icosaheral geometry and composed by six structural 
proteins (vp1, vp2, vp3, vp4, vp6 and vp7) and five non-structural proteins 
(NSP1 to NSP5).  
The first vaccine against rotavirus disease, RotaShield, was released in 
the US in August 1998 by Merck & Co, Inc. This simian tetravalent vaccine 
was withdrawn from the market by its manufacturer one year later after the 
discovery of a rare association with intussusception in vaccinated children 
[1]. In 2006, two vaccines based on live attenuated viruses, Rotateq from 
Merck & Co, Inc. and Rotarix from GlaxoSmithKline Inc. [2; 3], were 
licensed in the US and Europe yielding, to date, positive results [4; 5]. 
Nonetheless, the possibility of virus mutation and reversion to virulence, 
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reassortment and serious adverse events continues associated with this 
type of vaccines.  
To overcome such challenges, the use of virus-like particles (VLPs) as 
candidate vaccines may constitute an attractive alternative. These 
multimeric protein structures can mimic the structure of authentic viruses, 
preserving the native antigenic conformation of the immunogenic proteins, 
and do not possess the virus DNA, potentially yielding a safer and cheaper 
vaccine than those based on attenuated viruses. Moreover, VLPs can be 
engineered to contain structural proteins corresponding to different virus 
serotypes, thus providing a broader protection. With new VLP vaccines 
reaching the market, such as the human papillomavirus vaccine, this 
technology must be considered valid for the development of a rotavirus-like 
particle (RLP) based vaccine against rotavirus disease. 
RLPs are spherical shaped particles composed by three viral proteins (vp) 
of rotavirus arranged in a triple layered structure: the innermost layer is 
composed by 60 dimers of vp2 (102.7 kDa) [6]; the middle shell is formed 
by 260 trimers of vp6 (44.9 kDa) [7] and the third, outer layer is composed 
by 260 trimers of glycoprotein vp7 (37.2 kDa) [7]. RLPs are normally 
expressed in the baculovirus/insect cell system [8]. 
Due to the complexity of RLP structure, the achievement of economical 
volumetric productivities is extremely difficult; previous studies reported 
wasteful accumulation of unassembled proteins and formation of 
incomplete RLPs [9]. In fact, less than 12% of expressed proteins find their 
way into correctly assembled RLPs probably due to incorrect stoichiometric 
ratios or inadequate thermodynamic aggregation conditions.  
In this work we propose a deterministic mathematical model of the 
baculovirus/insect cell system for the production of viral proteins and RLPs. 
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The model addresses the most critical steps of baculovirus internalization 
and trafficking, and gene expression mechanisms. The main objective of 
this modelling study is to understand and quantify the effect on viral protein 
synthesis and RLP formation of different infection strategies, and evaluate 
the effect of different promoters. 
 
2. MODEL FORMULATION 
2.1. Process description 
The main steps involved in RLP production are represented schematically 
in Figure 26 for single (S2/6/7) and co-infection (Co2+6+7) strategies. In 
co-infection, three monocistronic recombinant baculoviruses, each one 
enclosing the genes coding for vp2, vp6 or vp7, were used. In single-
infection, tricistronic recombinant baculoviruses enclosing the genes coding 
for the three viral proteins simultaneously were used. 
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Figure 26. Schematic representation of the RLPs production process for single-infection 
S2/6/7 (A) and co-infection Co2+6+7 (B) strategies: 1. virus adsorptive endocytosis; 2. virus 
trafficking; 3. vDNA replication; 4. vDNA transcription into the corresponding mRNA; 5. 
protein synthesis; 6. RLPs assembly and 7. RLPs release to the extracellular medium. 
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Independently of the strategy, the triggering event is the baculovirus 
binding to the plasmatic membrane and their entry to the cell by adsorptive 
endocytosis [10]. Step 2 consists in virus trafficking into the cell nucleus. 
Baculoviruses are first enclosed within endossomes in the cytoplasmic 
space. As the pH inside the endosomes drops, the viruses’ nucleocapsids, 
containing the viral genes, are released to the cytoplasm and migrate to the 
cell nucleus. Then, the nucleocapsids bind to the nucleus membrane, 
thereby delivering the genes into the cell nucleus. Once inside the nucleus, 
viral genes are expressed in a well orchestrated cascade that is normally 
divided in three stages: early, late (6-15 hpi) and very late (>15 hpi) [11]. 
Viral DNA (vDNA) replication (step 3) commences at the beginning of the 
late phase. The vDNA is transcribed into the corresponding mRNA during 
the very late phase, under the control of the polh promoter or under the 
control of the p10 promoter, depending on the construct of the recombinant 
baculovirus used (step 4). Synthesized mRNA molecules leave the cell 
nucleus and migrate to ribosomes where viral proteins are synthesized 
(step 5). These newly synthesized proteins (vp2, vp6 and vp7) may 
assemble into trimers of vp6 and vp7, single-layered vp2 particles, double-
layered particles of vp2 and vp6 (DLPs) and correctly formed triple-layered 
RLP (step 6). This complex mixture of structures is released to the 
extracellular medium in the final step (step 7).  
2.2. Modelling assumptions 
A set of simplifying hypothesis were assumed: 
• Excess of nutrients: the extracellular nutrients do not limit the synthesis 
of virus related products; 
• Synchronous infection: in a batch culture of insect cells with a 
multiplicity of infection (MOI – number of virus per cell) higher than 2 
virus.cell-1, the ensuing infection process will be essentially 
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synchronous, i.e., all cells will go through the infection cycle 
simultaneously [12]. Such MOIs ensure that all cells are infected, 
preventing cell division from competing for nutrient resources needed 
for virus and protein synthesis [13]; 
• Infection kinetics is independent of the viral gene in the recombinant 
baculovirus. Power and Nielsen (1996) showed that recombinant 
baculovirus carrying different foreign genes present similar infection 
kinetics in Sf-9 suspension cultures; 
• Virus trafficking, encompassing attachment, endocytosis, uncoating 
and transport to the nucleus are independent of intracellular state; 
• One-half of internalized viruses are routed to lysosomes for 
degradation [13]; 
• The genes coding for each viral protein do not affect vDNA replication. 
The size of the monocistronic, bicistronic and tricistronic baculovirus 
constructs is similar; thus, vDNA replication kinetics is assumed to be 
the same for the different constructs; 
• Negligible virus budding and release: our data suggests that for MOIs 
> 2 virus.cell-1 the rate of virus budding is much lower than the vDNA 
replication rate. This hypothesis has also been defended by Rosinski 
et al. (2002); 
• Negligible vp2-vp6-vp7 interaction: the interaction between the 
different proteins during synthesis is unknown; 
• Stoichiometric RLP assembly: the final RLPs titer is determined by the 
limiting protein. 
2.3. Baculovirus adsorption 
According to Dee et al. (1995, 1997), the depletion of extracellular virus due 
to binding to cell surface is: 
( )
dV j k N N Va i u jdt
= − +       Eq. 5.1 
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with Vj the concentration of extracellular recombinant baculovirus coding for 
vpj (DNA.ml-1), where subscript index j=2,6,7 representing vp2, vp6 and vp7 
respectively, ka the attachment rate (ml.cell-1.h-1), considered here to be 
independent of the gene coding for the viral protein, Ni is the concentration 
of infected cells (cell.ml-1), Nu is the concentration of uninfected cells, 
(cell.ml-1) and t is time post-infection (hpi). The attachment rate is defined 
as follows [14]: 
)( Rkk fa α=        Eq. 5.2 
with kf the intrinsic forward rate constant for the binding of a single viral 
attachment protein to a cell membrane receptor, α is the number of 
attachment proteins per virus, ~1000 for baculovirus [15; 16] and R the 
number of free surface receptors per cell. In typical infection conditions 
(MOI < 50 virus.cell-1), the number of surface receptors per cell is normally 
in great excess, R∼11000 for Sf-21 cells [13], thus the attachment rate ka 
may be assumed to be time-invariant. According to Dee and Shuler (1997), 
the attachment rate constant variation between baculovirus infection for Sf-
21 and Sf-9 cells in suspended cultures is meaningless; thus, a ka of 
7.8×10-8 ml.cell-1.h-1 was adopted for this study [13]. The adsorption of 
baculoviruses to Sf-9 cells was also studied by Power et al. (1994) for MOIs 
< 10 virus.cell-1 in suspended cultures. It was verified that the attachment 
rate is independent of MOI, but slightly dependent of the cell density, as it is 
reported in the present study.  
For co-infection strategies (experiments 5, 6 and 8 in Table 15), the total 
extracellular virus concentration at a given instant, Vt (DNA.ml-1), is given 
by the sum of individual extracellular virus concentration: 
=
j
jVtV        Eq. 5.3 
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For single-infection strategies (experiments 1 to 4, 7 and 9 in Table 15), the 
total extracellular virus concentration is equal to the concentration of any 
extracellular virus carrying viral gene j:  
jjVtV ∀=    ,        Eq. 5.4 
Table 15. Experimental setup for protein expression. 
Cell Culture Conditions 250 ml Spinner @ CCI ~ 1x106 cell.ml-1 
Measured times 0/5/10/15/20/25/30/35/40/45/57/72/84/96/120/144 hpi 
Calibration Experiments 
Exp. 1: S2 - BacRF2A - MOI = 5 
Exp. 2: S6 - BacVP6C - MOI = 5 
Exp. 3: S7 - BacRF7 - MOI = 5 
Exp. 4: S2/6/7 - BRV RF VLP2/6/7 - MOI = 5 
Exp. 5: Co2+6+7 - BacRF2A + BacVP6C + BacRF7 - MOI = 15 
Validation Experiments 
Exp. 6: Co2+6 - BacRF2A + BacVP6C - MOI = 10 A 
Exp. 7: S2/6 – VP2(RF)/VP6(RF) VLPs - MOI = 5 A 
Exp. 8: Co2/6+7 - VP2(RF)/VP6(RF) VLPs + BacRF7 - MOI = 10 A 
Exp. 9: S2/6/7 - BRV RF VLP2/6/7 - MOI = 15 A 
A - mRNA data not available 
2.4. Infected and healthy cell population 
The material balance equation of infected cells has two terms. The first 
term accounts for the increase in infected cells concentration due to binding 
of baculoviruses to uninfected cells, Nu (cell.ml-1). The second term 
represents the cells death rate: 
1dNi k N V k Na u t d idt MOI
 
= −  
      Eq. 5.5 
The viability of infected cells exhibits two phases as previously described in 
the literature [17]. The first phase is characterized by a slight decrease in 
infected cells concentration related to the intrinsic cell death rate. In the 
second phase, cell lysis is considerably faster due to viral infection. 
Accordingly, the cell death rate, kd (h-1) has two terms: 
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1
1 2
D
D
k tdkd k k td d
δ
δ
<
= 
+ ≥
      Eq. 5.6 
with kd1 the intrinsic cell death rate, which is equal to 0.0008 h-1 [17; 18], 
kd2 the increase in cell death rate due to infection (h-1) and δD (hpi) the time 
instant when the cell death rate increases. Both kd2 and δD (hpi) show a 
relationship with the extent of host cells infection; namely, the parameter 
kd2 increases with the number of viruses infecting the cells:  
* 10
2 * log( ) 10
k DNAtotalkd k DNA DNAtotal total
 ≤
=  >
     Eq. 5.7 
with k* (h-1) the increase in cell death rate correspondent to 10 intracellular 
vDNA copies and DNAtotal the total number of intracellular vDNA copies 
(see equations 5.11 and 5.12). The calculation of δD is discussed at the end 
of this section. 
The material balance equation of uninfected cells, Nu (cell.ml-1), comprises 
two terms. The first term represents the “conversion” of uninfected cells into 
infected cells due to virus binding. The second term reports the intrinsic cell 
death rate: 
1
1
dNu k N V k Na u t d udt MOI
 
= − −  
      Eq. 5.8 
2.5. Replication of vDNA 
The dynamics of vDNA in the cell nucleus, DNAjnuc (DNA.cell-1) is given by 
the following material balance equation: 
( ) 1
                    ( , , ), , ,
nucdDNA Nj nucuk V t k DNAtraf a j traf RDNA jdt Ni
f tDNA rep DNA low DNA high
η τ
δ δ
  = − + +  
×
   Eq. 5.9 
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The first term accounts for the transport of vDNA from extracellular virus 
into the cell nucleus. Parameter ηtraf is the trafficking efficiency, which is the 
fraction of internalized genes that manage to enter in the cell nucleus. 
Considering that about half of internalized baculovirus is degraded, most 
likely in lysosomes which contain the hydrolytic enzymes able to degrade 
the virus rapidly [13; 19], then ηtraf is equal to 0.5. Since virus trafficking 
within the cell takes some time, this transport term has a delay τtraf (h). 
According to Dee and Shuler (1997), the mean time for trafficking is as 
follows: 43 min for endocytosis, 40 to 60 min for uncoating and 6 to 25min 
for transport to nucleus, which sum τtraf = 1.8 h. 
The second term is the vDNA replication kinetics, with kRDNA (h-1) the first 
order replication constant. The time-dependent function fDNA,rep (t, δDNA,low, 
δDNA,high) defines a time interval [δDNA,low , δDNA,high] for vDNA replication, 
accounting also for the effect of the metabolic decay on vDNA replication 
(see equation 5.17).  
The total number of vDNA copies inside the cell, DNAjT (DNA.cell-1), is the 
sum of vDNA within the nucleus and vDNA in the cytoplasm: 
1
                ( , , ), , ,
TdDNA Nj nucuk V k DNAtraf a j RDNA jdt Ni
f tDNA rep DNA low DNA high
η
δ δ
  = + +  
×
    Eq. 5.10 
The first term accounts for the internalization of extracellular virus while the 
second corresponds to the degradation kinetics in lysosomes. The third 
term reports the vDNA replication kinetics. The total number of vDNA 
copies inside the cell in the co-infection experiments (experiments 5, 6 and 
8 in Table 15) is given by the sum of individual intracellular vDNA copies: 
T
total j
j
DNA DNA=        Eq. 5.11 
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For single-infection experiments (experiments 1 to 4, 7 and 9 in Table 15), 
the total number of vDNA copies inside the cell corresponds to the 
individual intracellular vDNA copies: 
 Ttotal jDNA DNA j= ∀        Eq. 5.12 
2.6. Synthesis of mRNA 
The transcription of the genes coding for vp2, vp6 or vp7 into the 
corresponding mRNA, under the control of a very late promoter (either polh 
or p10 promoter), follows first order kinetics on the corresponding vDNA 
templates: 
,
,
( , , )
              
j nuc
SRNA j j VP VP,low VP,high
DRNA j j
dRNA
k DNA f t
dt
k RNA
δ δ=
−
    Eq. 5.13 
with RNAj (RNA.cell-1) the intracellular concentration of mRNA , kSRNA,j (h-1) 
the first order transcription rate and kDRNA,j the first order mRNA 
degradation rate (h-1). The transcription of vDNA and the synthesis of viral 
protein obey to temporal control mechanisms. Therefore, a time interval for 
mRNA synthesis [δVP,low, δVP,high] is defined by the function fVP (t, δVP,low, 
δVP,high) (see equation 5.18). 
2.7. Viral protein synthesis 
The kinetics of structural viral protein synthesis, VPj (μg.ml-1), was defined 
with Michaelis-Menten kinetics on mRNA: 
, , ,( , , )
j j
VP j VP VP low VP high i
RNA j
dVP RN A
k f t N
dt K RN A
δ δ=
+
   Eq. 5.14 
where kVP,j (μg.cell-1.h-1) is the maximum VPj synthesis rate and KRNA 
(RNA.cell-1) the half-saturation constant for intracellular mRNA. The 
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intracellular protein content, VPjint (μg.cell-1) is given by: 
( , , ),
intdVP RNAj jk f tVP j VP VP,low VP,highdt K RNARNA j
δ δ=
+
    Eq. 5.15 
Note that both VPj and VPjint account for assembled and unassembled 
proteins altogether.  
The maximum viral protein synthesis rate, kVP,j, shows an indirect 
relationship with the intracellular vDNA concentration probably via the effect 
of translation enhancing factors coded by early and/or late genes. Here, 
such effect has been expressed as follows: 
* 10,
, * log( ) 10,
k DNAVP j total
kVP j k DNA DNAVP j total total
 ≤
=  >
     Eq. 5.16 
with k*VP,j (μg.cell-1.h-1) the maximum VPj synthesis rate correspondent to 
10 intracellular vDNA copies and DNAtotal the total number of intracellular 
vDNA copies (see equations 5.11 and 5.12). 
2.8. Temporal control 
The expression of viral genes occurs in an ordered cascade of events, 
whereby the early genes transactivate directly or indirectly the late genes, 
which in turn transactivate the very late genes. This sequence of events 
results in well defined time intervals for vDNA replication and transcription, 
and for protein expression that may be expressed as functions of the 
intracellular viral load [18; 20; 21]. 
The vDNA replication, which commences in the late phase at δDNA,low = 6 
hpi [11], is strongly affected during the overall process since infected cells 
gradually lose their ability to synthesize vDNA. In their segregated 
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population framework, Licari and Bailey (1992) expressed this metabolic 
decay by a linear decay in time. The same concept was adopted here to 
define the time window for vDNA replication: 
, , , ,
, ,
,
0
( , , ) 1
0
DNA,low
DNA,low
DNA rep DNA low DNA high DNA,low DNA high
DNA high DNA low
DNA high
t
t
f t  t
t
δ
δδ δ δ δδ δ
δ
 <
−
= − ≤ <
− ≥
  Eq. 5.17 
The expression of viral proteins which are under the control of very late 
promoters, polh or p10, starts approximately at δVP,low = 15 hpi [11; 18; 20; 
22]. Hu and Bentley (2000, 2001) and Licari and Bailey (1992) considered 
a linear time decay function for viral protein production. Here, a similar 
approach was adopted: 
,
, ,
,
0
( , , ) 1
0
VP,low
VP,low
VP VP,low VP,high VP,low VP high
VP high VP low
VP high
t
t
f t  t
t
δ
δδ δ δ δδ δ
δ
 <
−
= − ≤ <
− ≥
   Eq. 5.18 
Interestingly, our data suggests the existence of three critical events 
practically coincident in time: 1. the increase in cell death rate; 2. the halt in 
vDNA replication and 3. the halt in viral protein expression. These major 
events are somehow interconnected in what appears to be an influence of 
intracellular viral load. This specific moment in time has been previously 
expressed as a function of the number of viruses infecting the host cell [18; 
20; 21]. Here, this time instant is expressed as a dynamic function of the 
intracellular vDNA: 
* 10
*, , 10
log( )
DNAtotal
DNA high VP high D DNAtotalDNAtotal
δ
δ δ δ δ
 ≤
= = =  >
   Eq. 5.19 
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with δ* (hpi) the critical time instant correspondent to 10 intracellular vDNA 
copies. 
2.9. RLPs assembly 
The assembly of RLPs is complex to model since they involve three viral 
proteins. During the assembly process, many different stable subunits are 
possible and there is yet limited knowledge of the details of RLPs assembly 
in insect cells [23]. A simpler approach was adopted, based on protein 
stoichiometric ratios between vp6 and vp2 (Y6/2), and between vp7 and vp2 
(Y7/2), and on their comparison with the composition of correctly assembled 
particles, as a mean to evaluate the dynamics of RLPs assembly for 
possible process limitations analysis. The relative mass composition of 
vp6/vp2 and vp7/vp2 in correctly assembled particles is Y6/2 = 2.8 (w/w) and 
Y7/2 = 2.4 (w/w) respectively. 
 
3. MATERIALS AND METHODS 
3.1. Cell culture and media 
Spodoptera frugiperda Sf-9 and Sf-21 cell lines, obtained from American 
Type Culture Collection (ATCC, Washington D.C., US), were cultivated in 
serum free media SF900II (Gibco, Glasgow, UK) at 27 ºC in 500 ml 
erlenmeyers (50 ml working volume) (DURAN, Mainz, Germany) at 90 rpm 
and routinely diluted every four days using an inoculum of 0.3×106 cell.ml-1. 
Cell concentration and viability were determined by counting cells on a 
Fuchs-Rosenthal haemocytometer (Brandt, Wertheim/Main, Germany) 
using the trypan blue exclusion dye (Merck, Darmstadt, Germany) method 
or using a Casy®1 Cell counter plus Analyzer System Model TTC (Innovatis 
AG, Reutlingen, Germany).  
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3.2. Baculoviruses design and infection strategies  
Different baculovirus constructs were used: 1. monocistronic recombinant 
baculoviruses BacRF2A [6], BacVP6C [24] and BacRF7 enclosing the 
genes coding for vp2, vp6 and vp7 respectively; 2. bicistronic recombinant 
baculoviruses VP2(RF)/VP6(RF) VLPs with genes coding for vp2 and vp6 
simultaneously; 3. tricistronic recombinant baculoviruses BRV RF VLP2/6/7 
whose genes encode the three viral proteins simultaneously. All genes 
were under the control of the polh promoter with the exception of the gene 
coding for vp7 in the tricistronic recombinant baculovirus that is under the 
control of p10 promoter.  
Two infection strategies were evaluated: 1. Co-infection – cells were 
infected with the two monocistronic baculovirus whose genes encode vp2 
and vp6 (Co2+6) (Exp. 6 in Table 15), with the three monocistronic 
baculoviruses (Co2+6+7) (Exp. 5 in Table 15) or with the bicistronic 
baculovirus plus the monocistronic baculovirus enclosing the gene coding 
for vp7 (Co2/6+7) (Exp. 8 in Table 15); 2. Single-infection – cells were 
infected with monocistronic baculoviruses enclosing the genes coding for 
vp2 (S2), vp6 (S6) or vp7 (S7) individually (Exp. 1, 2, 3 in Table 15), with the 
bicistronic baculovirus (S2/6) (Exp. 7 in Table 15) or with the tricistronic 
baculovirus (S2/6/7) (Exp. 4, 9 in Table 15). 
3.3. Infection procedure  
Recombinant baculoviruses were amplified by infecting Sf-9 or Sf-21 cells 
at a cell concentration of 1×106 cell.ml-1 and MOI of 0.1 virus.cell-1 in 250 ml 
working volume spinner flasks (Wheaton Science, New Jersey, US) stirred 
at 150 rpm and at 27 ºC. Baculovirus were harvested at 60-70% of cell 
viability, around 96-120 hpi, by centrifugation at 200 × g for 15 min at 4 ºC. 
Titers were assessed using several titration methods (see Roldão et al. 
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2009). For viral protein and RLP production, Sf-9 cells were infected at a 
cell concentration of 1×106 cell.ml-1 in 250 ml working volume spinner flasks 
(Wheaton Science, New Jersey, US) stirred at 150 rpm and at 27 ºC. 
3.4. Nucleic acid quantification 
High pure viral nucleic acid kit and high pure RNA isolation kit (Roche 
Diagnostics, Mannheim, Germany) were used for extraction and purification 
of recombinant baculovirus DNA and RNA, respectively. Purified samples 
were stored at -20 ºC for DNA and -80 ºC for RNA. RNA integrity was 
evaluated by agarose gel electrophoresis and total RNA content assessed 
by spectral absorption of UV light at 260 and 280 nm using a GeneQuant II 
unit (Pharmacia Biotech, Cambridge, UK). Synthesis of cDNA from purified 
RNA samples was performed using first strand cDNA synthesis kit (Roche 
Diagnostics, Mannheim, Germany) and sequence-specific primers 
designed for the genes coding for vp2, vp6 and vp7. The final cDNA was 
stored at -20 ºC. Purified DNA and cDNA were analyzed by real-time 
quantitative PCR in LightCycler®1.5 instrument (Roche Applied Science, 
Indianapolis, US) using Fast start DNA master SYBR Green I kit (Roche 
Diagnostics, Mannheim, Germany) and sequence-specific primers for the 
genes coding for vp2, vp6 and vp7 (see Vieira et al. (2005)). Based on the 
standard calibration curve of cross points vs log concentrations of the 
purified DNA standard with known concentration (virus.ml-1), the content in 
DNA of each sample was assessed. Degradation of mRNA was evaluated 
by adding Actinomycin D (1 μg.ml-1) (Sigma-Aldrich, St. Louis, US) to cells 
at 42 hpi, maximum pick of mRNA, to inhibit vDNA transcription. Then, cells 
were harvested, followed by RNA purification, cDNA synthesis and PCR 
quantification. 
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3.5. Viral protein analysis 
Protein analysis was performed by Western blot. Briefly, cell culture 
samples were diluted in NuPAGE® LDS sample buffer (Invitrogen, 
California, US) and incubated for 10 min at 70 ºC. Denatured proteins were 
separated by gel electrophoresis using 1 mm NuPAGE® 4-12% Bis-Tris 
pre-cast polyacrylamide gels in NuPAGE® MOPS SDS running buffer 
(Invitrogen, California, US). Proteins were transferred to a HybondTM-C 
extra nitrocellulose membrane (Amersham Biosciences, Fairfield, US) 
using a semi-dry transfer unit (GE Healthcare, Uppsala, Sweden) and 
probed using antibodies specific to target the proteins of interest (vp2, vp6 
and vp7). Different primary antibodies were used: 1) mouse monoclonal 
anti-vp2 IgG; 2) mouse monoclonal anti-vp6 IgG; 3) mouse monoclonal 
[511] anti-rotavirus (Abcam, Cambridge, UK); 4) goat polyclonal anti-
rotavirus (Abcam, Cambridge, UK); 5) rabbit polyclonal anti-rotavirus IgG. 
Blots were developed after incubation with alkaline phosphatase 
conjugated anti-mouse IgG, anti-goat IgG or anti-rabbit IgG (all from Sigma-
Aldrich, St. Louis, US) using 1-stepTM NBT/BCIP blotting detection reagents 
(Pierce, Rockford, US). Protein concentration was estimated by 
densitometry analysis of scanned images using the open source Image J 
software version 1.41a (http://rsb.info.nih.gov/ij/) or ImageQuant® software 
for Microsoft® Windows NT® (Molecular Dynamics, Inc., US, 1998).  
3.6. RLPs purification, quantification and characterization 
The purification of RLPs was performed using in-house developed methods 
consisting in depth filtration, ultrafiltration and size exclusion 
chromatography as stepwise unit operations [25; 26].  
The total protein content in purified RLPs was determined using the BCA 
protein quantification assay kit (96-well plate protocol) (Pierce, Rockford, 
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US). Characterization of RLPs (integrity and morphology) was performed 
by TEM as described elsewhere [26]. 
3.7. Parameter estimation algorithm 
A kinetic parameter estimation program was developed in MATLABTM (The 
MathWorks, Inc., US, 1994-2006). The program minimizes the residuals in 
the sense of least squares employing the Levenberg-Marquardt algorithm. 
The mathematical model equations 5.1 to 5.19 were integrated using the 
4th/5th order Runge-Kutta solver (MATLABs’ ode45 function) modified to 
handle ordinary differential equations with time delays. The final residuals 
and Jacobian matrix served to calculate an approximation to the Hessian 
matrix, thereby assuming that the final solution is a local optimum. The 
Hessian matrix enabled to calculate the parameters covariance matrix and 
parameters 95% confidence intervals. The MATLABs’ nlparci function was 
used for this calculation. 
The accuracy of baculovirus stock titers is determined by the consistency 
and reproducibility of the titration method. Commonly applied methods 
present errors between 7% and 36% [27] that inherently affect the MOI 
determination for a specific experiment. The experimental error in the 
determination of the MOI is critical because it propagates exponentially in 
the calculation of the intracellular vDNA templates, thus having a major 
impact on the overall virus dynamics. To overcome this problem, for the 
purpose of kinetic parameters estimation, equations 5.1 to 5.7 were 
“bypassed” and the data of the first 5 hpi was not considered for parameter 
calibration. This allowed estimating more accurately the vDNA replication, 
transcription and translation parameters. 
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4. RESULTS AND DISCUSSION 
4.1. Model calibration and validation 
The calibration of the mathematical model used 5 experiments (Exp 1-5 in 
Table 15) while model validation used 4 additional experiments (Exp 6-9 in 
Table 15). Estimated parameters related to baculovirus infection and 
trafficking are presented in table 16 while estimated parameters related to 
viral protein expression are presented in table 17.  
Table 16. Baculovirus infection and trafficking parameters. 
Parameter Value Reference 
ka  
kd1  
τtraf   
ηtraf 
k* 
δ*  
7.8×10-8ml.cell-1.h-1 
0.0008h-1 
1.8h 
0.5 
0.0017 ± 0.0003h-1 
233 ± 7h 
[19] 
[17; 18; 28] 
[13] 
[13] 
[28] 
[28] 
Table 17. Viral protein expression parameters. 
Parameter  vp2 vp6 vp7 
kRDNA (h-1)  0.19 ± 0.01 
δDNA,low (hpi)  6 
polh 0.12 ± 0.01 0.16 ± 0.02 0.11 ± 0.01 
kSRNA,j (h-1) 
p10 - - 0.46 ± 0.01 
kDRNA,j (h-1)  0.019 ± 0.004 0.025 ± 0.005 0.013 ± 0.004 
polh 0.19 ± 0.02 1.0 ± 0.1 0.058 ± 0.007 
k*VP,j (μg.cell-1.h-1)×10-6 
p10 - - 0.751 ± 0.007 
KRNA (RNA.cell-1)  0.2×104 A 
δVP,low (hpi)  15 
A - fitted by trial and error 
The parameters’ estimates show high statistical confidence. Figure 27 
shows model predictions against the corresponding measured variables for 
both the calibration and validation datasets. 
The 95% confidence prediction errors are as follows: Ni ± 0.10×106 cell.ml-
1, DNAjnuc ± 0.58×104 DNA.cell-1, RNAj ± 0.32×104 RNA.cell-1 and VPj ± 
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1.19×101 μg.ml-1. In the following sections, we analyze in detail the 
modelling results. 
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Figure 27. Model predictions over measured variables: infected cells concentration (A), 
intracellular vDNA (B) and mRNA (C) concentration, and total viral protein concentration (D). 
The full line (⎯) indicates the average model prediction and the dashed lines (---) represent 
95% confidence prediction errors. Open (,  and ) and closed (,  and ) symbols 
denote data resulting from calibration and validation experiments respectively. Triangles, 
squares and circles represent data of genes coding for vp2, vp6 and vp7 respectively. 
4.2. Effect of viral infection on cell death rate 
The intrinsic cell death rate of Sf-9 cells, kd1 = 0.0008h-1 is in agreement 
with previous studies [17; 18]. Upon viral infection, the increase in cell 
death rate, characterized here by kd2, exhibits some variability depending 
A B
C D
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on the viral loading. For example, the kd2 is reportedly higher in the 
Co2+6+7 strategy (MOI = 15 virus.cell-1) than in the S2, S6, S7 and S2/6/7 
experiments in consequence of the higher MOI used (MOI = 5 virus.cell-1), 
bringing about a more rapid decrease in cell viability (see for instance [29]). 
Higher MOI leads to higher packing of baculoviruses inside the cell 
inducing faster cell death through apoptosis. This effect on the kd2 is well 
described by the empirical function defined in equation 5.7, as 
demonstrated in figure 28. 
 
Figure 28. Dynamics of infected cell population. The lines and symbols denote model 
simulations and measurements respectively: experiment S2 (full line, ⎯, open triangles, ), 
experiment S6 (dashed line, ---, open squares, ), experiment S7 (dotted line, ⋅⋅⋅⋅, open 
circles, ), experiment Co2+6+7 (dash and dot line, -⋅-⋅-, open diamonds, ) and 
experiment S2/6/7 (dash-dot-dot line, ⋅⋅-⋅⋅-⋅⋅, closed triangles, ). 
4.3. The dynamics of intracellular vDNA 
Figure 29 shows vDNA measurements and model predictions for the 
experiments S2, S6, S7, Co2+6+7 and S2/6/7. The vDNA replication 
patterns are well described by first order replication kinetics, which is 
consistent with template-limited replication. The apparent vDNA replication 
rate is 0.19 ± 0.01 h-1 and appears to be independent of the construct used. 
Indeed, in the monocistronic and multicistronic vectors used in this work, 
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the size of genes coding for the three viral proteins represents less than 5% 
of the baculovirus genome size [30]. Therefore the genome size factor is 
expected to have a minor effect on the replication kinetics. At least nine 
genes are known to be involved in vDNA replication [31]. The expression of 
these genes, including the dnapol and dnahel, seems not to be a 
differentiation factor between the monocistronic and multicistronic vectors. 
 
 
 
Figure 29. Dynamics of intracellular vDNA2 (A), vDNA6 (B) and vDNA7 (C). The lines and 
symbols denote model simulations and experimental data respectively: experiments S2, S6 
and S7 (full line, ⎯, closed triangles, ), experiment Co2+6+7 (dashed line, ---,  closed 
diamonds, ) and experiment M2/6/7 (dotted line, ⋅⋅⋅⋅, closed squares, ). The evaluation of 
total intracellular vDNA effect on the time-schedule for viral replication (metabolic decay) 
was also assessed based on equations 5.17 to 5.19 (D). The full line (⎯) represents model 
simulation and closed diamonds () experimental data. 
The concentration of intracellular vDNA converges asymptotically to a 
maximum intracellular load (Figures 29A to 29C). Rosinski et al. (2002) 
suggested that the progressive decrease in vDNA replication rates could be 
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caused by a virus shift from DNA polymerase to its own dedicated viral 
RNA polymerase, which only acts on its unique promoter motifs. This 
hypothesis was supported by the observation that the maximum vDNA 
content coincided with the onset of very late gene expression, at 
approximately 20 hpi for a MOI of 20 virus.cell-1. In our system, the 
maximum vDNA levels are reached much later, between 48 hpi and 60 hpi, 
thus refuting the aforementioned hypothesis. 
This suggests that the halt of vDNA replication is practically coincident in 
time, with few exceptions, with the halt of protein expression and also with 
the increase in cell death rate. Therefore, this behaviour is here interpreted 
as being related with the intrinsic metabolic decay due to infection. In our 
model, the effect of the metabolic decay was expressed by equations 5.17 
and 5.19 as a function of intracellular vDNA. Figure 29D illustrates this 
dependency. The MOI plays here an important role. High MOIs result in 
faster vDNA replication and eventually in the reduction of the time interval 
for vDNA replication and protein expression. This effect has been 
previously observed in several studies [18; 20; 21; 32]. 
4.4. Virus budding 
In theory, the apparently constant vDNA concentration for t > δD (hpi) could 
result from vDNA release into the extracellular medium through virus 
budding that would compensate for vDNA replication (virus budding is 
known to commence around 17-20 hpi [12; 33]). However, according to 
Rosinski et al. (2002), virus budding is considerably lower than the 
intracellular replication. This suggests that the virus makes much more 
vDNA than it is able to encapsidate and release. To confirm this 
hypothesis, extracellular vDNA was quantified for the co-infection 
experiment Co2+6+7. The maximum extracellular vDNA obtained was 
2.54×109 copies.ml-1 (DNA2+DNA6+DNA7) at time t = 80.5 hpi, which 
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represents 11% of the intracellular vDNA, thus confirming that virus 
budding is much lower than vDNA replication for the MOI ranges used. 
4.5. mRNA synthesis 
Figure 30 shows mRNA measurements and model predictions for the 
experiments S2, S6, S7, Co2+6+7 and S2/6/7. 
  
 
Figure 30. Intracellular dynamics of RNA2 (A), RNA6 (B) and RNA7 (C). The lines and 
symbols denote model simulations and experimental data respectively: experiments S2, S6 
and S7 (full line, ⎯, closed triangles, ), experiment Co2+6+7 (dashed line, ---,  closed 
diamonds, ) and experiment M2/6/7 (dotted line, ⋅⋅⋅⋅, closed squares, ). 
Typically, intracellular mRNA increases fast at the onset of the infection 
cycle up to a maximum level after which it starts decaying. The increase in 
mRNA concentration follows closely the increase in vDNA. The maximum 
marks the time instant when the mRNA transcription rate becomes lower 
than the corresponding degradation rate. The halt in mRNA synthesis is 
practically coincident in time with the halt in vDNA replication. In general, 
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the higher the intracellular vDNA levels the higher are the corresponding 
mRNA levels. The only exception to this scenario was verified for the gene 
coding for vp7, whose transcription is controlled by different promoters: polh 
in monocistronic vectors (Exp. 1 to 4) and p10 in multicistronic vectors 
(Exp. 5). 
The synthesis of mRNA is well described by first order transcription 
kinetics. The characteristic transcriptional rates for the genes coding for 
vp2, vp6 and vp7 under the control of the polh promoter are 0.12 ± 0.01 h-1, 
0.16 ± 0.02 h-1 and 0.11 ± 0.02 h-1 respectively. These values fail to 
conform with the rule of the size of the genes: the smaller the gene the 
faster it is transcribed (the sizes of the genes coding for vp2, vp6 and vp7 
are 2690, 1356 and 1062 bp respectively). Presuming a characteristic RNA 
polymerase elongation rate profile, the resulting transcriptional rates should 
be such that ksrna,7 > ksrna,6 > ksrna,2. Since the aforementioned rates were 
consistent for S2, S6, S7 and Co2+6+7 experiments, a possible justification 
for this ranking is the use of different restriction sites for cloning. The 
transcription of polh and p10 genes, starts within a baculovirus late 
promoter motif TAAG [34]. Modifications in the 5’ untranslated regions 
(UTRs), between the TAAG motif and the ATG translational start codon, 
and in the 3’ UTR of the baculovirus genome are known to have some 
influence in the translation and transcription levels [35-40]. 
It should be noticed that the previous transcription rates were the same for 
all the experiments except for the transcription of the gene coding for vp7 
(under the control of p10 promoter) in M2/6/7 (Exp. 5), which was 0.46 ± 
0.01 h-1. This exceptionally high ksrna,7 resulted in a higher mRNA7 
concentration when compared to Co2+6+7, even though the concentration 
of vDNA7 was lower (Figure 29C vs 30C). The justification for this variation 
cannot be directly attributed to the strength of the promoter since the levels 
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of polh and p10 driven expression are expected to be similar [41]. The 
interaction between polh and p10 promoters are however known to 
influence the level of gene expression [42]. A relevant point is that, for the 
M2/6/7 experiment, where the transcription of the viral genes occurs from 
the same DNA template, the ranking of the transcriptional rates according 
to gene size is obeyed. 
4.6. Protein synthesis 
Figure 31 shows the dynamics of measured total (intracellular plus 
extracellular) protein, VPj (μg.ml-1), whereas Figure 32 shows model 
predictions of intracellular protein only. 
  
 
Figure 31. Total (intracellular plus extracellular) protein dynamics of vp2 (A), vp6 (B) and 
vp7 (C). The lines and symbols denote model simulations and experimental data 
respectively: experiments S2, S6 and S7 (full line, ⎯, closed triangles, ), experiment 
Co2+6+7 (dashed line, ---,  closed diamonds, ) and experiment M2/6/7 (dotted line, ⋅⋅⋅⋅, 
closed squares, ). 
Production Optimization of Rotavirus-Like Particles: A Systems Biology Approach 
177 
The dynamics of intracellular protein and vDNA show similar patterns. 
Intracellular protein concentration VPjint converges asymptotically to a 
maximum level that is highly correlated with the corresponding maximum 
vDNA level. Indeed, higher intracellular vDNA concentrations induce higher 
mRNA transcription levels and ultimately higher intracellular protein 
concentrations. This was verified, whenever the gene expression was 
under the control of the polh promoter. The unique exception was the gene 
coding for vp7 in M2/6/7 (under the control of p10 promoter), where 
significantly higher mRNA7 concentrations were achieved from significantly 
lower DNA7 templates (Figures 29C and 30C). 
 
 
Figure 32. Intracellular vp2 (A), vp6 (B) and vp7 (C) concentrations. The lines represent 
model simulations: the full line (⎯) denotes S2, S6 and S7 strategies, the dashed line (---) 
strategy Co2+6+7 and the dotted line (⋅⋅⋅⋅) strategy M2/6/7. 
Protein synthesis seems to be reasonably well described by Michaelis-
Menten kinetics on mRNA. The maximum protein synthesis rate varies 
considerably (see Table 17). The rate of protein synthesis may vary due to 
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codon usage and/or size of protein and also the time for maturation. The 
vp7 formation takes more time, approximately 0.5 h [43] since it is a 
glycosylated protein. 
4.7. Analysis of protein dynamics 
The following analysis will be focused on the dynamics of protein 
stoichiometric ratios and on their comparison with the composition of 
correctly assembled RLPs in the Co2+6+7 and M2/6/7 experiments. The 
relative mass composition of vp6/vp2 and vp7/vp2 in correctly assembled 
particles is Y6/2 = 2.8 (w/w) and Y7/2 = 2.4 (w/w) respectively. Figure 33 
shows the dynamics of Y6/2 and Y7/2 for the M2/6/7 and Co2+6+7 strategies. 
It is clear that in the M2/6/7 experiment there is an excess of vp7, especially 
during the first 48 hpi. During this period, approximately 80% (w/w) of the 
final vp7 was already synthesized (see Figure 31C). It is likely that the vp7 
outer layer can only be formed after the vp2 and vp6 layers are correctly 
assembled. Therefore, such high vp7 levels at the beginning will probably 
favour the assembly of malformed particles. The experimental Y6/2 is 
systematically above the theoretical value; hence, it is likely that vp2 is the 
limiting protein for the assembly of RLP. 
 
Figure 33. Dynamics of proteins stoichiometric ratios. The doted lines represent the relative 
mass composition of vp6/vp2 (Y6/2 = 2.8 (w/w)) and vp7/vp2 (Y7/2 = 2.4 (w/w)) in correctly 
assembled particles. Model simulations are denoted by symbols: closed squares () 
indicate Y6/2 whereas open squares () represents Y7/2 in Co2+6+7 strategy; closed 
triangles () and open triangles () represents Y6/2 and Y7/2 respectively in M2/6/7 strategy.  
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Analyzing the Co2+6+7 strategy, experimental values of Y7/2 are lower than 
the theoretical value. Thus, this strategy is prone to produce particles 
composed of vp2 and vp6 layers (vp6 is not limiting since Y6/2 > 2.8 (w/w)), 
but with the outer vp7 shell only partially formed or even completely absent. 
The volumetric productivity of M2/6/7 and Co2+6+7 strategies, after 
purification, reflects the observed strong under-expression of vp7 in the 
Co2+6+7, leading to a lower RLP titer: 430 μg/ml in Co2+6+7 and 662 
μg/ml in M2/6/7.  
In the end, single-infection strategies appear to be advantageous over co-
infection for RLP production. This suggests that process optimization can 
be achieved through the redesign of recombinant baculovirus vectors, 
namely at the promoters’ level since different promoters may induce 
different levels of expression at more convenient times for correct particle 
formation. On the other hand, the co-infection strategy offers additional 
degrees of freedom for process optimization and has thus gained more 
attention in recent years. Theoretically, the time evolution of vp2:vp6:vp7 
stoichiometric ratio can be manipulated by the MOI of the respective 
baculovirus and, to a less extent, by scheduling the time of infection (TOI) 
of individual monocistronic baculoviruses. In addition, RLPs production can 
be significantly improved by controlling the cell concentration at infection 
(CCI), as long as specific productivities could be maintained.  
 
5. CONCLUSIONS 
In this work we proposed a deterministic mathematical model of the 
baculovirus/insect cell system for the production of viral proteins and RLPs. 
The model addresses the most critical steps of baculovirus internalization 
and trafficking, and gene expression mechanisms. The main objective of 
Chapter 5. Model-based assessment of multiple infection strategies 
180 
this modelling study was to understand and quantify the effect on viral 
protein synthesis and RLP formation of different infection strategies, and 
evaluate the effect of different promoters. This modelling tool may allow 
redesigning better baculovirus vectors and is a starting point to optimize 
infection parameters such as MOI, TOI or CCI in co-infection experiments. 
The proposed model represents a good compromise between complexity 
and accuracy. A relatively small number of kinetic parameters are involved, 
which were estimated with high statistical confidence in most cases. From 
the analysis of the modelling results, the following more specific 
conclusions may be outlined: 
• A characteristic apparent vDNA replication rate of 0.19 ± 0.01 h-1 was 
obtained for monocistronic and multicistronic baculovirus constructs; 
• Virus budding is lower than vDNA replication for MOI > 2 virus.cell-1; 
• The vDNA translation and transcription is well described by first-order 
and Michaelis-Menten kinetics, respectively. Reproducible kinetic 
parameters for the polh and p10 promoters were obtained; 
• The p10 promoter in the M2/6/7 leads consistently to a much higher 
vp7 expression than when polh controls vp7 expression in the Co2+6+7 
and S7 experiments; 
• The time windows for effective vDNA, mRNA and protein synthesis are 
highly correlated. High MOIs tend to increase vDNA replication, but, at 
the same time, the metabolic burden is more severe, thereby 
decreasing the time window for effective protein expression; 
• In terms of RLP synthesis, single-infection experiment leads to both 
vp6 and vp7 over-expression. However, the high vp7 expression at the 
beginning of the infection cycle is undesirable. It is the expression of 
vp2 that limits the assembly of RLPs; 
• In co-infection experiments, vp7 is largely under-expressed. Thus, 
probably particles of vp2 and vp6 with incomplete vp7 shell are formed. 
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Optimized infection strategies are required to increase the expression 
of vp7. 
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Summary 
In this study, the theoretical effect of MOI and promoter strength on RLP 
production at single and co-infection strategies was investigated using the 
stochastic model developed in Chapter 3. 
RLP production can be optimized in single-infection strategies by 
manipulation of the MOI (lower MOIs) and/or by redesigning baculovirus 
vectors, in which the promoters controlling viral protein expression can be 
selected according to their strength (lowering the strength of the promoter 
controlling vp7 expression in relation to the other two promoters). At co-
infection strategies, high MOIs maximize RLP production; the redesign of 
baculovirus vectors configures a somewhat modest improvement potential. 
At low MOIs, single-infection strategies offer significant advantages over 
co-infection experiments, namely: 1) ni,267 can reach up to 3×106 cell.ml-1, 
contrasting with the 0.6×106 cell.ml-1 at co-infection; 2) higher RLP 
concentrations: 30-60 mg.L-1 against the 6-12 mg.L-1 at co-infection; 3) 
assembly efficiencies are higher: 72% against the 20-40% at co-infection. 
At high MOIs, the differences in model outputs for co- and single-infection 
strategies are meaningless. 
The findings described throughout this chapter demonstrate that the 
redesign of baculovirus vectors, in which the promoters controlling viral 
protein expression can be selected according to their strength, and the 
manipulation of the MOI have great potential for process optimization. The 
practical implementation of these concepts may not be easy since it 
depends on the available resources, namely the type of recombinant 
baculoviruses (tricistronic or monocistronic), and on the knowledge of 
molecular biology techniques, essential for the construction of novel 
recombinant baculoviruses. 
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1. INTRODUCTION 
One of the most promising immunization strategies against rotavirus 
disease consists on a subunit vaccine based on virus-like particles 
produced in the baculovirus/insect cell system - rotavirus-like particles 
(RLP) [1-4]. Yet, production of this vaccine candidate has been hindered by 
the complexity of the RLP production process, characterized by low 
volumetric productivities and high amounts of unassembled proteins (up to 
88% of the total mass of proteins expressed) [5-12]. 
Increased productivity and assembly efficiency can be achieved through 
the redesign of baculovirus vectors and through the infection strategy. Both 
factors are interlinked and cannot be analyzed separately. Two possible 
strategies can be pursued: 1. co-infection, where cells are infected with 
three monocistronic baculoviruses enclosing the genes coding for rotavirus 
proteins vp2, vp6 or vp7; 2. single-infection strategies, where cells are 
infected with tricistronic baculoviruses enclosing the genes coding for the 
three viral proteins simultaneously [12]. In single-infection, the control of 
protein expression is achieved at the genetic level, while in the co-infection 
strategy the same is attempted at the process level. 
Co-infection strategies allow to control the time and quantity of genes 
delivered into the insect cells. This strategy provides in theory some degree 
of control of relative protein expression titers, which is a key factor for 
assembly efficiency as demonstrated in Chapter 4. It is likely that 
productivities may be highly improved through manipulation of key process 
parameters such as the multiplicity of infection (MOI).  
In single-infection strategies, different promoters may induce different 
expression levels at more convenient times; hence, the optimization of RLP 
titer and assembly efficiency can be achieved via baculovirus vector 
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redesign. In theory, using promoters with different strengths, it would be 
possible to make vp2, vp6 and vp7 expression levels coincide with the 
stoichiometric composition of the RLP, the optimal condition for particle 
assembly (Chapter 5). 
This works aims at evaluating the effect of MOI (low and high) and 
promoter strength on RLP production for both scenarios of single and co-
infection strategies using the stochastic model developed in Chapter 3 [13]. 
 
2. THE MATHEMATICAL MODEL 
In this study, the stochastic model described in Chapter 3 was extended for 
simultaneous expression of the three viral proteins that compose RLP. The 
complete set of equations is presented in Table 18. Note that index k=2,6 
and 7 refer to vp2, vp6 and vp7 respectively, while in Chapter 2 only vp2 
was studied. Moreover, a stoichiometric assembly equation is included (last 
equation in Table 18). The assumptions behind this model were discussed 
previously in Chapter 3. The most critical of these, are the following: 
• nutrients are in excess, thus, not limiting cellular growth; 
• the sizes of the monocistronic and tricistronic baculovirus constructs 
are similar; thus, vDNA replication kinetics is assumed to be the same 
for the different constructs; 
• a characteristic host ribosomal elongation rate of 5.5×106 bp.rna-1.h-1 
and mRNA transcription rate of 325 bp.h-1 were assumed (estimated 
in Chapter 3). The main distinguishing factor in mRNA transcription 
rate and viral protein translation rate of vp2, vp6 and vp7 is the size 
of the underlying gene [13]; 
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Table 18. Mathematical model equations. 
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RLP 
production Limiting protein 
[ ] [ ] [ ]( )7/26/27/26/27/26/27/26/2 /YY1/Y1 vp7, /YY1/Y1 vp6, YY1vp2minRLP ++×++×++×=  
nu – concentration of uninfected cells (cell.ml-1); μmax – specific cell growth rate (0.03 h-1) [14]; kd – cell death rate (h-1); ni – concentration 
of infected cells (cell.ml-1); kd,int – intrinsic cell death rate of Sf-9 cells (0.0008 h-1) [10, 15, 16]; Δkd – increase in cell death rate due to 
infection (0.0017 ± 0.0003 h-1) [10]; TOI - time of infection (h); δ* - time required for the infection to accelerate host cell death (hpi); dnak - 
intracellular vDNA concentration delivered by virus k; k - denotes the foreign gene; rinf,k - rate of virus k entry into Sf-9 cells (dna.cell-1h-1); 
Xk - random variable denoting the number of viruses k per unit cell (dna.cell-1) which penetrate Sf-9 cells in the time interval [t, t+dt]; δre-inf - 
time period over which cells continue to be re-infected (10 hpi) [16]; ka - first order attachment constant (7.8×10-8 ml.cell-1.h-1) [17]; vk - 
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concentration of extracellular virus k (dna.ml-1); rbud,k - virus budding rate (dna.cell-1.h-1); ηt.- trafficking efficiency (0.5) [18]; rdnarep,k - vDNA 
replication rate (dna.cell-1.h-1); kRDNA - first-order vDNA replication constant (0.49 ± 0.03 h-1); δDNA,low - time for the onset of vDNA 
replication (6 hpi) [19, 20]; δ* - time at which vDNA replication stops (hpi); δ10 - time instant correspondent to 10 intracellular vDNA copies 
(233 ± 7 hpi) [10]; δbud,low and δbud,high - time of onset and halt of virus budding (16 and 52 hpi) [16, 21]; kbud - first-order virus budding 
constant (0.07 ± 0.02 h-1); rnak - intracellular concentration of mRNA coding for protein k (rna.cell-1); rtransc,k - transcription rate (rna.cell-1.h-
1); kDRNA,k – first-order degradation rate (0.019 ± 0.004 h-1) [10]; krna,elong - RNA polymerase elongation rate (325 ± 69 bp.h-1); Sk - size of 
gene k (2690 bp) [10]; δpolh,low - time post infection for the onset of polh promoter transcription (15 hpi) [10, 22]; vpk - concentration of 
intracellular viral protein k (μg.cell-1); rtransl,k – protein synthesis rate (μg.cell-1.h-1); krib,elong - the ribosomal elongation rate (5.5 ± 0.6 ×106 
bp.rna-1.h-1); mpk - molecular weight of vpk (1.69×10-13 μg) [23]; itransl - adimensional parameter to account for the hypothesis of a 
maximum translation capacity; Ltransl,max - maximum translation capacity (1.1 ± 0.3 ×107 rna.bp.cell-1); Y6/2 - stoichiometric ratio of vp6/vp2 
in correctly assembled RLP; Y7/2 - stoichiometric ratio of vp7/vp2 in correctly assembled RLP. 
• there is a maximum translation capacity constraint [13] and, as such, 
vp2, vp6 and vp7 translation compete for host translation machinery. 
This is the factor that distinguishes the expression of a single protein 
from multiple proteins; 
• virus budding is considered as it plays a key role at low MOIs [13]; 
• for simplicity and computational reasons, intracellular and total RLP 
production were calculated using the irreversible model (see Chapter 
4), i.e. assembly efficiency is determined by the limiting protein and 
RLP stoichiometry (last equation Table 18). 
Despite the obvious advantages in terms of computational time, this latter 
assumption is debatable. As shown in Chapter 4 (Figure 25), the 
irreversible model predicts higher efficiencies than the thermodynamic 
assembly model. However, as the ΔG0RLP decreases, i.e. physicochemical 
conditions are optimal for RLP assembly, the equilibrium model converges 
to the irreversible model. As such, the present analysis assumes that the 
host provides the ideal thermodynamic conditions for particle assembly.  
 
3. SENSITIVITY ANALYSIS OF MODEL PARAMETERS 
Model parameters sensitivity analysis was performed for the case of single 
protein expression, namely vp2, at a constant MOI of 0.1 virus.cell-1. Note 
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that this MOI was determined to be the optimal MOI for vp2 production in 
Chapter 3. The effect of 5%, 10%, 25% and 50% model parameters 
perturbations, either negative or positive, upon cellular growth, progeny 
virus synthesis, intracellular kinetics and protein expression was 
determined (Figures 34 to 37). 
Negative and positive perturbations in model parameters affect differently 
the output of the model. For example, a 50% increase in the value of μmax 
(specific cell growth rate) induces a higher variation in the concentration of 
uninfected cells (nu) when compared to 50% decrease; the opposite occurs 
for ka (first order attachment constant) and kRDNA (first-order vDNA 
replication constant) (Figure 34A). This is also observed for kRDNA in vDNA 
replication (Figure 36A) and for S2 (size of gene coding for vp2) in total 
protein concentration (Figure 37). 
Figures 34A to 34C show that the different cell populations are not 
significantly affected by small perturbations in model parameters. Severe 
deviations are only observed when high perturbations are imposed. The 
parameters contributing most for such variation and that are common to 
every population analysed (uninfected, infected and death cell population) 
are the μmax, ka, kRDNA and δbud,high (time of halt of virus budding). 
The first-order differential equation for cell growth clearly defines the 
correlation between uninfected cells concentration and μmax (see Table 18). 
Since this relationship is exponentially-based, a small perturbation in μmax, 
either positive or negative, is expected to induce a significant variation in 
the concentration of uninfected cells. This effect further propagates to the 
remaining cell populations analysed. Thus, the higher the perturbation in 
μmax, the higher is the variation in the concentration of infected and death 
cells.  
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The variations observed in all cell populations upon perturbations in ka can 
be interpreted in two different ways. One can speculate of the negative 
impact that ka decrease has on intracellular vDNA concentration and 
progeny virus synthesis (see equations in Table 18), with its subsequent 
influence on second round of infection, characteristic of the MOI used (MOI 
= 0.1 virus.cell-1 – asynchronous infection). However, the concentration 
levels of dna2 (Figure 36A) and v2 (Figure 35) are not significantly affected. 
This suggests that ka acts directly on the concentration of infected cells; the 
lower the attachment rate of baculovirus to infected cells, the less efficient 
is the infection process. Uninfected and death cell populations are also 
affected by this parameter, although indirectly via the aforementioned 
variations in the concentration of infected cells. 
Figure 34. Sensitivity analysis of uninfected, nu (A, cell.ml-1), infected, ninf (B, cell.ml-1) and 
death cells concentration, ndeath (C, cell.ml-1) with respect to model parameter perturbations 
(%) (0-0.8 - relative variation of model outputs upon parameter perturbation with respect to 
model outputs prior to parameter perturbation). 
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Variations in kRDNA impact directly on the concentration of intracellular 
vDNA (Figure 36A) and indirectly on Δkd (increase in cell death rate due to 
infection) and δ* (time required for the infection to accelerate host cell 
Production Optimization of Rotavirus-Like Particles: A Systems Biology Approach 
195 
death). Thus, the concentration of uninfected, infected and death cells are 
expected to be significantly affected. 
The kinetics of progeny virus synthesis is highly sensitive to parameters 
such as the δbud,high (time of halt of virus budding) and rbud (virus budding 
rate) (Figure 35). In addition, changes in the specific cell growth rate, μmax, 
induce significant variations in total virus concentration whereas practically 
no effect is observed for intracellular virus production. This result is rational 
because the specific cell growth rate does not affect either the infection 
process or the replication machinery (intracellular production is 
maintained). It only impacts on the final concentration of infected cells, thus 
indirectly affecting the total concentration of viruses. 
Figure 35. Sensitivity analysis of intracellular (A, virus.cell-1) and total (B, virus.ml-1) virus 
concentration (v2) with respect to model parameter perturbations (%) (0-0.8 - relative 
variation of model outputs upon parameter perturbation with respect to model outputs prior 
to parameter perturbation). 
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Interestingly, positive and negative perturbations in kRDNA impact differently 
on the synthesis of progeny viruses. Virus budding rate seems to saturate 
at relatively low vDNA levels (1.5 dna.cell-1.h-1) suggesting that the 
bottleneck for virus budding is either the encapsidation machinery or cells 
are unable to secrete more than a specific number of viruses without 
affecting the integrity of the cellular membrane. Although the intracellular 
vDNA levels had varied with the magnitude of perturbation (Figure 36A), 
the saturation threshold was reached in both situations (positive and 
negative kRDNA perturbations). Thus, the virus budding rate per se does not 
justify the aforementioned differences. Other factor must be also 
contributing, namely the time at which virus budding rate reached its 
saturation value. Indeed, this time was delayed when kRDNA decreased as 
result of lower intracellular vDNA content. In contrast, no significant 
variation was observed when kRDNA increased. Thus, the cumulative total of 
v2 (virus.cell-1 and virus.ml-1) is expected to vary significantly with the 
decreased in the value of kRDNA but not with the increase in kRDNA. 
B 
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Figure 36A to 36C indicates that intracellular concentrations of vDNA, 
mRNA and viral protein are extremely sensitive to δ10 and kRDNA. The dna2 
variation with kRDNA is linked to the vDNA replication pattern. Since vDNA 
replication follows first-order kinetics (consistent with template-limited 
replication), minor changes in the rate of vDNA synthesis propagates 
exponentially to the concentration of dna2. The δ10 parameter influences 
vDNA concentration by scheduling the specific times for vDNA replication 
to start and stop. Knowing that vDNA replication follows first-order kinetics, 
perturbations in this time-window impacts deeply on dna2. Interestingly, the 
percentage of dna2 variation seems to be correlated with the percentage of 
δDNA,low variation; the higher the parameter perturbation, the higher is the 
output variation.  
Figure 36. Sensitivity analysis of intracellular vDNA, dna2 (A, dna.cell-1), RNA, rna2 (B, 
rna.ml-1) and protein concentration, vp2 (C, μg.cell-1) with respect to model parameter 
perturbations (%) (0-12 - relative variation of model outputs upon parameter perturbation 
with respect to model outputs prior to parameter perturbation). 
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The dynamics of intracellular rna2 and vp2 follows closely dna2 dynamics 
[13]; for this reason, δ10 and kRDNA have also a deep impact on rna2 and 
vp2. Noteworthy is the higher influence of δ10 and kRDNA on final rna2 levels 
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when compared to the influence of mRNA related parameters such as the 
gene size, S2, and the RNA elongation rate, krna,elong. This suggests that 
rna2 concentration is more dependent on the replication levels of vDNA 
than on the efficiency of the transcriptional machinery. 
The parameters with major influence on intracellular and total protein 
concentration are the gene size, S2, the molecular weight of the viral 
protein, mp2, and the ribosomal elongation rate, krib,elong, besides the 
abovementioned parameters δ10 and kRDNA (Figure 36C and 37). While 
almost irrelevant for intracellular protein expression, the μmax parameter has 
a noteworthy impact on total protein concentration. 
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Figure 37. Sensitivity analysis of total protein concentration, vp2 (μg.ml-1) with respect to 
model parameter perturbations (%) (0-3 - relative variation of model outputs upon parameter 
perturbation with respect to model outputs prior to parameter perturbation). 
Figures 34 to 37 are just examples of the amount of information that is 
possible to obtain about a given system when models such as the ones 
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presented in Chapters 3, 4 and 5 are used. The data generated is of 
paramount importance for the identification of system’s critical parameters. 
The sensitivity analysis here performed demonstrates that model outputs 
are more sensitive to changes in parameters related with vDNA and protein 
synthesis, such as δ10, kRDNA, S2, mp2 and krib,elong, than to those linked to 
cell growth, infection process, virus budding, re-infection and mRNA. 
It should be highlighted that these parameters have been estimated in 
Chapter 3 with high confidence intervals (see Table 18). Nevertheless, 
unaccounted regulatory mechanisms may impact in these parameter 
values at very different experimental conditions. If regulatory mechanisms 
are to be included in the future, they should focus on the list of most 
sensitive parameters above. An oriented design of experiments covering 
different regions of the process could be performed to tackle this issue. 
 
4. OPTIMIZATION OF RLPS PRODUCTION 
Optimal process and vector design parameters that maximise RLP 
productivity and assembly efficiency were investigated through model 
simulations. The optimisation degrees of freedom were the MOI and the 
promoter strength. Both single-infection and co-infection strategies were 
evaluated regarding their maximum productivity and assembly efficiency 
potential. Simulation time was 100 hpi for all scenarios presented below. 
Process performance was evaluated at time t=100 hpi (end of process 
simulations).  
4.1. Single-infection strategies 
In single-infection strategies, the concentration of infected cells carrying the 
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genes coding for vp2, vp6 and vp7, ni,267, is identical to the overall 
concentration of infected cells, ni, The effect of MOI on ni,267 = ni is shown 
in Figure 38. 
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Figure 38. The effect of MOI in single-infection strategies: evaluating the intracellular 
(mg.cell-1) and total (mg.L-1) RLP production and the concentration of infected cells carrying 
the genes coding for vp2, vp6 and vp7, ni,267 (cell.ml-1). 
For synchronous infection (MOI > 2 virus.cell-1), 100% infection occurs 
within the first couple of hours, meaning that maximum infected cell density 
is likely to be coincident with the cell concentration at infection (1×106 
cell.ml-1). As time proceeds, infected cells began to die more rapidly as 
result of viral replication; the higher the viral load, the higher is the cell 
death rate. Thus, as MOI increases from 2 to 100 virus.cell-1, ni,267 
decreases accordingly (Figure 38). For asynchronous infection (MOI < 1 
virus.cell-1), only a small fraction of cells is infected initially; the lower the 
MOI, the lower is the concentration of infected cells. Uninfected cells will 
continue growing till the moment they are infected by newly formed viruses 
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that, in the meantime, bud from infected cells. Thus, ni,267 increases with 
the corresponding decrease in MOI. 
The intracellular kinetics of RLP production converge to a maximum value, 
consistent with saturation in the translation machinery as described in 
Chapter 3 for vp2 production (data not shown). This maximum was found 
to be a function of the MOI; the higher the MOI, the higher is the 
intracellular production of RLPs. The total concentration of RLPs depends 
more on the concentration of infected cells rather than on the intracellular 
production of RLPs. This explains why high intracellular RLP 
concentrations were not translated into high total RLP concentrations. 
Thus, the lower the MOI, the higher is ni,267 and the higher is the total 
concentration of RLPs. 
Noteworthy is the independency of the assembly efficiency on the MOI 
(data not shown). This result is however rational because the genes coding 
for vp2, vp6 and vp7 are enclosed within the same baculovirus genome. 
Thus, the MOI is expected to have no influence on the ratios vp6/vp2 and 
vp7/vp2; it only impacts on the expression levels of each viral protein. The 
estimated assembly efficiency was around 72%. 
In conclusion, it does not bring any advantage to increase the MOI to very 
high levels in single-infection experiments due to the saturation of protein 
translation machinery, which has a lower impact on total RLP concentration 
than that of the concentration of infected cells which is maximised at low 
MOIs. 
4.1.1. The effect of promoter strength 
Optimisation of RLP production and assembly efficiency via vector design 
was investigated. More specifically, the effect of promoter strength on RLP 
assembly was studied at aid of model simulations. The strength of the 
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promoter controlling vp2 expression (Pvp2) was kept constant in all 
simulations whereas the promoter strength ratios Pvp6/Pvp2 and Pvp7/Pvp2 
varied between 0.1 and 10. The transcription rate defined in Table 18 will 
be used to reflect these variations. For simplification, the case where all 
genes are under the control of promoters with equal strengths - Pvp6/Pvp2 = 
Pvp7/Pvp2 = 1 - will be called from here on as “standard case”. 
Variations in promoters’ strength had a meaningless effect on the final 
concentration of infected cells (data not shown) because the strength of a 
promoter does not impact on cellular growth; it only affects the transcription 
and translation mechanisms. In contrast, they had a major impact on 
intracellular and total RLP production and assembly efficiency; a 
representative example is shown in Figure 39. 
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Figure 39. The effect of promoter strength on total RLP concentration (A, mg.L-1) and 
assembly efficiency (B, %) for single-infection strategies at MOI=0.01 virus.cell-1. The 
horizontal green surfaces are purely illustrative; they reflect the total RLP concentration (61 
mg.L-1) and the assembly efficiency (72%) achieved in the case where all genes are under 
the control of promoters with equal strengths - Pvp2 = Pvp6 = Pvp7 = 1. They serve the 
purpose of aiding the reader in visualizing what conditions potentiate the increase in model 
outputs (region above the surface); below the surface, promoter strength variations have a 
negative impact on model output. 
The combination of promoters’ strength maximizing RLP production and 
assembly efficiency was Pvp6/Pvp2 = 1 and Pvp7/Pvp2 = 0.6, irrespective of 
the MOI (see example in Figure 39). By decreasing Pvp7/Pvp2 from 1 
(standard case) to 0.6, the expression of vp7 decreased in consequence of 
lower rna7 concentration. As a result, the ratio vp6/vp7 increased to levels 
close to the RLP stoichiometric ratio (1.21), meaning that few vp7 and vp6 
were not assembled into RLPs. Although the ratio vp6/vp2 had remained 
below the stoichiometric ratio of 2.84 (vp6 is the limiting protein), the 
aforementioned combination of promoters’ strength was the one minimizing 
more the total amount of unassembled proteins (see example in Figure 40).  
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Figure 40. The effect of promoter strength on intracellular protein expression (mg.cell-1) for 
single-infection strategies at MOI=0.01 virus.cell-1. Graph A represents the standard case 
(Pvp2 = Pvp6 = Pvp7 = 1) while graph B represents the infection strategy where Pvp6/Pvp2 = 1 
and Pvp7/Pvp2 = 0.6. 
If vp6 is the limiting protein in the standard case, one could speculate that 
Pvp6/Pvp2 higher than 1 would even the relation between vp6 and the other 
two proteins. However, since maximum translation capacity is a function of 
RNA levels (see Table 18), the increase in Pvp6 induces higher translation 
machinery utilization, positively impacting on the concentration of vp6 but 
strongly inhibiting the expression of vp2 and vp6. Consequently, RLP 
production and assembly efficiency are compromised. These results 
suggest that the balance between promoter strength and translation 
machinery utilization is critical for maximum process performance. 
Figure 41 depicts the maximum increase in intracellular and total RLP 
production that can be achieved through genetic redesign for a selective 
range of MOIs studied in Figure 38. In other words, for each MOI, it 
compares the best case achieved by manipulation of promoters’ strength 
with the standard case. 
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Figure 41. The effect of promoter strength on intracellular (mg.cell-1) and total (mg.ml-1) RLP 
production for single-infection strategies: maximum increase in RLP production (%) that can 
be achieved through genetic redesign for a selective range of MOIs. 
An improvement between 7% and 18% in RLP production and around 24% 
in assembly efficiency was achieved when compared to the standard case. 
Although configuring a somewhat modest improvement potential, these 
data demonstrate that the redesign of baculovirus vectors, in which the 
promoters controlling viral protein expression can be selected according to 
their strength, can improve RLP production and minimize the amount of 
unassembled proteins. 
4.2. Co-infection strategies 
The effect of MOI on cell growth, RLP production and assembly efficiency 
in co-infection strategies was investigated through model simulations. The 
number of monocistronic baculoviruses coding for vp2 per cell (MOI2) used 
for process simulations varied from 0.01 to 100 virus.cell-1; the number of 
monocistronic baculoviruses coding for vp6 and vp7 per cell, MOI6 and 
MOI7 respectively, were defined so that MOI6/MOI2 and MOI7/MOI2 could 
vary between 0.01 and 10. For each MOI2, the optimal MOI6 and MOI7 
maximizing process outputs were selected for representation in Figure 42. 
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Figure 42. The effect of MOI on intracellular (mg.cell-1) and total (mg.ml-1) RLP production, 
assembly efficiency (%), concentration of infected cells carrying the genes coding for vp2, 
vp6 and vp7, ni,267 (cell.ml-1) and maximum ni,267, ni,267,max (cell.ml-1) for co-infection 
strategies. The overall infected cell concentration is denoted by ni. For each MOI2, the 
optimal MOI6 and MOI7 maximizing process outputs were selected for representation. 
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As expected, the probability of a cell being infected by the three 
monocistronic baculoviruses was found to be highly dependent on the MOI 
(Figure 42). The sigmoidal curve of ni,267/ni as function of MOI shows that 
high MOIs favours the synchronous infection of insect cells with the three 
monocistronic baculoviruses, mostly as a consequence of the high initial 
concentration of baculoviruses; thus, ni,267/ni converged to 1 and maximum 
ni,267 values (ni,267,max) coincided with the initial uninfected cell concentration 
(1×106 cells.ml-1). As the MOI decreases (< 2 virus.cell-1), the probability of 
a cell population not being infected with the three recombinant 
baculoviruses increases due to the random nature of virus binding to the 
host cells surface. For these reason, the ratio ni,267/ni as well as the ni,267,max 
are significantly lower than the ones observed for high MOIs. The apparent 
local minimum of ni,267,max at MOI2=1 virus.cell-1 can be explained by the 
following factors: the MOI is insufficient to ensure that all cells are infected 
by the three baculoviruses but sufficiently high for 100% infection in the first 
infection cycle. By the time that virus budding commences, re-infection is 
no longer possible; hence, most of the cells will remain infected by only one 
or two baculoviruses, which significantly reduces ni,267,max. 
The profiles of ni,267 and ni,267,max with respect to MOI are very similar. At 
low MOIs they almost coincide, meaning that maximum concentration of 
cells carrying the genes coding for the three viral proteins are achieved at 
the end of process simulations. At high MOIs (> 2 virus.cell-1) they differ 
significantly; the lower ni,267 values are related with the “metabolic burden” 
effect caused by the high intracellular viral load. Therefore, the advantage 
of using low MOIs for achieving high infected cell concentrations, as in 
single infection experiments, turns out to be useless in co-infection 
experiments as the probability of a host cell carrying the three genes coding 
for vp2, vp6 and vp7, proteins necessary to build the RLP, is very low. 
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The intracellular RLP concentration profile follows closely the one of single-
infection (compare Figure 38 and Figure 42); upon an apparent plateau for 
MOI < 10 virus.cell-1, intracellular RLP production increases with the 
increase in the MOI. The profile of total RLP concentration is different. At 
MOIs < 10 virus.cell-1, the distinguish factor in RLP production is ni,267; thus, 
the profile of total RLP concentration resembles the one observed for ni,267 
and ni,267,max. At higher MOIs, the distinguish factor is the intracellular RLP 
production; hence, the profile follows closely the one of intracellular RLP 
production. Most importantly, Figure 42 indicates that, has opposed to 
single infection experiments, the total concentration of RLPs increases with 
the increase in MOI in co-infection experiments. 
The assembly efficiency was found to be correlated with the MOI: it 
increases with increasing MOI due to the aforementioned random infection 
effect (see ni,267/ni correlation with MOI) with a local minimum at MOI2=1 
(Figure 42). At MOI2, MOI6 and MOI7 < 2 virus.cell-1, the percentage of cells 
expressing either one or two viral proteins is around 75%, contrasting with 
the residual value observed at higher MOIs. Thus, the amount of 
unassembled proteins is expected to be much higher, drastically reducing 
the assembly efficiency. The local minimum at MOI2=1 virus.cell-1 is directly 
linked to the minimum observed for ni,267,max. 
For the MOI2 evaluated, the combination of MOI6 and MOI7 maximizing 
RLP production and assembly efficiency varied considerably. For MOI2, 
MOI6 and MOI7 higher than 2 virus.cell-1, these variables are maximized 
whenever: 
• MOI6/MOI2 ≈ 2.1 
• MOI7/MOI2 ≈ 1.2 
At these conditions, not only all cells are infected synchronously and by at 
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least one recombinant baculovirus coding for vp2, vp6 and vp7 (ni,267 → ni) 
but also the expression levels of the three viral proteins almost obey to the 
stoichiometry of the particle, thus reducing the amount of waste proteins. At 
low MOIs (MOI2, MOI6 and MOI7 < 2 virus.cell-1), there is no clear trend in 
the MOI6/MOI2 and MOI7/MOI2 ratios, which is intrinsically related with the 
high degree of stochasticity of the infection process at such low MOIs. 
In conclusion, these results demonstrate that high MOIs maximize RLP 
production at co-infection strategies, which is precisely the opposite trend 
verified for the single infection strategy.  
4.2.1. Are traditional co-infection strategies suboptimal? 
The production of RLPs is commonly performed using identical number of 
recombinant baculoviruses coding for vp2, vp6 and vp7 (MOI2 = MOI6 = 
MOI7). This strategy was compared to optimal MOI combinations of 
individual baculoviruses in terms of relative RLP production and assembly 
efficiency. 
It is evident from Figure 43 that traditional strategies are far-off from being 
the ideal ones; intracellular and total RLP concentrations and assembly 
efficiency are significantly lower, independently of the MOI. In fact, at the 
MOIs normally used for RLP production (MOI2 = MOI6 = MOI7 = 3 to 5 
virus.cell-1), model simulations show that a 1-fold increase in total RLP 
concentration, the most important performance criterion, is achievable by 
oriented-manipulation of the MOI2, MOI6 and MOI7. 
These results highlight the window of productivity gains that are possible 
through model-based optimisation for design of novel optimal infection 
strategies. 
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Figure 43. Comparison of model outputs for traditional co-infection strategies 
(MOI2=MOI6=MOI7) and model-designed strategies based on oriented-manipulation of the 
MOI of individual baculoviruses. The fold increase denotes the increase in intracellular 
(mg.cell-1) and total (mg.ml-1) RLP production and in assembly efficiency (%) by oriented-
manipulation of the MOI of individual baculoviruses in relation to traditional co-infection 
strategies. 
4.2.2. Promoter effect at co-infection strategies 
To test whether, at co-infection strategies, promoter strength impacts or not 
on RLP production, different scenarios were evaluated: the strength of the 
promoter controlling vp2 expression (Pvp2) was maintained constant in all 
simulations whereas Pvp6/Pvp2 and Pvp7/Pvp2 were varied between 0.1 and 
10. For a selected combination of MOI2, MOI6 and MOI7, the optimal 
combination of promoters’ strengths in terms of relative RLP production and 
assembly efficiency was compared to the co-infection strategy where all 
genes are under the control of promoters with equal strengths (Pvp6/Pvp2 = 
Pvp7/Pvp2 = 1) and the improvement in model outputs calculated (Figure 44). 
No significant variation in ni,267 and ni,267/ni was observed for the MOI2 = 5 
and 10 virus.cell-1; at lower MOIs, there was an increase in ni,267 and 
ni,267/ni which is linked to the stochasticity of the infection process (data not 
shown). This is rational because the promoter strength does not impact 
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directly or indirectly (via vDNA replication rate or synthesis and budding of 
progeny viruses) on cellular growth; it only affects the transcription and 
translation mechanisms. 
Optimal combination of promoters’ strengths had a positive impact on 
intracellular RLP production at MOI2 = 5 and 10 virus.cell-1 (Figure 44). 
Indeed, by controlling the relative strength of each promoter (Pvp6/Pvp2 and 
Pvp7/Pvp2), there was a better adjustment of the expression levels of the 
three viral proteins to what thermodynamically favours RLP assembly. This 
reduced the amount of unassembled proteins and increased not only the 
assembly efficiency but also the total RLP concentration. At MOI2 = 0.1 and 
1 virus.cell-1, no significant variation in intracellular RLP concentration was 
observed; hence, the increase in total RLP concentration and assembly 
efficiency is the result of the increase in ni,267. 
 
Figure 44. Comparison of model outputs (intracellular (mg.cell-1) and total (mg.ml-1) RLP 
production and assembly efficiency (%)) for co-infection strategies where the genes coding 
for the three viral proteins are under the control of promoters with equal strengths (Pvp6/Pvp2 
= Pvp7/Pvp2 = 1) and co-infection strategies maximizing RLP production based on the 
manipulation of the strength of each promoter. The fold increase denotes the increase in 
model outputs by oriented-manipulation of the strength of each promoter. 
Summing up, the redesign of baculovirus vectors in co-infection strategies, 
in which the promoters controlling viral protein expression can be selected 
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according to their strength, is a potential route for optimizing RLP 
production and assembly efficiency. 
4.3. What to choose: single-infection or co-infection? 
Model simulations indicate that single-infections give better results than co-
infections. This is clearly evident for low MOIs (Figure 45). Since single-
infections are more competent than co-infections in guaranteeing that 
infected cells carry all genes required for the expression of the three viral 
proteins, significant differences in ni,267, ni,267/ni and total RLP concentration 
were observed. Intracellular RLP production and assembly efficiency were 
not so strongly influenced by the stochasticity of the infection process; 
nonetheless, variations as high as 67% were observed. At high MOIs, the 
difference between single- and co-infection outputs is meaningless. This 
shows that the statistics of infection is no longer a key factor; RLP 
production becomes controlled by the expression levels of each viral 
protein. 
 
Figure 45. Single-infection vs co-infection: the effect of MOI on ni,267 (concentration of 
infected cells carrying the genes coding for vp2, vp6 and vp7), ni,267/ni (ratio between ni,267 
and the overall infected cell concentration, ni), RLP production (RLP) and assembly 
efficiency (Asseff). 
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By redesigning baculovirus vectors in single-infection strategies, in which 
the promoters controlling viral protein expression can be selected according 
to their strength, it is possible to improve RLP production even further (see 
section 4.1.1). In conclusion, these findings clearly demonstrate that single-
infections offer a greater potential for RLP process optimization than co-
infection strategies. 
 
5. CONCLUSIONS AND FUTURE PERSPECTIVES 
From the model sensitivity analysis and RLP production optimisation study 
performed in this chapter, the following main conclusions can be outlined: 
Sensitivity analysis 
• vDNA and protein related parameters, such as δ10, kRDNA, S2, mp2 
and krib,elong, are much more relevant than cell growth and mRNA 
parameters for protein expression - model outputs are highly 
sensitive to changes in these parameters; 
• Variations in parameters related with the infection process, virus 
budding and re-infection have a minor influence on model outputs; 
RLP optimization: single-infection 
• The concentration of infected cells carrying the genes coding for 
vp2, vp6 and vp7, ni,267, matches the overall concentration of 
infected cells, ni, irrespective of the MOI; 
• ni,267 is higher at low MOIs (1-3×106 cell.ml-1) than at high MOIs (0.5-
1×106 cell.ml-1); 
• The specific concentration of RLPs is function of the MOI – it 
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increases from 2.3×10-8 mg.cell-1 (low MOIs) to 2.8×10-8 mg.cell-1 
(high MOIs); 
• The total concentration of RLPs decreases from 60 mg.L-1 to 25 
mg.L-1 with the increase in the MOI; 
• The assembly efficiency is independent of the MOI, being around 
72%; 
• The strength of the promoters controlling the expression of vp2, vp6 
and vp7 have no influence on ni,267; in contrast, optimal combination 
of promoters’ strengths induces an improvement in intracellular and 
total RLP production (7% to 18%) and in assembly efficiency (24%); 
• In summary, process optimization in single-infection strategies can 
be achieved by manipulation of the MOI (lower MOIs) and/or by 
redesigning baculovirus vectors, in which the promoters controlling 
viral protein expression can be selected according to their strength 
(lowering the strength of the promoter controlling vp7 expression in 
relation to the other two promoters); 
RLP optimization: co-infection 
• High MOIs favours the infection of insect cells with the three 
monocistronic baculoviruses (ni,267/ni → 1); as the MOI decreases, 
the infection process becomes stochastic and cells are likely to be 
infected by only one or two of the three recombinant baculoviruses 
(minimum of ni,267/ni at 0.2); 
• Intracellular RLP production follows a two-step profile: upon an 
apparent plateau for MOIs < 10 virus.cell-1 (2.4-2.6×10-8 mg.cell-1), 
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intracellular RLP concentrations increase with the increase in the 
MOI (2.6-3×10-8 mg.cell-1); 
• Total RLP production increases with the MOI (6-30 mg.L-1); 
• The assembly efficiency is correlated with the MOI: there is a local 
minimum at MOI2 = 1 virus.cell-1 (20%); for lower MOIs, the 
efficiencies vary between 20% and 40%; for higher MOIs, the 
assembly efficiency increases to 80%; 
• For MOI2, MOI6 and MOI7 higher than 2 virus.cell-1, RLP production 
and assembly efficiency are maximized whenever MOI6/MOI2 ≈ 2.1 
and MOI7/MOI2 ≈ 1.2; at lower MOIs, there is no clear trend in the 
MOI6/MOI2 and MOI7/MOI2 ratios maximizing process outputs; 
• In summary, high MOIs maximize RLP production; the redesign of 
baculovirus vectors configures a somewhat modest improvement 
potential; 
RLP optimization: single-infection or co-infection? 
At low MOIs, single-infection strategies offer significant advantages over 
co-infection experiments, namely: 
• ni,267 can reach up to 3×106 cell.ml-1, contrasting with the 0.6×106 
cell.ml-1 at co-infection; 
• Higher total RLP concentrations: 30-60 mg.L-1 against the 6-12 
mg.L-1 at co-infection; 
• Assembly efficiencies are higher: 72% against the 20-40% at co-
infection; 
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At high MOIs, the differences in model outputs for co- and single-infection 
strategies are meaningless: 
• ni,267 levels are within 0.5-1×106 cell.ml-1; 
• Maximum total RLP concentration is around 30 mg.L-1; 
• Maximum assembly efficiencies are between 72-80%. 
The findings described throughout Chapter 6 demonstrate that the redesign 
of baculovirus vectors, in which the promoters controlling viral protein 
expression can be selected according to their strength, and the 
manipulation of the MOI have great potential for process optimization. The 
practical implementation of these concepts may not be easy since it 
depends on the available resources, namely the type of recombinant 
baculoviruses (tricistronic or monocistronic), and on the knowledge of 
molecular biology techniques, essential for the construction of novel 
recombinant baculoviruses. 
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1. DISCUSSION 
In previous Chapters, in silico baculovirus/insect cells optimisation tools for 
heterologous protein production and for virus like particles production were 
developed. The target product was rotavirus-like-particles (RLP), one of the 
most promising immunization strategies against rotavirus disease. RLP is 
representative of many other biotherapeutic candidates with major 
production hurdles. The extensive production of this vaccine candidate has 
been hindered essentially due to the complexity of the RLP production 
process, which commonly leads to very low yields and volumetric 
productivities. In this Chapter, it is highlighted the value added but also the 
main pitfalls of the computational tools developed in previous Chapters for 
the optimisation of the baculovirus/insect cells system. 
1.1. MOI controllability 
The ability to control the multiplicity of infection (MOI) is a mandatory 
guideline for ensuring batch consistency. Without accurate MOI control, 
optimisation of the baculovirus/insect cell system for heterologous protein 
expression becomes compromised. This implies accurate estimation of 
baculovirus titers so that the MOI measurement encloses as little variability 
as possible. In order to identify the titration methods that better combine 
accuracy with the method’s cost and work intensity, a comparative study 
was performed in Chapter 2. 
The endpoint dilution, microculture tetrazolium and flow cytometric assays 
presented the best compromise between cost, time and accuracy. Their 
cost was similar and, in average, 75% lower than those reported for the 
alamarblue, real time Q-PCR and plaque assays. This analysis was based 
on the cost of consumables; costs associated with equipment and human 
resources were not considered since these differ from lab to lab. 
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The standard errors were below the 28-36% reported for the alamarblue 
and growth cessation assays but slight above the ones achieved for the 
plaque assay and real time Q-PCR (7-10%). These values are in 
agreement with literature values and within acceptable variations defined 
by regulatory agencies [1-3]. The titration time is their main disadvantage; 
nonetheless, it may be viewed as a reasonable price to pay for estimating 
accurate titers. 
Interestingly, real time Q-PCR was found to be one of the techniques 
estimating viral titers statistically different from the average. The presence 
of defective interfering particles (DIPs) in viral stocks is the main cause. 
Since it is impossible to discriminate between infectious particles and DIPs 
with this technique, both viruses were counted as infectious and, thus, titers 
were over-estimated. This demonstrates how important it is to control the 
passage number of baculoviruses. Indeed, although their effect becomes 
more pronounced from passage 20 onwards, DIPs can be detected as 
soon as passage 10 and reach up to 60% of total replicated viruses [4]. 
Thus it may be realistic to expect a MOI variability of around 20%. 
1.2. Model-based optimisation of the MOI for single protein 
expression 
To investigate the implications of MOI on recombinant protein expression in 
the baculovirus/insect cell system, a stochastic structured model was 
developed in Chapter 3.  
The proposed model represents an advance over previous modelling 
studies [5-7] since it combines an explicit stochastic infection process with 
mass action kinetics describing the dynamics of vDNA, mRNA and foreign 
protein synthesis. In addition, it explores the hypothesis of gene size being 
the main factor affecting the rate of protein expression in the host cell. 
Production Optimization of Rotavirus-Like Particles: A Systems Biology Approach 
223 
Model simulations confirmed that optimal MOIs are typically low, in 
agreement with experimental observations and other modelling studies [6; 
8]. Indeed, at MOIs lower than 1 virus.cell-1 protein expression was 
maximized as a result of higher infected cell concentration at the end of 
bioreaction - asynchronous infection [9]. On the other extreme, for MOIs 
higher than 1 virus.cell-1, lower protein concentrations were achieved in 
consequence of protein expression saturation and low infected cell 
concentration – synchronous infection [9]. This means that it does not bring 
any advantage to increase the MOI to very high levels as the translation 
machinery saturates, thus resulting in no improvement in protein 
expression. 
Chapter 3 results clearly indicate that intracellular vDNA content reaches a 
maximum level which was found to be a trade-off between high MOIs (more 
‘seeds’ for vDNA replication with reduced time window for its replication) 
and extended virus budding effect at low MOIs (more virus for infection 
over a longer period of time). The time at which it occurs is coincident with 
the halt in mRNA and protein synthesis, and inversely proportional to the 
MOI. The higher the MOI, the more severe is the “metabolic burden” and, 
consequently, the lower is the time window for intracellular vDNA, mRNA 
and protein synthesis, in agreement with the literature [6; 10-12]. 
An interesting result is that the gene size did not affect the optimal MOI for 
protein expression. This is reasonable because the recombinant gene size 
does not affect either the infection kinetics or the vDNA replication rate or 
the budding of progeny virus. It only affects the transcription and translation 
mechanisms, meaning that it only impacts on the intracellular accumulation 
of protein. This means that different proteins are expected to have optimal 
productivities around the same MOI obtained for vp2: 
• MOI = 0.01 – 0.1 virus.cell-1 
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On the other hand, gene size impacts negatively on protein expression as 
showed elsewhere [6]; the larger the gene size, the lower is the final 
protein concentration. 
A final point is the effect of MOI errors on protein optimisation. Taking the 
example of vp2 and a typical error in MOI of 20% around the optimum 
value of 0.01 virus.cell-1, a degradation between 5% and 30% in the 
concentration of viral protein is expected (see Figure 19 in Chapter 3). 
These results emphasize the importance of accurate titration methods for 
the controllability of the MOI and, consequently, protein expression. 
1.3. Model-based optimisation of RLP production 
1.3.1. RLP assembly controllability 
The thermodynamic equilibrium-based model proposed in Chapter 4 
provides a means to assess RLP assembly controllability under a particle 
stability viewpoint. More specifically, the model establishes a relationship 
between particle formation and the Gibbs free energy of protein subunit 
association, ΔG0n, and protein concentration. As discussed before, 
intracellular protein concentration is a function of the MOI; as such, the MOI 
is a potential effector of RLP assembly efficiency. The Gibbs free energy of 
protein subunit association, ΔG0n, is a very complex function of intracellular 
physicochemical environment and it is not clear in how far it can be 
manipulated in vivo. 
Pseudo-critical protein concentration 
Model simulations showed that there is a minimum concentration of protein 
structural subunits needed to ensure a measurable particle formation, i.e., a 
pseudo-critical concentration, as previously suggested by Zlotnick (1994) 
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[24]. At very low concentrations, few particles are formed; above a given 
critical value, most subunits assemble into intact icosahedra (RLP). 
Importantly, this concentration threshold was found to be correlated with 
the ΔG0n. From a thermodynamic viewpoint, an increase in the Gibbs free 
energy of protein subunit association (less negative) means that particle 
assembly is less favourable. The way to compensate for this loss in intact 
particles due to ΔG0n is to increase the concentration of protein subunits in 
order to shift the equilibrium towards product formation. Thus, at higher 
ΔG0n, the protein’s pseudo-critical concentration also increases. 
Maximising RLP assembly efficiency  
The model suggests that the key factor for ensuring 100% RLP assembly 
efficiency is providing vp2, vp6 and vp7 at the exact RLP stoichiometric 
ratios. Model simulations confirmed that thermodynamics favours the 
formation of intact icosahedra at low Gibbs free energy values (< -2 
kcal.mol-1) and whenever vp2, vp6 and vp7 are provided at the exact RLP 
stoichiometric ratios. Significant deviations to this optimal operating point 
were however observed at high Gibbs free energies, namely a translocation 
of proteins pseudo-critical concentrations (optimum concentrations are no 
longer coincident with the stoichiometric ratio of RLP) and a crisp transition 
from intact icosahedra to unassembled subunits. 
Gibbs free energy of protein subunit association 
From the relationships developed in the thermodynamic equilibrium-based 
model, we were able to understand and quantify the impact of Gibbs free 
energy of subunit association on optimal initial vp2, vp6 and vp7 
concentrations and on RLP assembly efficiency. A field to be explored in 
the future is the design of optimization strategies based on oriented 
manipulation of physico-chemical parameters (e.g. temperature, pH, [NaCl] 
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and concentration of divalent ions) with impact on Gibbs free energy of 
subunit association. This is particularly important for the design of in vitro 
assembly/disassembly experiments. 
1.3.2. RLP optimization by oriented-manipulation of the MOI 
Independently of the infection strategy (single- or co-infection) RLP 
production and assembly were found to be highly dependent on the MOI 
(Chapter 6). It should be noted that optimization of RLP production implies 
the maximisation of protein expression and also the maximisation of 
assembly efficiency. These two goals are not necessarily compatible and 
achievable at the same operational MOI.  
Single infection strategies 
For single-infection strategies, model simulations showed that increasing 
the MOI to very high levels did not bring any advantage as RLP yields are 
controlled by the stoichiometry of the particle, which is independent of the 
MOI, and by high protein concentrations, achieved at low MOIs. Indeed, 
although the intracellular RLP production had increased with the MOI, the 
total RLP concentration decreased due to lower concentration of infected 
cells. The assembly efficiency was found to be independent of the MOI. 
Interestingly, the profile of RLP production (Figure 38 in Chapter 6) closely 
resembles the one of vp2 production (Figure 19 in Chapter 3): a minimum 
at MOIs around 5-10 virus.cell-1 and a maximum at MOI of 0.01 virus.cell-1. 
These results indicate that optimal MOIs for protein expression in single-
infection strategies are independent on the number of recombinant proteins 
to express. 
Co-infection strategies 
In co-infection strategies, high MOIs maximize RLP production. Since the 
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concentration of infected cells carrying the genes coding for vp2, vp6 and 
vp7 was MOI independent (when MOI > 10 virus.cell-1) and intracellular 
RLP production increased with the MOI, the higher the MOI, the higher was 
the total RLP production. 
The model shows that the combination of MOI2, MOI6 and MOI7 (number of 
monocistronic baculoviruses coding for vp2, vp6 and vp7 per cell, 
respectively) maximizing RLP production and assembly efficiency varied 
considerably. For MOI2, MOI6 and MOI7 higher than 2 virus.cell-1, these 
variables are maximized whenever: 
• MOI6/MOI2 ≈ 2.1 
• MOI7/MOI2 ≈ 1.2 
At these conditions, not only all cells are infected synchronously and by at 
least one recombinant baculovirus coding for vp2, vp6 and vp7 (ni,267 → ni) 
but also the expression levels of the three viral proteins almost obey to the 
stoichiometry of the particle, thus reducing the amount of waste proteins. At 
low MOIs (MOI2, MOI6 and MOI7 < 2 virus.cell-1), there is no clear trend in 
the MOI6/MOI2 and MOI7/MOI2 ratios, which is intrinsically related with the 
high degree of stochasticity of the infection process at such low MOIs. 
1.3.3. RLP optimization via genetic redesign 
Genetic controllability 
The other alternative is RLP optimization through genetic engineering. A 
critical hypothesis of the model was that under the control of a given very 
late promoter (p10 or polh) the transcription and translation rates are linear 
functions of the gene size. It means that when multiple proteins are 
expressed under the control of the same promoter, then the relative size of 
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the gene coding for a given protein determines the relative transcription and 
translation rates of that particular protein in comparison to others expressed 
within the same cell. Thus, the rate of protein expression can be controlled 
either thorough multiple copies of the gene under the control of the same 
promoter or by the choice of the promoter itself. Although possible in 
theory, controllability of protein expression at the genetic level may not be 
straightforward. Noteworthy is the non conformity of the transcriptional 
rates in co-infection experiments with the rule of the gene size verified in 
Chapter 5. Although the specific reasons for this discrepancy are not 
known, one can speculate on the use of different restriction sites for cloning 
since they have shown to have some influence in the translation and 
transcription levels [16-21]. For single-infection experiments where the 
transcription of the viral genes occurs from the same vDNA template and 
the gene coding for vp7 is under the control of p10 promoter instead of the 
polh one, the ranking of the transcriptional rates according to gene size was 
obeyed. This may suggest that the p10 promoter has a higher potential for 
vp7 expression than the polh promoter. Although inconsistent with 
literature, where p10 and polh promoters were shown to have similar 
strengths [22], the levels of gene expression are known to be affected by 
the interaction between both [23], possibly justifying the aforementioned 
conclusion. 
Optimisation potential 
While in single-infection the redesign of baculovirus vectors at the 
promoters’ level has enormous potential for process optimization, no 
significant improvements are observed in co-infection strategies (Chapter 
6). 
In single-infection strategies, model simulations showed that the 
concentration of infected cells carrying the genes coding for vp2, vp6 and 
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vp7, ni,267, was not improved by manipulation of promoters’ strength. In 
contrast, improvements between 7% and 18% in intracellular and total RLP 
production and around 24% in assembly efficiency were achieved. 
Irrespective of the MOI evaluated, the combination of promoters’ strength 
maximizing RLP production and assembly efficiency was Pvp6/Pvp2 = 1 and 
Pvp7/Pvp2 = 0.6 (Pvp2, Pvp6 and Pvp7 - the strength of the promoters controlling 
vp2, vp6 and vp7 expression, respectively). 
In co-infection strategies, no significant variation in ni,267 was observed for 
high MOIs; at lower MOIs, there was an increase in ni,267. This improvement 
is more likely to be related with the stochasticity of the infection process 
than linked to the promoters’ strength. This is rational because the 
promoter strength does not impact directly or indirectly (via vDNA 
replication rate or synthesis and budding of progeny viruses) on cellular 
growth; it only affects the transcription and translation mechanisms. 
Optimal combination of promoters’ strengths had a positive impact on 
intracellular RLP production at high MOIs. By controlling the relative 
strength of each promoter (Pvp6/Pvp2 and Pvp7/Pvp2), there was a better 
adjustment of the expression levels of the three viral proteins to what 
thermodynamically favours RLP assembly. This reduced the amount of 
unassembled proteins and increased not only the assembly efficiency but 
also the total RLP concentration. At low MOIs, no significant variation in 
intracellular RLP concentration was observed; hence, the increase in total 
RLP concentration and assembly efficiency is the result of the increase in 
ni,267. 
1.3.4. Single infection or co-infection: what to choose? 
In general, single-infection strategies offer significant advantages over co-
infection experiments. This is particularly visible at low MOIs where the 
higher cell density achieved at single-infection led to higher RLP production 
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(30-60 mg.L-1 against the 6-12 mg.L-1 at co-infection). Assembly efficiencies 
were also higher: 72% against the 20-40% at co-infection. At high MOIs, 
there was no significant difference between both strategies; the 
concentration of infected cells carrying the genes coding for vp2, vp6 and 
vp7, the intracellular and total RLP production and the assembly 
efficiencies were comparable. 
These results are consistent with the ones reported by Belyaev and Roy in 
1993 and 1994 for the Bluetongue virus (BTV)-VLP. In their study, the 
expression of the four main proteins of BTV (vp2, vp3, vp5 and vp7) in a 
four-gene baculovirus vector has led to the formation of highly stable 
double-layered BTV-VLPs, contrasting with the single-layered or double-
shelled VLPs with highly variable protein ratios obtained by co-infection 
with two dual-gene baculovirus vectors [13; 14]. 
 
2. CONCLUSIONS 
Based on the work presented in this thesis and the above discussion, the 
following set of conclusions can be outlined: 
• In silico baculovirus/insect cells optimization tools are essential for 
enhancing productivities of complex biotherapeutics in this system. 
Major steps were undertaken in this thesis towards the in silico 
implementation of baculovirus/insect cells, namely the development of 
stochastic/thermodynamic-equilibrium models of protein expression 
and VLP assembly. It combines complex mathematical/statistical 
formulations (stochasticity, segregation, molecular thermodynamic 
equilibrium) with experimental intra and extracellular data (vDNA 
replication, very late transcription, protein synthesis and VLP 
formation); 
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• A striking outcome of the model is the independency of vDNA 
replication rate on the infection strategy. Irrespective of the baculovirus 
vector used in this study (monocistronic or tricistronic), the sizes of the 
genes coding for the foreign proteins represent less than 5% of the 
baculovirus genome size [15]. This explains why the genome size 
factor had a minor effect on the vDNA replication kinetics; 
• The “metabolic burden” effect (decreases the time window for vDNA 
replication), intracellular vDNA (high vDNA loads result in high mRNA 
levels) and protein saturation (the translation machinery saturates – no 
advantage in increasing the MOI to very high levels) are critical factors 
affecting protein expression;  
• The endpoint dilution, microculture tetrazolium and flow cytometric 
assays were found to be the titration methods combining better cost, 
time and error. MOI errors can be kept within 20%, which is acceptable 
for a process optimization program; 
• Maximum protein production is achieved at low MOIs, normally in the 
range of 0.01 to 0.1 pfu.cell-1 independently of the size of the gene 
under the control of the polh promoter; 
• Gene size does not affect the optimal MOI ranges for protein 
expression but impacts negatively on protein concentrations - the 
larger the gene size, the lower is the protein concentration; 
• Single-infection strategies with tricistronic baculoviruses induce higher 
RLP production than co-infection strategies with monocistronic 
baculoviruses; 
• The redesign of baculovirus vectors in single-infection strategies, in 
which the promoters controlling viral protein expression can be 
selected according to their strength, and the manipulation of the MOI, 
in both single- and co-infection strategies, have great potential for 
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process optimization; 
• A pseudo-critical protein concentration defines the outcome of the 
assembly process, either unassembled protein subunits or intact 
icosahedra. This threshold was found to be correlated with the Gibbs 
free energy of subunit association, ΔG0n - as ΔG0n increases the 
protein’s pseudo-critical concentration also increases; 
• RLP yields are thermodynamically maximized whenever vp2, vp6 and 
vp7 are provided at the exact RLP stoichiometric ratio and at high initial 
protein concentrations; 
• RLP formation can be controlled by oriented-manipulation of solution 
properties with impact on ΔG0n (e.g. temperature, pH, ionic strength 
and divalent ions concentration). This is particularly important in cases 
where the concentration of proteins is below a pseudo-critical value; 
• Inadequate thermodynamic conditions and incorrect protein 
concentration ratios are responsible for the high percentage of 
unassembled proteins at the end of a RLP production process. 
The present thesis attempts to make the point that in the production of 
complex biotherapeutics, such as RLP, where bottlenecks are likely to be 
posed at the molecular level, Systems Biology approaches are essential 
tools to overcome such bottlenecks. A major benefit is that Systems 
Biology allows to identify the intrinsic limitations of the production platform 
and to guide in conformity process development efforts. Moreover, it 
provides unprecedented level of detail, which in some problems is 
absolutely essential to find the hidden “secretes” eventually boosting 
process productivities and product quality. For the model system studied in 
this thesis, predicted improvements in RLP production would allow 
increasing the number of vaccine doses produced per batch. Indeed, based 
on recovery yields of 37% upon purification [25] and assuming a vaccine 
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dose of 2-20 μg of RLP in mice [26] or 200-250 μg in gnotobiotic pigs [27; 
28], the model-based strategies would provide on average 21 times more 
vaccine doses than traditional RLP production processes (~2 mg/L). Even if 
the RLP yields calculated in Chapter 6, based on particle stoichiometry and 
the limiting protein, had been calculated based on literature assembly 
efficiencies (~11% [29]), a 3-fold increase would still be expected. 
These theoretical results suggest that the integration of the model-based 
strategies explored in this thesis within a flexible vaccine production 
platform will be essential to accelerate the timeline for moving RLP vaccine 
candidate into the market. 
 
3. FUTURE WORK 
This thesis represents a contribution for the clarification of some critical 
aspects of RLP production in the baculovirus/insect cell system and for the 
design of optimization schemes capable of maximizing the objective 
function, RLP production. In addition, it provides a computational 
framework with potential for process production development and 
optimization of viral proteins and virus-like particles in a broad sense. 
Still, to achieve a robust and efficient RLP production platform, some trends 
identified throughout this thesis need verification: 
• The positive impact on RLP production of redesigning baculovirus 
vectors, in which the promoters controlling viral protein expression can 
be selected according to their strength; 
• The increase in RLP production using the optimal combination of MOI2, 
MOI6 and MOI7 at co-infection and the best MOI at single-infection; 
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• Control the formation of RLPs in vivo by oriented manipulation of 
solution properties with impact on Gibbs free energy of subunit 
association (e.g. temperature, pH, ionic strength and divalent ions 
concentration); this is even more essential if an assembly/reassembly 
step is required for improved purification. 
whereas other issues require further investigation: 
• Evaluate the effect of promoters’ class (early, late or very late 
promoter), TOI and CCI on the performance of single or co-infection 
strategies; 
• Integration of the information coming from -omic technologies into a 
global optimization model for supporting decision-making at the 
engineering level; 
• Development of optimization strategies based on metabolic 
engineering; 
• The impact of different culture modes (e.g. perfusion) and key process 
parameters (e.g. temperature shifts) on RLP production; 
• From a clinical perspective - the formulation of the vaccine (buffer, 
adjuvant or delivery system), the dosage and the storage condition; 
• Generation of chimeric RLPs for broader protection against different 
rotavirus serotypes or for the development of newer vaccines against 
emergent diseases; 
• Application of this modelling framework to other economically relevant 
viruses (e.g. adeno-associated virus), heterologous proteins or VLPs. 
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